{"allTrials": {"@totalCount": "41", "@xmlns": "http://www.67bricks.com/isrctn", "fullTrial": [{"trial": {"@lastUpdated": "2008-09-05T00:00:00.000Z", "@version": "19", "isrctn": {"@dateAssigned": "2008-09-05T00:00:00.000Z", "#text": "99801051"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "Assessment of growth and body composition in preterm infants in relation to two different protein intakes: a randomised controlled trial", "scientificTitle": null, "acronym": null, "studyHypothesis": "The goal is to evaluate the safety and the effects on neonatal growth and body composition of two distinct strategies (intervention and control) for parenteral nutrition.", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "Safety/tolerance:\n1. Haemo-gas analysis twice a week for the first 15 days\n2. Blood urea nitrogen and serum ammonium on the 1st day of life, on the 4th/5th, on the 7th/8th and 15th day of life\n3. Blood amino acid profile on the 1st day of life (before starting NPT) and on the 4th/5th and 15th day of life", "secondaryOutcome": "Efficacy:\n1. Body composition (assessed by means of deuterium and air plethismography-Pea Pod) at birth, at 15 days of life and at 36 weeks of post-conceptional age\n2. Growth (weight assessed daily, length and head circumference assessed weekly)\n3. Anabolism assessed by means of nitrogen balance on 2nd, 5th, and 8th day of life\n4. Blood amino acid profile on the 1st day of life (before starting NPT) and on the 4th/5th and 15th day of life", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Ethics approval received from the Ethical Committee FONDAZIONE IRCCS Ospedale Maggiore Policlinico Mangiagalli Regina Elena on the 24th March 2006."}, "externalRefs": {"doi": "10.1186/ISRCTN99801051", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "N/A"}, "trialDesign": {"studyDesign": "Randomised controlled trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Hospital"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2008-09-01T00:00:00.000Z", "overallEndDate": "2009-06-01T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": "Italy"}, "trialCentres": {"trialCentre": {"@id": "b9d79a6c-5282-4b4b-ba06-787262f3fb8f", "name": "Via Commenda 12", "address": null, "city": "Milano", "state": null, "country": "Italy", "zip": "20122"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. Birth weight between 1000 and 1500 g\n2. Being male\n3. Being adequate for gestational age (birth weight greater than or equal to 10th percentile according to the Babson and Benda's chart updated) \n4. Need for oxygen (O2) less than 40% within the first 72 hours", "ageRange": "Neonate", "gender": "Male", "targetEnrolment": "18", "totalFinalEnrolment": null, "totalTarget": "9 patients per group (18 in total)", "exclusion": "1. Starting parenteral nutrition (NPT) after the first 24 hours of life\n2. Chromosomal abnormalities \n3. Metabolic disease\n4. Congenital infections (toxoplasmosis, rubella, cytomegalovirus, herpes simplex and human immunodeficiency virus [HIV] [TORCH])\n5. Score of severity of clinical conditions at birth (CRIBB) greater than 4", "patientInfoSheet": "Not available in web format, please use the contact details below to request a patient information sheet", "recruitmentStart": "2008-09-01T00:00:00.000Z", "recruitmentEnd": "2009-06-01T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Preterm infant nutrition and body composition", "diseaseClass1": "Nutritional, Metabolic, Endocrine", "diseaseClass2": "Preterm infant nutrition"}}, "interventions": {"intervention": {"description": "To detect a difference of 3.0 g/kg per day in weight gain between the two treatment groups (a = 0.25; power = 80%, assuming SD = 2.0 g/kg per day), 9 patients are required for each group. \n\nPreterm infants will be randomised to receive two different schedules of NPT: high or low protein intake for two weeks. The high protein intake consists of at maximum 3.5 g/Kg/d starting from 2.5 g/Kg/d and the low protein intake consists of 2.5 g/Kg/d starting from 1.5 g/Kg/d.", "interventionType": "Other", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": null}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": null, "publicationStage": null, "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": null, "parties": {"funderId": "Funder18019-0", "contactId": "Contact56003_18019", "sponsorId": "Sponsor54569"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact56003_18019", "title": "Prof", "forename": "Paola", "surname": "Roggero", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Via Commenda 12", "city": "Milano", "country": "Italy", "zip": "20122", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected"}, "sponsor": {"@id": "Sponsor54569", "organisation": "Institute of Paediatrics and Neonatology (Italy)", "website": "http://www.mangiagalli.it", "sponsorType": "Research organisation", "contactDetails": {"address": "University Medical School of Milan\nVia Commenda 12", "city": "Milano", "country": "Italy", "zip": "2012", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected", "gridId": "grid.4708.b", "rorId": "https://ror.org/00wjc7c48"}, "funder": {"@id": "Funder18019-0", "name": "Fondazione IRCCS Ospedale Maggiore Policlinico Mangiagalli Regina Elena (Italy)", "fundRef": null}}, {"trial": {"@lastUpdated": "2008-09-01T00:00:00.000Z", "@version": "21", "isrctn": {"@dateAssigned": "2008-09-01T00:00:00.000Z", "#text": "53149519"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "Sustained release particle of 5-fluorouracil combining transcatheter arterial chemoinfusion to treat hepatocellular carcinoma with portal vein tumour thrombus", "scientificTitle": "Sustained release particle of 5-fluorouracil (Sinofuan\u00ae) combining transcatheter arterial chemoinfusion to treat hepatocellular carcinoma with portal vein tumour thrombus: a randomised controlled trial", "acronym": null, "studyHypothesis": "The prognosis of patients with hepatocellular carcinoma (HCC) accompanied by portal vein tumour thrombus (PVTT) is generally poor. A literature review regarding transcatheter arterial chemoinfusion (TAC) was difficult due to differences in techniques, patient selection, and underlying liver function. In fact, this was an exclusion criterion for some treatments. \n\nSinofuan\u00ae is a newly approved fluorouracil sustained release particle for HCC in China. It can steadily release fluorouracil for hundreds of hours and maintains effective concentration around its implanting site. Because the portal vein tumour thrombus is mainly composed of tumour tissue, it is supposed that the direct implantation of Sinofuan\u00ae into the thrombus should result in a better outcome than single TAC therapy. This trial is designed to examine this hypothesis.", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "1. Patient dies, measured at one month and six months\n2. Disappearance of portal vein thrombus, measured at one month", "secondaryOutcome": "1. Closure of portal vein lateral flow, measured at one and two months\n2. Decreased size of thrombus less than or equal to 20% of original, measured at one month, two months, four months and six months", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Ethics approval received from the Ethics Committee of the Affiliated 10th People's Hospital, Tongji University (China) on the 5th March 2008."}, "externalRefs": {"doi": "10.1186/ISRCTN53149519", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "N/A"}, "trialDesign": {"studyDesign": "Single-centre, non-blinded, randomised, controlled study", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Hospital"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2008-03-17T00:00:00.000Z", "overallEndDate": "2009-09-30T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": "China"}, "trialCentres": {"trialCentre": {"@id": "4fbfe736-116a-402a-aa3b-191a92f96a24", "name": "YanChang Road, 301", "address": null, "city": "Shanghai", "state": null, "country": "China", "zip": "200072"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. Image-proven HCC\n2. Irresectable tumour\n3. Failure to previous treatment\n4. Child-Pugh scale less than or equal to 10\n5. Aged 30 - 80 years, either sex\n6. Tumour thrombus is proven within portal vein and its section area exceeds 50% of vessel by computed tomography (CT)", "ageRange": "Adult", "gender": "Both", "targetEnrolment": "30", "totalFinalEnrolment": null, "totalTarget": "30", "exclusion": "1. Uncontrolled hypertension\n2. Unstable angina\n3. Arrhythmias requiring treatment\n4. Myocardial infarction (MI)\n5. Congestive heart failure or cardiomyopathy requiring treatment", "patientInfoSheet": "Not available in web format, please use the contact details below to request a patient information sheet", "recruitmentStart": "2008-03-17T00:00:00.000Z", "recruitmentEnd": "2009-09-30T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Hepatocellular carcinoma/portal vein tumour thrombus", "diseaseClass1": "Cancer", "diseaseClass2": "Hepatocellular carcinoma"}}, "interventions": {"intervention": {"description": "1. Intervention: percutaneously implant the sustained release particle of 5-fluorouracil in the tumour thrombus and treat HCC with TAC\n2. Control: single treatment of HCC with TAC\n\nFor the intervention group, the sustained release particle of 5-fluorouracil will be percutaneously implanted once and only once. Within one week, TAC will be performed to treat HCC. The total duration of treatment will be no more than one week. The duration of follow-up is six months.", "interventionType": "Drug", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": "5-fluorouracil (Sinofuan\u00ae)"}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": null, "publicationStage": null, "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": null, "parties": {"funderId": "Funder17645-0", "contactId": "Contact55616_17645", "sponsorId": "Sponsor54191"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact55616_17645", "title": "Prof", "forename": "Maoquan", "surname": "Li", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "YanChang Road, 301", "city": "Shanghai", "country": "China", "zip": "200072", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected"}, "sponsor": {"@id": "Sponsor54191", "organisation": "Affiliated 10th People's Hospital of Tongji University (China)", "website": null, "sponsorType": "Hospital/treatment centre", "contactDetails": {"address": "YanChang Road, 301", "city": "Shanghai", "country": "China", "zip": "200072", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected", "gridId": "grid.412538.9", "rorId": "https://ror.org/03vjkf643"}, "funder": {"@id": "Funder17645-0", "name": "Affiliated 10th People's Hospital of Tongji University (China)", "fundRef": null}}, {"trial": {"@lastUpdated": "2008-09-04T00:00:00.000Z", "@version": "21", "isrctn": {"@dateAssigned": "2008-09-01T00:00:00.000Z", "#text": "25330204"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "Surveillance of results of long-term prophylactic treatment of von Willebrand disease with Wilate\u00ae", "scientificTitle": null, "acronym": "WILCOME", "studyHypothesis": "Long-term prophylactic treatment of von Willebrand disease (VWD) patients in clinical practice.", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "To assess the bleeding frequency in VWD patients prior to and after introduction of regular prophylactic therapy with the VWF-containing concentrate Wilate\u00ae. Outcomes will be measured at baseline, 6 and 12 months after treatment. Please note that the number of days the patients missed school or work, as well as occurred adverse drug reactions are documented when the patient visits his doctor, so outcomes may be measured more frequently than every 6 months.", "secondaryOutcome": "1. To describe the joint morbidity prior to and during prophylaxis with Wilate\u00ae, using the haemophilia joint health score\n2. To monitor absence from school/work prior to and during prophylaxis with Wilate\u00ae\n3. To evaluate the patient's health-related quality of life prior to and during prophylaxis with Wilate\u00ae and the patient's self-reported health status prior to and during prophylaxis with Wilate\u00ae, using the validated generic instruments of World Health Organization Quality of Life-BREF (WHOQOL-BREF) (for adults) and the generic children's health-related quality of life (KINDL) (for children), and the disease specific VWD-QoL questionnaire\n4. To assess treatment satisfaction and treatment efficacy prior to and during prophylaxis with Wilate\u00ae, using a 4-point Verbal Rating Scale (VRS), and the Hemo-SatA treatment questionnaire adapted for VWD (VWD-Sat)\n5. To evaluate the tolerability of prophylactic treatment with Wilate\u00ae:\n5.1. Using a 3-point VRS\n5.2. By documenting all possibly related adverse drug reactions by the patients, and \n5.3. By assessing and - if applicable - reporting all adverse drug reactions by the treating physician occurring during the treatment period with Wilate\u00ae\n\nOutcomes will be measured at baseline, 6 and 12 months after treatment. Please note that the number of days the patients missed school or work, as well as occurred adverse drug reactions are documented when the patient visits his doctor, so outcomes may be measured more frequently than every 6 months.", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Ethics approval received from the Ethics Committee of University Hospital Malm\u00f6 on the 7th August 2008."}, "externalRefs": {"doi": "10.1186/ISRCTN25330204", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "WIL-18"}, "trialDesign": {"studyDesign": "Prospective, open-labelled, international multi-centre post-marketing surveillance", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Non randomised controlled trial", "trialSettings": {"trialSetting": "Not specified"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2008-09-01T00:00:00.000Z", "overallEndDate": "2013-01-01T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": ["Austria", "Germany", "Russian Federation", "Sweden"]}, "trialCentres": {"trialCentre": {"@id": "7bf4b575-c281-4573-b76c-951b1f72e690", "name": "Oberlaaerstrasse 235", "address": null, "city": "Vienna", "state": null, "country": "Austria", "zip": "1100"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. Male and female patients of any age \n2. Suffering from congenital VWD \n3. In need of replacement therapy with factor concentrate\n4. Patients starting with a prophylactic treatment must have documentation of at least three apparently spontaneous bleeding episodes (any bleeding site and treated with factor concentrate) in the 6 months prior to enrolment\n5. Patients switching from a prophylactic treatment with another factor concentrate to prophylaxis with Wilate\u00ae should have anamnesis of bleeds with respective documentation in the period of 12 months prior to enrolment", "ageRange": "Not Specified", "gender": "Both", "targetEnrolment": "24", "totalFinalEnrolment": null, "totalTarget": "24", "exclusion": "1. Presence of a bleeding disorder other than VWD\n2. History of non-compliance\n3. Difficulties in achieving venous access that would prohibit prophylaxis\n4. Incapability to follow the requirements of the surveillance, e.g. unable to keep a patient diary", "patientInfoSheet": "Not available in web format, please use the contact details below to request patient information material", "recruitmentStart": "2008-09-01T00:00:00.000Z", "recruitmentEnd": "2013-01-01T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "von Willebrand's disease", "diseaseClass1": "Haematological Disorders", "diseaseClass2": "Other coagulation defects"}}, "interventions": {"intervention": {"description": "Treatment details: \nThe following dosing regimes are only recommendations, based on the Swedish experience with the long-term prophylaxis in VWD:\n1. For mucosal, joint bleeds and menorrhagia, the suggested prophylactic dosing is 30 IU Wilate\u00ae (corresponding to 30 IU FVIII:C)/kg body weight 2 - 3 times/week\n2. For gastrointestinal bleeds, the suggested prophylactic dosing is 40 IU Wilate\u00ae (40 IU FVIII:C)/kg body weight 2 - 3 times/week\nWilate\u00ae is administered as an intravenuos bolus injection. Dose and dosing schedule are at the full discretion of the treating physician.  \n \nQuality of life:\nThe Quality of Life assessments performed during the surveillance will include: \n1. The patient's self-reported health-related quality of life prior to and during prophylaxis with Wilate using the validated generic instruments WHOQOL-BREF (for adults and/or parents/legal guardians) and KINDL (for children), and\n2. A disease-specific VWD-QoL questionnaire (for adults, children and their parents/legal guardians)\n\nQuality of life assessments will be measured prior to the start of the prophylaxis, as well as after 6 and 12 months of treatment.", "interventionType": "Drug", "pharmaceuticalStudyTypes": null, "phase": "Phase IV", "drugNames": "Wilate\u00ae"}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": null, "publicationStage": null, "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": null, "parties": {"funderId": "Funder18075-0", "contactId": "Contact56063_18075", "sponsorId": "Sponsor54629"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact56063_18075", "title": "Ms", "forename": "Martina", "surname": "Jansen", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Oberlaaerstrasse 235", "city": "Vienna", "country": "Austria", "zip": "1100", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+43 (0)1 61032 1208"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "martina.jansen@octapharma.com"}}, "privacy": "Public"}, "sponsor": {"@id": "Sponsor54629", "organisation": "Octapharma AG (Switzerland)", "website": "http://www.octapharma.com", "sponsorType": "Industry", "contactDetails": {"address": "Seidenstrasse 2", "city": "Lachen", "country": "Switzerland", "zip": "8853", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+41 (0)55 4512140"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "robert.kuhelj@octapharma.ch"}}, "privacy": "Public", "gridId": "grid.476576.1", "rorId": "https://ror.org/002k5fe57"}, "funder": {"@id": "Funder18075-0", "name": "Octapharma AG (Switzerland)", "fundRef": null}}, {"trial": {"@lastUpdated": "2008-08-29T00:00:00.000Z", "@version": "21", "isrctn": {"@dateAssigned": "2008-08-29T00:00:00.000Z", "#text": "55370829"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "Pulmonary Vein Isolation using Robotic navigation: a prospective randomised trial with invasive follow-up", "scientificTitle": null, "acronym": "RoboticPVI", "studyHypothesis": "Non-inferiority trial of robotic navigation (RN) guided pulmonary vein isolation compared to manually steered catheter approach.", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "Recovery of any pulmonary veins (PVs), measured after a follow up of one year is completed.", "secondaryOutcome": "Peri-/post-procedural complications.", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Ethics approval received from the Hamburg Ethics Committee on the 5th May 2008 (ref: 2801/2008)."}, "externalRefs": {"doi": "10.1186/ISRCTN55370829", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "RN/2"}, "trialDesign": {"studyDesign": "Prospective randomised non-blinded clinical trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Hospital"}, "trialTypes": {"trialType": "Diagnostic"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2007-01-12T00:00:00.000Z", "overallEndDate": "2008-01-03T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": "Germany"}, "trialCentres": {"trialCentre": {"@id": "f5514632-87a4-4372-918b-7ce2fab07dd2", "name": "Martinistr. 52", "address": null, "city": "Hamburg", "state": null, "country": "Germany", "zip": "20249"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. Documented, symptomatic atrial fibrillation lasting less than 48 hours \n2. No prior history of electrical cardioversion\n3. Both genders aged from 18 - 70 years", "ageRange": "Adult", "lowerAgeLimit": {"@unit": "Years", "@value": "18.0"}, "gender": "Both", "targetEnrolment": "50", "totalFinalEnrolment": null, "totalTarget": "50", "exclusion": "1. Left Atrial (LA) diameter greater than 60 mm\n2. Refuse to give written informed consent\n3. Non-elegibility for interventional therapy", "patientInfoSheet": "Not available in web format, please use the contact details below to request a patient information sheet", "recruitmentStart": "2007-01-12T00:00:00.000Z", "recruitmentEnd": "2008-01-03T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Atrial Fibrillation", "diseaseClass1": "Circulatory System", "diseaseClass2": "Atrial Fibrillation"}}, "interventions": {"intervention": {"description": "Catheter ablation with colled tip electrode with conduction block of all 4 vein proven by circumferential mapping catheter.", "interventionType": "Other", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": null}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": null, "publicationStage": null, "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": null, "parties": {"funderId": "Funder17464-0", "contactId": "Contact55426_17464", "sponsorId": "Sponsor54006"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact55426_17464", "title": "Dr", "forename": "Daniel", "surname": "Steven", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Martinistr. 52", "city": "Hamburg", "country": "Germany", "zip": "20249", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "d.steven@uke.uni-hamburg.de"}}, "privacy": "Public"}, "sponsor": {"@id": "Sponsor54006", "organisation": "University Heart Center Hamburg (Germany)", "website": "http://www.uke.uni-hamburg.de/zentren/herz/index.php", "sponsorType": "Hospital/treatment centre", "contactDetails": {"address": "Martinistr. 52", "city": "Hamburg", "country": "Germany", "zip": "20249", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+49 (0)49 42803 4125"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "info@uke.de"}}, "privacy": "Public", "gridId": "grid.13648.38", "rorId": "https://ror.org/01zgy1s35"}, "funder": {"@id": "Funder17464-0", "name": "Investigator initiated and funded (Germany)", "fundRef": null}}, {"trial": {"@lastUpdated": "2008-08-28T00:00:00.000Z", "@version": "20", "isrctn": {"@dateAssigned": "2008-08-28T00:00:00.000Z", "#text": "66931248"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "The role and modulation of the adaptive immune response in human limb ischaemia reperfusion injury by ischaemic preconditioning", "scientificTitle": null, "acronym": null, "studyHypothesis": "That local ischaemic preconditioning will alter bedside physiological parameters and systemic T cell activation, cytokine production and release in otherwise healthy patients undergoing lower limb surgery under tourniquet control.", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "1. Change in perioperative systemic mean arterial pressure and heart rate\n2. Alterations in systemic T cell subsets as evaluated by flow cytometry, assessed on the systemic venous blood collected on admission, at 4 and 24 hours post reperfusion (post-operatively)\n3. Alterations in systemic cytokine levels (Interleukin-2 [IL2] and interferon, gamma [IFNg]), assessed on the systemic venous blood collected on admission, at 4 and 24 hours post reperfusion (post-operatively)\n4. Co-culture production of IL-2, IL-4, IL-10 and IFNg, assessed using the samples taken from patients 4 hours post reperfusion. Controls were taken from healthy volunteers.\n5. Co-culture alteration in T cell subsets, assessed using the samples taken from patients 4 hours post reperfusion. Controls were taken from healthy volunteers.", "secondaryOutcome": "No secondary outcome measures", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Clinical Research Ethical Committee at University College Hospital Galway. Date of approval: 15/12/2005 (ref: 48/05)"}, "externalRefs": {"doi": "10.1186/ISRCTN66931248", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "N/A"}, "trialDesign": {"studyDesign": "Prospective, single-centre, randomised controlled trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Hospital"}, "trialTypes": {"trialType": "Prevention"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2006-07-01T00:00:00.000Z", "overallEndDate": "2007-06-30T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": "Ireland"}, "trialCentres": {"trialCentre": {"@id": "94a09e60-089b-485a-8c49-d8158c3b17fa", "name": "Department of Surgery", "address": null, "city": "Galway", "state": null, "country": "Ireland", "zip": "-"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "Patients (both males and females) diagnosed with anterior cruciate ligament rupture by magnetic resonance imaging (MRI) or arthroscopy and undergoing patellar tendon graft reconstruction under tourniquet control.", "ageRange": "Adult", "gender": "Both", "targetEnrolment": "25", "totalFinalEnrolment": null, "totalTarget": "25", "exclusion": "1. Age under 18 or over 45\n2. Having smoked in the preceding 3 months\n3. Diagnosis of systemic auto-immune condition (e.g., thyroxicosis, inflammatory bowel/ coeliac disease, rheumatoid arthritis, systemic lupus erythematosus [SLE])\n4. Diabetes\n5. Concurrent medical condition\n6. Pregnancy\n7. Medications other than simple analgesics and non-steroidal anti-inflammatory drugs (NSAID)", "patientInfoSheet": null, "recruitmentStart": "2006-07-01T00:00:00.000Z", "recruitmentEnd": "2007-06-30T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Reperfusion injury", "diseaseClass1": "Surgery", "diseaseClass2": "Surgical operation and other surgical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure"}}, "interventions": {"intervention": {"description": "Consecutive patients undergoing anterior cruciate ligament repair were randomised to surgery alone or surgery preceded by three 5 minute cycles of local ischaemic preconditioning to the operative limb within 1 hour of surgery. Surgery to include 1 hour of limb ischaemia. An operative tourniquet was placed on the upper thigh and the limb was exsanguinated using a Rhys Davies air sleeve. Tourniquet pressure was set at 100 mmHg above systolic brachial blood pressure. Ischaemia was verified by arterial doppler distal to the tourniquet. Systemic venous blood was collected on admission, at 4 and 24 hours post reperfusion (post-operatively).", "interventionType": "Procedure/Surgery", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": null}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": null, "publicationStage": null, "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": null, "parties": {"funderId": "Funder18034-0", "contactId": "Contact56020_18034", "sponsorId": "Sponsor54585"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact56020_18034", "title": "Prof", "forename": "Michael", "surname": "Kerin", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Department of Surgery\nClinical Science Institute\nNewcastle Road\nNational University of Ireland Galway", "city": "Galway", "country": "Ireland", "zip": "-", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected"}, "sponsor": {"@id": "Sponsor54585", "organisation": "National University of Ireland Galway (Ireland)", "website": "http://www.nuigalway.ie/surgery", "sponsorType": "University/education", "contactDetails": {"address": "c/o Prof Michael Kerin \nUniversity College Hospital \nDepartment of Surgery \nClinical Science Institute", "city": "Galway", "country": "Ireland", "zip": "-", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected", "gridId": "grid.6142.1", "rorId": "https://ror.org/03bea9k73"}, "funder": {"@id": "Funder18034-0", "name": "National University of Ireland Galway, Department of Surgery (Ireland)", "fundRef": null}}, {"trial": {"@lastUpdated": "2008-08-21T00:00:00.000Z", "@version": "19", "isrctn": {"@dateAssigned": "2008-08-21T00:00:00.000Z", "#text": "91680999"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "Effects of omega-7 sea buckthorn oil capsule on mucous membranes of post-menopausal women [omega 7-tyrni\u00f6ljykapseleiden k\u00e4ytt\u00f6 vaihdevuosioireiden, em\u00e4ttimen ja muiden limakalvojen kuivuuden ja virtsatieoireiden hoidossa]", "scientificTitle": null, "acronym": "SBMUCOS2008", "studyHypothesis": "Increased oxidative stress to the secretion glands and the cells of mucous membranes is part of the mechanism of ageing-related dryness and inflammation in the mucous membranes of female subjects. Sea buckthorn oil supports the health of mucous membranes by supplying the body with lipid nutrients required for maintaining the structure and function and for regeneration of mucous membranes. High content of antioxidants in sea buckthorn oil will increase the antioxidant capacity and reduce lipid peroxidation of plasma. Supplementation with sea buckthorn oil will decrease the plasma C-reactive protein (CRP) level indicating reduced inflammation in the body.", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "1. Dryness, itching, pain, burning and/or inflammation in the mucosa of the genital tract at baseline, after one and four months of supplementation\n2. Vaginal PH at baseline, after one and four months of supplementation\n3. Maturation index of vaginal mucosa at baseline, after one and four months of supplementation", "secondaryOutcome": "1. Plasma total anoxidative capacity at baseline, after one and four months of supplementation\n2. Plasma isoprostane level at baseline, after one and four months of supplementation\n3. Plasma C-reactive protein level at baseline, after one and four months of supplementation", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Ethics approval received from the Ethical Committee of the Hospital District of Southwest Finland on the 5th August 2008 (ref: 7/2008 \u00a7 254)."}, "externalRefs": {"doi": "10.1186/ISRCTN91680999", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "SBRE2008"}, "trialDesign": {"studyDesign": "A randomised, double blind, placebo-controlled, single-centre parallel study", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Hospital"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2008-08-18T00:00:00.000Z", "overallEndDate": "2009-03-30T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": "Finland"}, "trialCentres": {"trialCentre": {"@id": "eb295447-cd6e-4bdd-b5eb-ac7c83d92917", "name": "Aromtech Ltd", "address": null, "city": "Turku", "state": null, "country": "Finland", "zip": "20520"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. Healthy post-menopausal females aged 55 - 70 years \n2. Dryness, itching, pain, burning and/or inflammation in the mucosa of the genital tract\n3. Problem of the genital tract mucosa shall not have clear association with severe diseases", "ageRange": "Senior", "gender": "Both", "targetEnrolment": "100", "totalFinalEnrolment": null, "totalTarget": "100", "exclusion": "1. Severe diseases and/or receiving systematic medications such as hormone replacement therapy, anti-inflammatory and cholesterol lowering drugs\n2. Diabetes\n3. Hormonal, renal, haematological, or hepatic dysfunction", "patientInfoSheet": "Not available in web format, please use the contact details below to request a patient information sheet", "recruitmentStart": "2008-08-18T00:00:00.000Z", "recruitmentEnd": "2009-03-30T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Mucosa membrane dryness", "diseaseClass1": "Urological and Genital Diseases", "diseaseClass2": "Menopausal and other perimenopausal disorders"}}, "interventions": {"intervention": {"description": "Group one: omega 7 capsules 2 x 2 capsules per day for 4 months\nGroup two: placebo capsules (medium chain triglycerides), 2 x 2 capsules per day for 4 months", "interventionType": "Drug", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": "Sea buckthorn oil"}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": null, "publicationStage": null, "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": null, "parties": {"funderId": ["Funder18056-0", "Funder18056-1"], "contactId": "Contact56043_18056", "sponsorId": "Sponsor54608"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact56043_18056", "title": "Dr", "forename": "Baoru", "surname": "Yang", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Aromtech Ltd\nTykist\u00f6katu 4 D (DIO)", "city": "Turku", "country": "Finland", "zip": "20520", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected"}, "sponsor": {"@id": "Sponsor54608", "organisation": "Turku University Central Hospital (Finland)", "website": "http://www.tyks.fi", "sponsorType": "Hospital/treatment centre", "contactDetails": {"address": "c/o Risto Erkkola\nDepartment of Gynecology\nTYKS, PL 52", "city": "Turku", "country": "Finland", "zip": "20521", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected", "gridId": "grid.410552.7", "rorId": "https://ror.org/05dbzj528"}, "funder": [{"@id": "Funder18056-0", "name": "Finnish Funding Agency for Technology and Innovation (TEKES) (Finland)", "fundRef": null}, {"@id": "Funder18056-1", "name": "Aromtech Ltd (Finland)", "fundRef": null}]}, {"trial": {"@lastUpdated": "2008-08-28T00:00:00.000Z", "@version": "24", "isrctn": {"@dateAssigned": "2008-08-21T00:00:00.000Z", "#text": "50562632"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "Evaluation of neurosurgical resection strategies in temporal lobe epilepsy", "scientificTitle": "Prospective and randomised multicentre trial investigating the pros and cons of different extent of mesial resection in surgery for mesial temporal lobe epilepsy", "acronym": null, "studyHypothesis": "There is an ongoing debate about the mesial resection extent in the surgical treatment of temporal lobe (TL) epilepsy patients and its relation to seizure freedom and neuropsychological outcome. Surgical resection strategies developed from larger resections removing up to 2/3 of the temporal lobe to more selective and smaller resection types.\n\nThe objective of this study is to assess the significance of the extent of resection of mesial structures (hippocampus and parahippocampus) to achieve seizure freedom after surgery for temporal lobe epilepsy. \n\nThe main goals of this project are to test two hypotheses:  \n1. Smaller TL resections are associated with less neuropsychological deterioration\n2. Post-operative seizure freedom is comparably good in smaller mesial resection", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "Seizure freedom at one year after surgery: defined as class I in the Engel Outcome Scale. The Engel Outcome Scale is administered post-operatively and determines the improvement/worsening after surgical intervention as follows:\n1. Engel class I: seizure-free\n2. Engel class II: almost seizure-free\n3. Engel class III: significant seizure reduction\n4. Engel class IV: no significant improvement\n\nPatients belonging to Engel class I are termed as seizure free, the remaining patients (Engel II - IV) as non-seizure free patients in the present study.\n\nSecondary analysis:\nSeizure freeness in subgroups (based on neuropathological analyses), e.g. patients with mesial temporal sclerosis.", "secondaryOutcome": "Neuropsychological testing:\nEach patient underwent comprehensive neuropsychological testing pre-operatively and 12-months post-operatively. For the comprehensive purpose of this study, various neuropsychological parameters are aggregated, resulting in scores for seven major cognitive domains:\n1. Verbal learning and memory: two parallel versions of a pre- and post-operative verbal learning test (Verbaler Lern- und Merkf\u00e4higkeitstest [VLMT]). The VLMT (German adaptation of the Rey Auditory Verbal Learning Test) requires five trials of learning and recall of a word list consisting of 15 words, free recall immediately after distraction (learning/recall of a second list in one trial) and a recall after a half-hour delay, which is followed by a recognition trial (list with original words plus distractors). \n2. Figural learning and memory was obtained using the DCS-R, a German revised version of the DCS, a design list learning test (Diagnostikum f\u00fcr Zerebralsch\u00e4digung) \n3. Language functions: \n3.1. Confrontation naming, Boston Naming Test\n3.2. Phonematic and semantic fluency\n3.3. Token Test, a subtest of the Aachener Aphasie-Test (a german test battery for aphasia) which is seen to measure verbal comprehension \n4. Attention functions:\n4.1. D2-Test, a letter cancellation test\n4.2. The c.I.T., a short test to measure cerebral insufficiency (Kurztest f\u00fcr cerebrale Insuffizienz) \n5. Psychomotor speed, mental tracking and cognitive flexibility:\n5.1. Trail Making Test A and B (TMT-A/B)\n5.2. Motoric sequences after Lurija\n5.3. Purdue Pegboard\n5.4. Finger Tapping Test\n6. Visual and spatial abilities:\n6.1. Subtest LPS-7 of the Leistungspr\u00fcfsystem (LPS), a german intelligence battery \n6.2. The Mosaic-Test, a subtest of the German version of the Wechsler Adult Intelligence Scale-Revised (HAWIE-R)\n6.3. Labyrinth test\n7. Behaviour and personality features:\n7.1. German version of the Beck Depression Inventory (BDI)\n7.2. FPZ (Fragebogen zur Pers\u00f6nlichkeit bei zerebralen Erkrankungen), an unpublished German CNS-disease related personality questionnaire\n7.3. Quality of Life Inventory in Epilepsy, 10-item version (QOLI-10) \n\nAll neuropsychological results were classified into five categories (0 = noticeably abnormal, 1 = moderately abnormal, 2 = borderline, 3 = without pathological findings, 4 = above average).", "trialWebsite": "http://www.meb.uni-bonn.de/epileptologie/sfb-tr3/", "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Ethics approval received from the Ethics Committee of the University of Bonn Medical Centre on the 2nd February 2001 (ref: 237/00)"}, "externalRefs": {"doi": "10.1186/ISRCTN50562632", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "N/A"}, "trialDesign": {"studyDesign": "Prospective, interventional, randomised multicentre study", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Hospital"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2002-10-15T00:00:00.000Z", "overallEndDate": "2008-06-30T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": "Germany"}, "trialCentres": {"trialCentre": {"@id": "8f3b2a81-69fe-403c-9970-4110b3214de7", "name": "Sigmund-Freud-Str. 25", "address": null, "city": "Bonn", "state": null, "country": "Germany", "zip": "53105"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. Patients suffering from intractable temporal lobe epilepsy \n2. Drug resistance: seizure history lasting more than two years \n3. Pre-surgical evaluation led to the recommendation of either a partial temporal lobe resection combined with amygdalohippocampectomy or a more restricted selected selective amygdalohippocampectomy (SAH)\n4. Only cases with mesial involvement were included\n5. Patients had to be at least 18 years old (either sex) and able to understand the study plan \n6. Written informed consent", "ageRange": "Adult", "lowerAgeLimit": {"@unit": "Years", "@value": "18.0"}, "gender": "Both", "targetEnrolment": "250", "totalFinalEnrolment": null, "totalTarget": "200 to 250", "exclusion": "1. Previous temporal lobe surgery\n2. Inability to do undergo neuropsychological testing because of retardation or foreign language\n3. Mesial resection restricted to uncus and amygdala\n4. No usable pre-operative magnetic resonance imaging (MRI) for volumetrical analyses\n5. Pathology not allowing for randomisation (far dorsal reaching resection necessary)", "patientInfoSheet": "Patient information can be found at:\nhttp://www.ukb.intern/42256BC8002AF3E7/vwWebPagesByID/8BE510569EF540CCC12571D40056E8CD", "recruitmentStart": "2002-10-15T00:00:00.000Z", "recruitmentEnd": "2008-06-30T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Intractable mesial temporal lobe epilepsy (MTLE)", "diseaseClass1": "Nervous System Diseases", "diseaseClass2": "Epilepsy"}}, "interventions": {"intervention": {"description": "As part of the presurgical evaluation patients underwent neuropsychological testing and MRI scanning. Healthy volunteers also underwent neuropsychological testing to serve as a control group regarding the cognitive abilities of the patients. \n\nPatients were randomised to either a short (2.5 cm of hippocampal resection) or a long (3.5 resection length) resection group. The length of resection was to be determined intra-operatively after the opening of the temporal horn by using millimetre paper from the anterior tip of the temporal horn backwards placed on the hippocampal head along its length axis. Furthermore, manual volumetry of structural MRI datasets was used to evaluate the intended resection length.\n\nPost-operatively, patients are seen for MRI-scanning, neuropsychological testing and medical consultation 3, 6 and 12 months after surgery.", "interventionType": "Other", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": null}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": "2004 Results article in http://www.ncbi.nlm.nih.gov/pubmed/14742620 Cortical damage results ():\n2004 Results article in http://www.ncbi.nlm.nih.gov/pubmed/15230706 Neuropsychological outcome results ():\n2004 Results article in http://www.ncbi.nlm.nih.gov/pubmed/15270763 One year follow-up results ():\n2005 Results article in http://www.ncbi.nlm.nih.gov/pubmed/16014650 Children and aduly comparative study results ():\n2007 Results article in http://www.ncbi.nlm.nih.gov/pubmed/17131114 MRI volumetry results ():\n2007 Other publications in http://www.ncbi.nlm.nih.gov/pubmed/17728360 Research ():\n2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/17941848 Memory and non-memory function results ():\n2008 Other publications in http://www.ncbi.nlm.nih.gov/pubmed/17955042 Comment ():\n2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18155965 Cognitive rehabilitation results ():\n2008 Other publications in http://www.ncbi.nlm.nih.gov/pubmed/18410360 Review ():\n2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18425622 Prospective study results ():", "publicationStage": "Results", "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": {"output": [{"@id": "e9c00fa2-5f7d-4437-810c-85479c1dbb63", "@outputType": "resultsarticle", "@artefactType": "ExternalLink", "@dateCreated": "2004-02-01T00:00:00.000Z", "@dateUploaded": "", "@peerReviewed": "true", "@patientFacing": "false", "@createdBy": "Data migration", "externalLink": {"@url": "http://www.ncbi.nlm.nih.gov/pubmed/14742620"}, "description": "Cortical damage results ():", "productionNotes": null}, {"@id": "291b6abf-2081-455c-a507-c4560e799360", "@outputType": "resultsarticle", "@artefactType": "ExternalLink", "@dateCreated": "2004-07-01T00:00:00.000Z", "@dateUploaded": "", "@peerReviewed": "true", "@patientFacing": "false", "@createdBy": "Data migration", "externalLink": {"@url": "http://www.ncbi.nlm.nih.gov/pubmed/15230706"}, "description": "Neuropsychological outcome results ():", "productionNotes": null}, {"@id": "33e34297-a1f8-496e-85a9-31fbd94b8358", "@outputType": "resultsarticle", "@artefactType": "ExternalLink", "@dateCreated": "2004-08-01T00:00:00.000Z", "@dateUploaded": "", "@peerReviewed": "true", "@patientFacing": "false", "@createdBy": "Data migration", "externalLink": {"@url": "http://www.ncbi.nlm.nih.gov/pubmed/15270763"}, "description": "One year follow-up results ():", "productionNotes": null}, {"@id": "fa9341db-20a8-4012-acc6-636a65c04cc2", "@outputType": "resultsarticle", "@artefactType": "ExternalLink", "@dateCreated": "2005-12-01T00:00:00.000Z", "@dateUploaded": "", "@peerReviewed": "true", "@patientFacing": "false", "@createdBy": "Data migration", "externalLink": {"@url": "http://www.ncbi.nlm.nih.gov/pubmed/16014650"}, "description": "Children and aduly comparative study results ():", "productionNotes": null}, {"@id": "5c31c9d4-5d01-4aa4-bf97-2731e3e3c492", "@outputType": "resultsarticle", "@artefactType": "ExternalLink", "@dateCreated": "2007-03-01T00:00:00.000Z", "@dateUploaded": "", "@peerReviewed": "true", "@patientFacing": "false", "@createdBy": "Data migration", "externalLink": {"@url": "http://www.ncbi.nlm.nih.gov/pubmed/17131114"}, "description": "MRI volumetry results ():", "productionNotes": null}, {"@id": "3eec45e8-c691-4403-a4f9-f4a3034e2aa8", "@outputType": "otherpublications", "@artefactType": "ExternalLink", "@dateCreated": "2007-12-01T00:00:00.000Z", "@dateUploaded": "", "@peerReviewed": "true", "@patientFacing": "false", "@createdBy": "Data migration", "externalLink": {"@url": "http://www.ncbi.nlm.nih.gov/pubmed/17728360"}, "description": "Research ():", "productionNotes": null}, {"@id": "a88dfc2b-efda-44aa-9542-818d7d097d10", "@outputType": "resultsarticle", "@artefactType": "ExternalLink", "@dateCreated": "2008-01-01T00:00:00.000Z", "@dateUploaded": "", "@peerReviewed": "true", "@patientFacing": "false", "@createdBy": "Data migration", "externalLink": {"@url": "http://www.ncbi.nlm.nih.gov/pubmed/17941848"}, "description": "Memory and non-memory function results ():", "productionNotes": null}, {"@id": "be10a298-650a-4227-a153-61896c1c6b2b", "@outputType": "otherpublications", "@artefactType": "ExternalLink", "@dateCreated": "2008-02-01T00:00:00.000Z", "@dateUploaded": "", "@peerReviewed": "true", "@patientFacing": "false", "@createdBy": "Data migration", "externalLink": {"@url": "http://www.ncbi.nlm.nih.gov/pubmed/17955042"}, "description": "Comment ():", "productionNotes": null}, {"@id": "0acb023d-8bf8-4028-8925-f0b622b04fa7", "@outputType": "resultsarticle", "@artefactType": "ExternalLink", "@dateCreated": "2008-04-01T00:00:00.000Z", "@dateUploaded": "", "@peerReviewed": "true", "@patientFacing": "false", "@createdBy": "Data migration", "externalLink": {"@url": "http://www.ncbi.nlm.nih.gov/pubmed/18155965"}, "description": "Cognitive rehabilitation results ():", "productionNotes": null}, {"@id": "9f8edb4a-ff70-4c04-9ed7-57806b19edfc", "@outputType": "otherpublications", "@artefactType": "ExternalLink", "@dateCreated": "2008-08-01T00:00:00.000Z", "@dateUploaded": "", "@peerReviewed": "true", "@patientFacing": "false", "@createdBy": "Data migration", "externalLink": {"@url": "http://www.ncbi.nlm.nih.gov/pubmed/18410360"}, "description": "Review ():", "productionNotes": null}, {"@id": "50785382-5fbb-42ac-b189-216ee36e174e", "@outputType": "resultsarticle", "@artefactType": "ExternalLink", "@dateCreated": "2008-08-01T00:00:00.000Z", "@dateUploaded": "", "@peerReviewed": "true", "@patientFacing": "false", "@createdBy": "Data migration", "externalLink": {"@url": "http://www.ncbi.nlm.nih.gov/pubmed/18425622"}, "description": "Prospective study results ():", "productionNotes": null}]}, "parties": {"funderId": "Funder18038-0", "contactId": "Contact56024_18038", "sponsorId": "Sponsor54589"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact56024_18038", "title": "Prof", "forename": "Johannes", "surname": "Schramm", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Sigmund-Freud-Str. 25", "city": "Bonn", "country": "Germany", "zip": "53105", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected"}, "sponsor": {"@id": "Sponsor54589", "organisation": "German Research Council (Deutsche Forschungsgemeinschaft [DFG]) (Germany)", "website": "http://www.dfg.de/", "sponsorType": "Research council", "contactDetails": {"address": "Kennedyallee 40", "city": "Bonn", "country": "Germany", "zip": "53175", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected", "gridId": "grid.424150.6", "rorId": "https://ror.org/018mejw64"}, "funder": {"@id": "Funder18038-0", "name": "German Research Council (Deutsche Forschungsgemeinschaft [DFG]) (Germany)", "fundRef": null}}, {"trial": {"@lastUpdated": "2008-08-19T00:00:00.000Z", "@version": "20", "isrctn": {"@dateAssigned": "2008-08-19T00:00:00.000Z", "#text": "66488490"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "Diagnostic accuracy of recently proposed criteria for inflammatory back pain (IBP) in suspected ankylosing spondylitis (AS) and early axial spondyloarthritis (axial SpA)", "scientificTitle": null, "acronym": "DIVERS", "studyHypothesis": "Sensitivity of at least 70% and specificity of at least 70% for the previously proposed criteria for inflammatory back pain (IBP).", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "Sensitivity, specificity and positive likelihood-ratio (LR+) if two out of four parameters of IBP are present.", "secondaryOutcome": "Sensitivity, specificity and positive likelihood-ratio (LR+) if three or four out of four parameters of IBP are present.", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Ethics approval received from the Ethics Committee of Charit\u00e9 - University Medicine Berlin on the 8th July 2008 (ref: EA4/058/08)."}, "externalRefs": {"doi": "10.1186/ISRCTN66488490", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "N/A"}, "trialDesign": {"studyDesign": "Observational diagnostic accuracy study", "primaryStudyDesign": "Observational", "secondaryStudyDesign": "Non randomised controlled trial", "trialSettings": {"trialSetting": "Hospital"}, "trialTypes": {"trialType": "Diagnostic"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2008-09-01T00:00:00.000Z", "overallEndDate": "2010-08-01T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": "Germany"}, "trialCentres": {"trialCentre": {"@id": "edd69452-fa3f-4144-9bd6-4f67fc7c4bc6", "name": "Hindenburgdamm 30", "address": null, "city": "Berlin", "state": null, "country": "Germany", "zip": "12200"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "Patients (aged greater tha 18 years, either sex) with chronic back pain (greater than 3 months) of unknown origin:\n1. Referred to the rheumatologist because of suspected AS/axial SpA\n2. Seen by primary care physicians/orthopaedists, who agree to subsequently be referred to the rheumatologists", "ageRange": "Adult", "lowerAgeLimit": {"@unit": "Years", "@value": "18.0"}, "gender": "Both", "targetEnrolment": "550", "totalFinalEnrolment": null, "totalTarget": "550", "exclusion": "Patients with a definite diagnosis (cause) related to their back pain.", "patientInfoSheet": "Not available in web format, please use the contact details below to request a patient information sheet", "recruitmentStart": "2008-09-01T00:00:00.000Z", "recruitmentEnd": "2010-08-01T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Ankylosing spondylitis (AS), early axial spondyloarthritis (axial SpA)", "diseaseClass1": "Musculoskeletal Diseases", "diseaseClass2": "Ankylosing spondylitis"}}, "interventions": {"intervention": {"description": "Experimental group (no medical intervention): \nThe diagnostic accuracy of IBP will be investigated in four private practices and two hospitals by assessing IBP by an independent and blinded observer (rheumatologist in each setting) in patients with undiagnosed chronic back pain who are referred because of suspected SpA. \n\nIBP will also be assessed by primary care physicians or orthopaedists in patients with chronic back pain of unclear origin, and also self-assessed by the patient prior to referral to the Rheumatology Department at Charit\u00e9 CBF for further work-up. \n\nThe total duration of the trial is two years. There is no follow-up.", "interventionType": "Other", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": null}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": null, "publicationStage": null, "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": null, "parties": {"funderId": "Funder17961-0", "contactId": "Contact55944_17961", "sponsorId": "Sponsor54508"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact55944_17961", "title": "Dr", "forename": "Martin", "surname": "Rudwaleit", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Hindenburgdamm 30", "city": "Berlin", "country": "Germany", "zip": "12200", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+49 (0)30 8445 4547"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "martin.rudwaleit@charite.de"}}, "privacy": "Public"}, "sponsor": {"@id": "Sponsor54508", "organisation": "Charite - University Medicine Berlin (Charite - Universitatsmedizin Berlin) (Germany)", "website": "http://www.charite.de/", "sponsorType": "University/education", "contactDetails": {"address": "c/o Dr. Krukenkamp\nCharit\u00e9platz 1\nVirchowweg 1", "city": "Berlin", "country": "Germany", "zip": "10117", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "c.krukenkamp@charite.de"}}, "privacy": "Public", "gridId": "grid.6363.0", "rorId": "https://ror.org/001w7jn25"}, "funder": {"@id": "Funder17961-0", "name": "German Research Council (Deutsche Forschungsgemeinschaft [DFG]) (Germany)", "fundRef": null}}, {"trial": {"@lastUpdated": "2008-08-19T00:00:00.000Z", "@version": "19", "isrctn": {"@dateAssigned": "2008-08-19T00:00:00.000Z", "#text": "59953554"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "Sleep in addiction care", "scientificTitle": "Sleep in substance use disordered patients in addiction care", "acronym": null, "studyHypothesis": "Sleep will improve by a cognitive behavioural therapeutic intervention in patients admitted to an addiction care clinic that show problems in initiating and maintaining sleep in the subacute detoxification phase.", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "1. Subjective sleep efficiency as measured by a sleep log. The sleep log will be recorded by the participants during the 6-week treatment period.  The sleep log has several outcome measures: time in bed (TIB), total sleep time (TST), sleep onset latency (SOL), sleep efficiency (SE), wake after sleep onset (WASO) and number of awakenings (AWAK). \n2. Sleep quality measured by the Pittsburgh Sleep Quality Index (PSQI) at timepoints T0, T1, T2, T3 and T4\n\nTimepoints:\nT0 = Day of clinical intake\nT1 = 4th week of treatment\nT2 = 6th week of treatment, before randomisation\nT3 = At the end of sleep training\nT4 = 2 months after the sleep training", "secondaryOutcome": "Vigilance during the day as measured by the Sustained Attention to Response Task  (SART) at T1, T2, T3 and T4. SART will be carried out once a week during the period between T2 and T3. \n\nTertiary outcome measures:\n1. Severity of dependency on drugs/ alcohol measured by the Composite International Diagnostic Interview - Substance Abuse Module (CIDI-SAM) at T0 and T4\n2. Addiction measured using the addiction scales of the Addiction Severity Index (ASI) at T0 and T4\n3. Presence of any psychiatric disorder assessed by the Mini International Neuropsychiatric Interview (MINI)\n4. Presence of sleep disorders assessed by the SLEEP-50 at T0, T1, T2, T3 and T4\n5. Symptom assessment by the Symptom Check List (SCL-90) at T0, T1, T2, T3 and T4\n6. Quality of life assessed by the EQ-5D at T0, T1, T2, T3 and T4\n7. Actigraphy at T1, T2, T3 and T4. The actigraph registers movements of the right arm in right handed subjects for 48 hours or more.  \n8. Go/No-Go response-inhibition task (T1)\n\nTimepoints: \nT0 = Day of clinical intake \nT1 = 4th week of treatment \nT2 = 6th week of treatment, before randomisation \nT3 = At the end of sleep training \nT4 = 2 months after the sleep training", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "To be submitted in July 2008 (as of 21/05/2008)"}, "externalRefs": {"doi": "10.1186/ISRCTN59953554", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "3.000.014"}, "trialDesign": {"studyDesign": "Randomised, open clinical trial, in two addiction care centres.", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Other"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2008-09-01T00:00:00.000Z", "overallEndDate": "2012-09-01T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": "Netherlands"}, "trialCentres": {"trialCentre": {"@id": "877a1813-ff9b-4261-a457-bb759a3b3a52", "name": "Wanssumseweg 12", "address": null, "city": "Oostrum", "state": null, "country": "Netherlands", "zip": "5807 EA"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. Both males and females, age limit: 65 \n2. Patients who are admitted for at least 5 weeks to an addiction clinic \n3. Those who are \"clean\" i.e. addicted patients that do not use drugs/alcohol anymore\n4. Score of 5 or higher in the Pittsburgh Sleep Quality Index (PSQI)", "ageRange": "Other", "gender": "Both", "targetEnrolment": "90", "totalFinalEnrolment": null, "totalTarget": "90", "exclusion": "1. Patients with sleep problems other than problems of initiating or maintaining sleep\n2. Diagnosis of severe depression, attention deficit hyperactivity disorder (ADHD) \n3. Patients who have a primary benzodiazepine addiction", "patientInfoSheet": "Not available in web format, please use the contact details below to request a patient information sheet", "recruitmentStart": "2008-09-01T00:00:00.000Z", "recruitmentEnd": "2012-09-01T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Insomnia in patients with substance use disorder", "diseaseClass1": "Mental and Behavioural Disorders", "diseaseClass2": "Nonorganic sleep disorders"}}, "interventions": {"intervention": {"description": "The study is a randomised controlled trial in a cohort of patients referred to addiction care (2 addiction clinics). The duration of the study for the participating patients is 15 weeks, plus a follow up at 2 months after completion of the intervention. In order to gather a large study population, the research takes 1.5 years. \n\nInitially, 600 eligible patients will be enrolled in the study and will undergo various baseline assessments (T0; see primary and secondary outcome measures) and start standard treatment for their sleep problems. During the 4th week in treatment (T1), those who still continue with the treatment will be asked to undergo additional assessments (see primary and secondary outcome measures). In the 5th week of treatment, the patients who show problems in initiating or maintaining sleep at T1 are selected for the next stage of the study. The selected patients (90 patients) are randomly assigned to one of the two treatment groups. \n\nThe participants allocated to the intervention group receive sleep training, consisting of sleep hygiene, sleep education and cognitive behavioural therapy. Cognitive behavioural therapy will be given in 6 sessions of 2 hours, as developed by I. Verbeek (1999; http://www.ncbi.nlm.nih.gov/pubmed/10616231). \n\nThe control group receives standard care (and no sleep training). This means a daily programme of cognitive therapy, group meetings, creative therapy, movement therapy, coffee breaks etc., the regular treatment for a normal addiction clinic. \n\nThe total duration of follow-up per individual is 2 months. On completion of this follow-up assessment, the participants in the control group will also receive the interventions if they wish.", "interventionType": "Other", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": null}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": null, "publicationStage": null, "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": null, "parties": {"funderId": "Funder17824-0", "contactId": "Contact55806_17824", "sponsorId": "Sponsor54371"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact55806_17824", "title": "Miss", "forename": "Ellis", "surname": "Magnee", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Wanssumseweg 12", "city": "Oostrum", "country": "Netherlands", "zip": "5807 EA", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+31 478 527815"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "emagnee@ggznml.nl"}}, "privacy": "Public"}, "sponsor": {"@id": "Sponsor54371", "organisation": "Mental Health Group in North and Middle Limburg (GGZ Noord- en Midden-Limburg) (Netherlands)", "website": "http://www.ggznml.nl", "sponsorType": "Hospital/treatment centre", "contactDetails": {"address": "Stationsweg 46", "city": "Venray", "country": "Netherlands", "zip": "5803 AC", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected", "gridId": "grid.491220.c", "rorId": "https://ror.org/00b3xjw51"}, "funder": {"@id": "Funder17824-0", "name": "Mental Health Group in North and Middle Limburg (GGZ Noord- en Midden-Limburg) (Netherlands)", "fundRef": null}}, {"trial": {"@lastUpdated": "2008-09-02T00:00:00.000Z", "@version": "22", "isrctn": {"@dateAssigned": "2008-03-31T00:00:00.000Z", "#text": "54112208"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "A study to assess whether complications of anti-coagulation treatment with vitamin K antagonists will diminish by supplementation of vitamin K", "scientificTitle": null, "acronym": "VIKS-2B", "studyHypothesis": "The bleeding complications of treatment with vitamin K antagonists will be less in number and severity when supplementation with vitamin K is given.", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "1. Number of (bleeding) complications\n2. Severity of (bleeding) complications\n\nDuration of follow-up: start of intervention to two years after the end of recruitment period.", "secondaryOutcome": "How do polymorphisms of the enzymes vitamin K epoxide reductase complex subunit 1 (VKORC1) and cytochrome P450 2C9 (CYP2C9) influence the effect of vitamin K supplementation?\n\nDuration of follow-up: start of intervention to two years after the end of recruitment period.", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Ethics approval received from the Medical Ethics Committee of Leiden University Medical Center on the 4th March 2008."}, "externalRefs": {"doi": "10.1186/ISRCTN54112208", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "P07.243"}, "trialDesign": {"studyDesign": "Randomised double-blind placebo-controlled single-centre trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Hospital"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2009-04-01T00:00:00.000Z", "overallEndDate": "2012-03-31T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": "Netherlands"}, "trialCentres": {"trialCentre": {"@id": "4dbff433-578d-445a-a175-eb8ac9ceff52", "name": "Leiden University Medical Center", "address": null, "city": "Leiden", "state": null, "country": "Netherlands", "zip": "2300 RC"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. Starting treatment with vitamin K antagonists less then four weeks before inclusion\n2. Treatment with vitamin K antagonists for a minimal period of six months, with the therapeutic range of International normalised ratio (INR) between 2.5 and 3.5\n3. Age between 18 and 85 years, either sex\n4. Measurement of the INR by the Thrombosis Service Leiden \n5. Informed consent", "ageRange": "Adult", "lowerAgeLimit": {"@unit": "Years", "@value": "18.0"}, "upperAgeLimit": {"@unit": "Years", "@value": "85.0"}, "gender": "Both", "targetEnrolment": "2200", "totalFinalEnrolment": null, "totalTarget": "2200 patients", "exclusion": "1. Treatment for liver failure\n2. Dialysis, both peritoneal and haemodialysys\n3. Pregnancy, or wish to get pregnant; lactational period\n4. Known to have a chronic condition with a life expectancy of less than six months\n5. An expected interruption of treatment with oral anti-coagulants for one week or longer\n6. Participation in the self-management protocol", "patientInfoSheet": "Not available in web format, please use the contact details below to request a patient information sheet", "recruitmentStart": "2009-04-01T00:00:00.000Z", "recruitmentEnd": "2012-03-31T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Anti-coagulation treatment", "diseaseClass1": "Haematological Disorders", "diseaseClass2": "Other coagulation defects"}}, "interventions": {"intervention": {"description": "The participants will be randomly allocated to the following two groups in equal numbers: \nTreatment group: vitamin K, 1 capsule a day (1 dd) in the dose found in VIKS-2A (see http://www.controlled-trials.com/ISRCTN37109430: A study to find the optimal dose for vitamin K supplementation in patients being treated with vitamin K antagonists to create an anti-coagulation effect)\nControl group: placebo 1 dd \n\nThe duration of the intervention is flexible; this depends on the rate of recruitment. We aim to achieve the target number of recruitment in one year, and then the treatment will continue for two years. Therefore, in this case, the first and last participants will receive the intervention for three and two years, respectively.", "interventionType": "Supplement", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": "Vitamin K supplementation"}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": null, "publicationStage": null, "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": null, "parties": {"funderId": "Funder17613-0", "contactId": "Contact55583_17613", "sponsorId": "Sponsor54159"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact55583_17613", "title": "Dr", "forename": "FJM", "surname": "van der Meer", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Leiden University Medical Center \nDepartment of Thrombosis and Heamostasis \nP.O. Box 9600", "city": "Leiden", "country": "Netherlands", "zip": "2300 RC", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+31 (0)71 526 3901"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "f.j.m.van_der_meer@lumc.nl"}}, "privacy": "Public"}, "sponsor": {"@id": "Sponsor54159", "organisation": "Netherlands Heart Foundation (Nederlandse Hartstichting) (The Netherlands)", "website": "http://www.hartstichting.nl", "sponsorType": "Charity", "contactDetails": {"address": "P.O. Box 300", "city": "The Hague", "country": "Netherlands", "zip": "2501 CH", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+31 (0)70 315 5555"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "info@hartstichting.nl"}}, "privacy": "Public", "gridId": "grid.453051.6", "rorId": "https://ror.org/05nxhgm70"}, "funder": {"@id": "Funder17613-0", "name": "Netherlands Heart Foundation (Nederlandse Hartstichting) (The Netherlands)", "fundRef": null}}, {"trial": {"@lastUpdated": "2008-09-02T00:00:00.000Z", "@version": "22", "isrctn": {"@dateAssigned": "2007-12-19T00:00:00.000Z", "#text": "03911524"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "PRE-emptive therapy of acute Graft Versus Host Disease according to specific proteomic patterns after allogeneic haematopoietic stem cell transplantation", "scientificTitle": null, "acronym": "PRE-GVHD", "studyHypothesis": "Reduction of both severity and/or incidence of acute graft versus host disease (aGvHD) greater than grade II in the pre-emptively treated population as compared to placebo treated group.", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "Occurrence of aGvHD (greater than grade II) in placebo versus treatment group, between time of randomisation and 100 days after HSCT.", "secondaryOutcome": "1. Increased overall survival in treatment group (day +365)\n2. Reduction of severity of aGvHD (day +120)\n\nScientific endpoints (measured at end of study: three years): \n1. Differentiation of aGvHD grade II to IV according to polypeptide markers\n2. Organ specific aGvHD pattern\n3. Generation of proteomic patterns for steroid resistant GvHD (will be acquired during the study)\n4. Normalisation of aGvHD proteome pattern in response to treatment", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "The collection/analysis of residual material as used in this study has already been approved by the Ethics Committee of the Hannover Medical School in November 2002 and November 2005 (ref: 3097)."}, "externalRefs": {"doi": "10.1186/ISRCTN03911524", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "497Ganser_Weissinger"}, "trialDesign": {"studyDesign": "Prospective, double-blinded randomised placebo-controlled multi-centre study", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Hospital"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2008-01-01T00:00:00.000Z", "overallEndDate": "2010-12-31T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": "Germany"}, "trialCentres": {"trialCentre": {"@id": "034b0afa-e213-4f55-93bd-47576d39fd78", "name": "Hannover Medical School", "address": null, "city": "Hannover", "state": null, "country": "Germany", "zip": "30625"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. All patients greater than 18 years after allogeneic haematopoietic stem cell transplantation (allo-HSCT)\n2. Informed consent", "ageRange": "Adult", "lowerAgeLimit": {"@unit": "Years", "@value": "18.0"}, "gender": "Both", "targetEnrolment": "580", "totalFinalEnrolment": null, "totalTarget": "580 screening, 260 elegible, 90 randomisation", "exclusion": "1. Severe infections at the time of aGvHD-pattern positivity\n2. No informed consent", "patientInfoSheet": null, "recruitmentStart": "2008-01-01T00:00:00.000Z", "recruitmentEnd": "2010-12-31T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Graft versus host disease after allogeneic haematopoietic stem cell transplantation", "diseaseClass1": "Injury, Occupational Diseases, Poisoning", "diseaseClass2": "Failure and rejection of transplanted organs and tissues"}}, "interventions": {"intervention": {"description": "Experimental intervention: \nPre-emptive immunosuppressive treatment (daily 2 mg methylprednisone/kg body weight [BW]) immediately at occurrence of an aGvHD grade II-specific proteome pattern.\n\nControl intervention: \nPlacebo immediately at occurrence of a positive aGvHD grade II-specific proteome pattern.\n\nDuration of intervention per patient: \n2 mg/kg/kg BW steroids for five days if no clinical symptoms occur (taper steroids according to taper protocol), or until severity increases (clinical symptoms of aGvHD grade II; increase of symptoms in severity after three days, no change for seven days, intermediate response for 14 days). \n\nIn case of clinical aGvHD (greater than grade II) unblinding is necessary: the placebo group will start standard treatment with 2 mg methylprednisone/kg BW, treatment group will be open for second line therapy (e.g. 2 mg methylprednisone/kg BW and Antithymocyte Globulin (ATG) or clinic specific second line therapy).\n\nExperimental and/or control off label or on label in Germany: not applicable.\nFollow-up per patient: 100 days after HSCT.", "interventionType": "Drug", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": "Methylprednisone"}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": null, "publicationStage": null, "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": null, "parties": {"funderId": "Funder16650-0", "contactId": "Contact54608_16650", "sponsorId": "Sponsor53163"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact54608_16650", "title": "Prof", "forename": "Eva M.", "surname": "Mischak-Weissingger", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Hannover Medical School\nDepartment of Haematology, Haemostasis, Oncology and Stem Cell Transplantation\nCarl-Neuberg-Str. 1", "city": "Hannover", "country": "Germany", "zip": "30625", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+49 (0)511 532 9518"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "mischak-weissinger.eva@mh-hannover.de"}}, "privacy": "Public"}, "sponsor": {"@id": "Sponsor53163", "organisation": "Hannover Medical School (Germany)", "website": "http://www.mh-hannover.de/index.php?id=2&L=1", "sponsorType": "Hospital/treatment centre", "contactDetails": {"address": "c/o Prof. Dr. med. Arnold Ganser\nDirector\nDepartment of Haematology, Haemostasis, Oncology and Stem Cell Transplantation\nCarl-Neuberg-Str. 1", "city": "Hannover", "country": "Germany", "zip": "30625", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+49 (0)511 532 3021"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "Ganser.Arnold@mh-hannover.de"}}, "privacy": "Public", "gridId": "grid.10423.34", "rorId": "https://ror.org/00f2yqf98"}, "funder": {"@id": "Funder16650-0", "name": "German Federal Ministry of Education and Research (Bundesministerium F\u00fcr Bildung und Forschung [BMBF]) (Germany) (ref: 497Gasnser_Weissinger)", "fundRef": null}}, {"trial": {"@lastUpdated": "2008-08-22T00:00:00.000Z", "@version": "18", "isrctn": {"@dateAssigned": "2007-09-28T00:00:00.000Z", "#text": "79824117"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "Effects of shoe type on ankle sprain recovery", "scientificTitle": null, "acronym": null, "studyHypothesis": "Does the type of shoe worn in the early period early after ankle sprain influence recovery?", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "Self-assessment of ankle function via questionnaire", "secondaryOutcome": "Not provided at time of registration", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Not provided at time of registration"}, "externalRefs": {"doi": "10.1186/ISRCTN79824117", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "N0013180317"}, "trialDesign": {"studyDesign": "Randomised controlled trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Hospital"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2006-05-18T00:00:00.000Z", "overallEndDate": "2007-12-31T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": ["England", "United Kingdom"]}, "trialCentres": {"trialCentre": {"@id": "e6be3f1f-a538-4855-a159-8870d69c6f3e", "name": "Centre for Applied Biomedical Research (CABR)", "address": null, "city": "London", "state": null, "country": "United Kingdom", "zip": "SE1 9RT"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. 2 groups of 20 individuals contacted within 3 days of presenting to Guy's Minor Injury Unit with sprained ankle\n2. Aged 18-60 years old", "ageRange": "Adult", "lowerAgeLimit": {"@unit": "Years", "@value": "18.0"}, "upperAgeLimit": {"@unit": "Years", "@value": "60.0"}, "gender": "Not Specified", "targetEnrolment": "40", "totalFinalEnrolment": null, "totalTarget": "40", "exclusion": "1. Subjects with abnormal sensory problems in the thigh and lower leg, subjects with any neurological problem affecting their balance and subjects will be excluded. \n2. Patients who have had musculoskeletal or neurological problem affecting their legs or low back which required medical attention in the last 6 months will also be excluded.", "patientInfoSheet": null, "recruitmentStart": "2006-05-18T00:00:00.000Z", "recruitmentEnd": "2007-12-31T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Injury, Occupational Diseases, Poisoning: Ankle sprain", "diseaseClass1": "Injury, Occupational Diseases, Poisoning", "diseaseClass2": "Ankle sprain"}}, "interventions": {"intervention": {"description": "A randomised controlled trial involving participants being assigned control shoe (rocker) or experimental shoe (MDT). \nMeasurements will be taken before and after to assess the difference. Subjects will be given instructions and diary for 1 week before returning for testing.", "interventionType": "Other", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": null}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": null, "publicationStage": null, "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": null, "parties": {"funderId": "Funder17023-0", "contactId": "Contact54984_17023", "sponsorId": "Sponsor53549"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact54984_17023", "title": "Dr", "forename": "Matt", "surname": "Morrissey", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Centre for Applied Biomedical Research (CABR)\nKings College London\nGuys Campus\nSt Thomas Street", "city": "London", "country": "United Kingdom", "zip": "SE1 9RT", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+44 02078486678"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "matt.morrissey@kcl.ac.uk"}}, "privacy": "Public"}, "sponsor": {"@id": "Sponsor53549", "organisation": "Record Provided by the NHSTCT Register - 2007 Update - Department of Health", "website": "http://www.dh.gov.uk/Home/fs/en", "sponsorType": "Government", "contactDetails": {"address": "The Department of Health, Richmond House, 79 Whitehall", "city": "London", "country": "United Kingdom", "zip": "SW1A 2NL", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+44 (0)20 7307 2622"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "dhmail@doh.gsi.org.uk"}}, "privacy": "Public"}, "funder": {"@id": "Funder17023-0", "name": "Guy's and St. Thomas' NHS Foundation Trust (UK), Own account NHS R&D Support Funding", "fundRef": null}}, {"trial": {"@lastUpdated": "2008-09-05T00:00:00.000Z", "@version": "23", "isrctn": {"@dateAssigned": "2007-09-28T00:00:00.000Z", "#text": "17706253"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "A double blind randomised controlled trial comparing porcine dermal collagen patch saphenoplasty with conventional saphenofemoral ligation to prevent recurrent saphenofemoral incompetence", "scientificTitle": null, "acronym": null, "studyHypothesis": "To compare the use of porcine dermal collagen patch saphenoplasty with standard saphenofemoral flush ligation in primary and recurrent varicose vein surgery. Post-operative subjective and objective measures of the presence and severity of varicosity recurrence shall be compared.", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "The study shall be designed to demonstrate a 50% reduction in the clinical presence of recurrence at 5 years. Therefore, the null hypothesis is that no statistically significant difference exists in the clinically assessed recurrence rates at 5 years between PermacolTM  and standard surgical groups.", "secondaryOutcome": "1. Annual clinical recurrence rates\n2. Radiographically demonstrable recurrence rates at 1 year and 5 years\n3. Visual analogue pain scores\n4. SF36 and EUROQOL questionnaire scores\n5. Local complication rate: fistula, haematoma, groin wound infection\n6. Serious adverse event rates", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Not provided at time of registration"}, "externalRefs": {"doi": "10.1186/ISRCTN17706253", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "N0672184853"}, "trialDesign": {"studyDesign": "Double blind (patient and assessor blind) randomised controlled Study", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Hospital"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": "Stopped", "reasonAbandoned": "Never started.", "overallStartDate": "2006-07-10T00:00:00.000Z", "overallEndDate": "2011-07-09T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": ["England", "United Kingdom"]}, "trialCentres": {"trialCentre": {"@id": "1ef63a92-faf8-4897-a072-facf6294646f", "name": "Northern Lincolnshire & Goole Hospitals NHS Trust", "address": null, "city": "Grimsby", "state": null, "country": "United Kingdom", "zip": "DN33 2BA"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "All patients with primary or recurrent, uni or bilateral varicose veins with clinical evidence of saphenofemoral incompetence and who fulfill the following criteria will be considered eligible for the trial:\n1. Clinically fit for general anaesthesia\n2. Have the need for saphenofemoral junction ligation during varicose vein surgery\n3. Should have the legal age and ability to provide informed consent\n4. Have no known allergies to the products being tested\n5. Agree to their GP being informed of their participation", "ageRange": "Not Specified", "gender": "Not Specified", "targetEnrolment": "80", "totalFinalEnrolment": null, "totalTarget": "To achieve adequate compliance with the protocol and follow up it is anticipated that 80 patients in total will be recruited. 40 patients will be randomly allocated into each arm of the study.", "exclusion": "1. Patients not able or unwilling to provide informed consent\n2. Undergoing formal anti-coagulation for previous thromboembolic phenomena\n3. Known allergies to the products being investigated\n4. Do not agree to their GP being informed of their participation", "patientInfoSheet": null, "recruitmentStart": "2006-07-10T00:00:00.000Z", "recruitmentEnd": "2011-07-09T00:00:00.000Z", "recruitmentStatusOverride": "Stopped"}, "conditions": {"condition": {"description": "Cardiovascular: Varicose veins", "diseaseClass1": "Circulatory System", "diseaseClass2": "Varicose veins"}}, "interventions": {"intervention": {"description": "Randomisation and Blinding:\nRandomisation will be computer generated using the Statistical Package for Social Sciences (SPSS) and   shall occur only once informed consent has been obtained and following induction of general anaesthesia.  Each treatment, either porcine dermal collagen patch  or   saphenofemoral junction ligation alone will be documented on paper and placed in numbered envelopes and sealed.  The envelopes will then be opened in numerical order.  The surgeon will not know which mesh is to be used until the time the envelope is opened.  The patient and post-operative assessor will not know which mesh has been used in their operation.  \nA master list of the randomisation will be kept in the Research and Development Department and be used solely for code breaking purposes should any adverse events occur.  Adverse events will be reported by study documentation and to the Trust Risk Management department in line with Trust procedure.\n\nSurgery:\nAll surgery shall be performed under general anaesthesia. Patients shall receive deep vein thrombosis (DVT) prophylaxis where clinically appropriate and according to local protocols. Surgery shall be performed by the Principle and Co-Investigators using established standard techniques of saphenofemoral junction ligation and varicose vein surgery. Briefly, following dissection to demarcate the saphenofemoral junction all tributaries shall be ligated. Disconnection of the saphenofemoral junction shall then be followed by flush suture ligation using a polygalactin suture with stripping of the saphenous vein to below the knee. In the presence of bifid long saphenous veins each shall be disconnected and suture ligated separately. If randomized to PermacolTM group a small patch of porcine dermal collagen shall be sutured over the obliterated saphenofemoral junction prior to closure of the fascial layers. If randomized to the standard technique alone this step shall be omitted. Standardized wound closure and dressing shall be performed. Discharge shall be with standard simple analgesia after adequate voiding of urine and ambulation. It is anticipated that this shall be the same day for most patients. Patients shall receive instructions to remove their dressings on the third post-operative day and thereafter to wear a Class II compression stocking for 6 weeks.\n\nAssessments:\nAt 1 and 5 years follow up, a Research Nurse assessor, blinded to the technique used, shall administer pain visual analogue scales and objective, validated measures of QoL; namely the Short Form 36TM (SF36TM) and EUROQOLTM questionnaires. Patients shall be clinically examined for evidence of recurrent varicose veins and an objective measure of severity recorded using the venous disability score (VDS), venous clinical severity score (VCSS) and venous segmental disease score (VSDS).\nPatients shall undergo a hand held Doppler ultrasound examination of the saphenofemoral junction to document the presence of radiologically apparent recurrence. This shall be defined as the presence of a new vein with diameter at least 4 mm and with pathologic reflux in direct connection with incompetent varicose veins at thigh level.\n\nAdded 05 September 2008: recruitment never started on this site.", "interventionType": "Drug", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": "porcine dermal collagen patch"}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": null, "publicationStage": null, "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": null, "parties": {"funderId": ["Funder17151-0", "Funder17151-1"], "contactId": "Contact55112_17151", "sponsorId": "Sponsor53677"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact55112_17151", "title": "Prof", "forename": "A K", "surname": "Samy", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Northern Lincolnshire & Goole Hospitals NHS Trust\nDiana Princess of Wales Hospital\nScartho Road", "city": "Grimsby", "country": "United Kingdom", "zip": "DN33 2BA", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+44 01472 874111"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "ahmed.samy@nlg.nhs.uk"}}, "privacy": "Public"}, "sponsor": {"@id": "Sponsor53677", "organisation": "Record Provided by the NHSTCT Register - 2007 Update - Department of Health", "website": "http://www.dh.gov.uk/Home/fs/en", "sponsorType": "Government", "contactDetails": {"address": "The Department of Health, Richmond House, 79 Whitehall", "city": "London", "country": "United Kingdom", "zip": "SW1A 2NL", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+44 (0)20 7307 2622"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "dhmail@doh.gsi.org.uk"}}, "privacy": "Public"}, "funder": [{"@id": "Funder17151-0", "name": "Northern Lincolnshire and Goole Hospitals NHS Trust (UK), R&D Department supports admin cost", "fundRef": null}, {"@id": "Funder17151-1", "name": "Permacol is provided free of charge by Tissue Science Laboratories (UK)", "fundRef": null}]}, {"trial": {"@lastUpdated": "2008-08-27T00:00:00.000Z", "@version": "22", "isrctn": {"@dateAssigned": "2007-09-28T00:00:00.000Z", "#text": "59113767"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "A prospective study to assess the effectiveness of lignocaine versus normal saline in the reduction of pain associated with dressing removal in fingertip injuries", "scientificTitle": null, "acronym": null, "studyHypothesis": "Does local anaesthetic (lignocaine) reduce pain associated with dressing removal of fingertip injuries when compared to normal saline?", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "The reduction in the level of pain on dressing removal of patients with fingertip wounds as shown on the linear visual analogue pain scale, 0-10, 0 being the lowest level of pain and 10 the highest level of pain.", "secondaryOutcome": "No secondary outcome measures", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Not provided at time of registration"}, "externalRefs": {"doi": "10.1186/ISRCTN59113767", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "N0077183569"}, "trialDesign": {"studyDesign": "Randomised controlled trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Hospital"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": "Stopped", "reasonAbandoned": "Too much bureaucracy", "overallStartDate": "2006-08-21T00:00:00.000Z", "overallEndDate": "2008-01-31T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": ["England", "United Kingdom"]}, "trialCentres": {"trialCentre": {"@id": "bb504c0a-5c2f-4793-88a7-a20c70119700", "name": "Derby Hospitals NHS Foundation Trust", "address": null, "city": "Derby", "state": null, "country": "United Kingdom", "zip": "DE1 2QY"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. Patients sustaining a nail bed injury\n2. Patients who are old enough to give consent (over 16 years old)\n3. Patients willing to participate", "ageRange": "Adult", "gender": "Not Specified", "targetEnrolment": "98", "totalFinalEnrolment": null, "totalTarget": "98", "exclusion": "1. Patients who are unable to give consent\n2. Previous injury or surgery to the presenting digit\n3. Patients within any other concomitant trial involving analgesics, patient allergy to lignocaine", "patientInfoSheet": null, "recruitmentStart": "2006-08-21T00:00:00.000Z", "recruitmentEnd": "2008-01-31T00:00:00.000Z", "recruitmentStatusOverride": "Stopped"}, "conditions": {"condition": {"description": "Signs and Symptoms: Pain", "diseaseClass1": "Signs and Symptoms", "diseaseClass2": "Pain"}}, "interventions": {"intervention": {"description": "Patients will be recruited from the Pulvertaft Hand Center upon clinic appointment. This is a stop interview /evaluation that takes place in the Hand Clinic. Certain data will be collected - age, sex, nature of injury, etc. This will be kept confidential. Patients will be asked whether they would like to be involved in the study. Those patients who agree will be asked to sign a consent form. The patients who do not wish to participate in the study will receive the normal standard of care for such injuries, ie. normal saline.\n\nThe following protocol will be set up: \n- Affected finger will be immersed in 10 milliliters of local anaesthetic (lignocaine) or normal saline. \n- The dressing is then removed by the sister in the clinic and the patient asked to log their level of pain. This will be achieved by a simple (linear analogue) scoring system.\n\nThe whole process will be randomised and blind to those involved in the study to avoid or prevent bias.\n\nAdded 27 August 2008: trial was stopped.", "interventionType": "Drug", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": "lignocaine versus normal saline"}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": null, "publicationStage": null, "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": null, "parties": {"funderId": "Funder17004-0", "contactId": "Contact54965_17004", "sponsorId": "Sponsor53530"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact54965_17004", "title": "Mr", "forename": "D N", "surname": "Quinton", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Derby Hospitals NHS Foundation Trust \nDerbyshire Royal Infirmary\nLondon Road", "city": "Derby", "country": "United Kingdom", "zip": "DE1 2QY", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+44 01332 347141 ext: 2249"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "david.quinton@derbyhospitals.nhs.uk"}}, "privacy": "Public"}, "sponsor": {"@id": "Sponsor53530", "organisation": "Record Provided by the NHSTCT Register - 2007 Update - Department of Health", "website": "http://www.dh.gov.uk/Home/fs/en", "sponsorType": "Government", "contactDetails": {"address": "The Department of Health, Richmond House, 79 Whitehall", "city": "London", "country": "United Kingdom", "zip": "SW1A 2NL", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+44 (0)20 7307 2622"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "dhmail@doh.gsi.org.uk"}}, "privacy": "Public"}, "funder": {"@id": "Funder17004-0", "name": "Derby Hospitals NHS Foundation Trust (UK), NHS R&D Support Funding", "fundRef": null}}, {"trial": {"@lastUpdated": "2008-08-28T00:00:00.000Z", "@version": "23", "isrctn": {"@dateAssigned": "2007-09-28T00:00:00.000Z", "#text": "52893628"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "A comparison of co-codamol and modified-release morphine sulphate for step-down analgesia in patients following thoracotomy", "scientificTitle": null, "acronym": null, "studyHypothesis": "1. The purpose of this study is to find out whether co-codamol or modified-release morphine provide better post-operative pain control following thoracotomy. \n2. The secondary objective is to compare the incidence of complications and compare the compliance of the two analgesia regimens. Common complications include nausea, vomiting, pruritis (itchiness), sedation, lightheadedness, mobility and  constipation.", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "1. Adequacy of pain control as measured by the visual analogue scale (0=no pain, 10=excruciating) \n2. How  frequently breakthrough analgesia is used overall satisfaction of pain control", "secondaryOutcome": "Complications: nausea/vomiting, sedation, constipation, pruritis, mobility and compliance", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Not provided at time of registration"}, "externalRefs": {"doi": "10.1186/ISRCTN52893628", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "N0201184743"}, "trialDesign": {"studyDesign": "Randomised controlled trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Hospital"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": "Stopped", "reasonAbandoned": "Poor recruitment", "overallStartDate": "2006-06-21T00:00:00.000Z", "overallEndDate": "2008-04-01T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": ["England", "United Kingdom"]}, "trialCentres": {"trialCentre": {"@id": "7a6e73eb-9657-418c-a101-888600be4c2d", "name": "Royal Brompton & Harefield NHS Trust", "address": null, "city": "London", "state": null, "country": "United Kingdom", "zip": "SW3 6NP"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. Patients >18 years\n2. First-time thoracotomy patient\n3. Informed consent", "ageRange": "Adult", "lowerAgeLimit": {"@unit": "Years", "@value": "18.0"}, "gender": "Not Specified", "targetEnrolment": "60", "totalFinalEnrolment": null, "totalTarget": "60 patients", "exclusion": "1. Patients <18 years\n2. Pregnancy \n3. Breast-feeding\n4. Not able to give informed consent\n5. Already taking analgesia at time of admission", "patientInfoSheet": null, "recruitmentStart": "2006-06-21T00:00:00.000Z", "recruitmentEnd": "2008-04-01T00:00:00.000Z", "recruitmentStatusOverride": "Stopped"}, "conditions": {"condition": {"description": "Signs and Symptoms: Pain", "diseaseClass1": "Signs and Symptoms", "diseaseClass2": "Pain"}}, "interventions": {"intervention": {"description": "Patients undergoing thoracotomy for the first time and not taking regular analgesia for another condition can be considered  for this study.\n\nAnalgesia in the immediate post-operative period will be decided by consensus of surgeon, anaesthetist and the patient. They include epidural analgesia, PVB (paravertebral continuous analgesia) catheter and intravenous morphine either by  continuous infusions or PCA. Every effort is made to ensure satisfactory pain relief.\n\nOral analgesia is commenced at least four hours before the paravertebral, epidural or IV morphine is stopped.\n\nPatients will be randomised, by opening an envelope, into one of two groups to determine which of the two regimens they will receive:\nGroup 1: Co-codamol 30/500 2 tablets QDS PO.  And unless contraindicated*: Diclofenac 75mg SR BD PO. For breakthrough pain: Tramadol 50\u2212100mg QDS/PRN PO\nGroup 2: Paracetamol 1g QDS PO, MST Continus 20mg BD PO. And unless contraindicated*: Diclofenac 75mg SR bd PO. For breakthrough pain:  Oramorph 10mg 1hrly/PRN PO\n\nThe MST dose should be adjusted on the second day to incorporate the 24 hour oramorph requirement.\n* The contraindications for NSAIDs are gastroduodenal disease, renal impairment or a poor urine output. When used, patients should also receive omeprazole 20mg OD for gastric protection.\n\nAdded 28 August 2008: trial stopped due to poor recruitment.", "interventionType": "Drug", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": "co-codamol and modified-release morphine sulphate"}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": null, "publicationStage": null, "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": null, "parties": {"funderId": "Funder17059-0", "contactId": "Contact55020_17059", "sponsorId": "Sponsor53585"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact55020_17059", "title": "Prof", "forename": "Peter", "surname": "Goldstraw", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Royal Brompton & Harefield NHS Trust\nSydney Street", "city": "London", "country": "United Kingdom", "zip": "SW3 6NP", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+44 (0)20 7352 8121"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "P.Goldstraw@rbh.nthames.nhs.uk"}}, "privacy": "Public"}, "sponsor": {"@id": "Sponsor53585", "organisation": "Record Provided by the NHSTCT Register - 2007 Update - Department of Health", "website": "http://www.dh.gov.uk/Home/fs/en", "sponsorType": "Government", "contactDetails": {"address": "The Department of Health, Richmond House, 79 Whitehall", "city": "London", "country": "United Kingdom", "zip": "SW1A 2NL", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+44 (0)20 7307 2622"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "dhmail@doh.gsi.org.uk"}}, "privacy": "Public"}, "funder": {"@id": "Funder17059-0", "name": "Royal Brompton and Harefield NHS Trust (UK), No External Funding, NHS R&D Support Funding", "fundRef": null}}, {"trial": {"@lastUpdated": "2008-09-02T00:00:00.000Z", "@version": "18", "isrctn": {"@dateAssigned": "2007-08-06T00:00:00.000Z", "#text": "40084595"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "A pilot study on the use of low dose erythropoietin in the management of human immunodeficiency virus (HIV) associated anaemia in Uganda", "scientificTitle": null, "acronym": "The Wepox study", "studyHypothesis": "Erythropoietin is efficacious in improving the haemoglobin among anaemic HIV+ individuals at a lower than the currently recommended dose of 40,000 IU per week or 100 - 300 IU/Kg three times per week.", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "Change in haemoglobin, measured at week 0 and end of week 4.", "secondaryOutcome": "1. Quality of life improvement, measured at week 0 and end of week 4 using a visual analogue scale (LASA) and the Medical Outcomes Study HIV Health Survey (MOSHIV) instrument\n2. Adverse events", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Ethics approval received from:\n1. Ethics committee of the Faculty of Medicine, Makerere University on 29th December 2005. Renewed on the 23rd April 2007 and will expire on 23rd October 2007. \n2. Uganda National Council for Science and Technology (UNCST) on 18th January 2006. Renewed on the 10th May 2007 and will expire on the 13th April 2008 (ref: HS103)."}, "externalRefs": {"doi": "10.1186/ISRCTN40084595", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "HS 103"}, "trialDesign": {"studyDesign": "Open label randomised trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Not specified"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2006-03-01T00:00:00.000Z", "overallEndDate": "2008-04-01T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": "Uganda"}, "trialCentres": {"trialCentre": {"@id": "7bc3aba2-b7f0-45af-87b2-a4abdc649a01", "name": "Plot 893 Ring Road", "address": null, "city": "Kampala", "state": null, "country": "Uganda", "zip": "P.O. Box 10005"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. Documented HIV positive\n2. Grade 1 and 2 anaemia\n3. Informed consent\n4. Age 18 to 65 years", "ageRange": "Adult", "lowerAgeLimit": {"@unit": "Years", "@value": "18.0"}, "gender": "Both", "targetEnrolment": "120", "totalFinalEnrolment": null, "totalTarget": "120", "exclusion": "1. Recent blood loss\n2. Active opportunistic infection\n3. Presence of fever at the time of enrolment\n4. Pregnancy\n5. Cancer chemotherapy\n6. Severe microcytosis\n7. Systemic hypertension\n8. Known allergy to erythropoietin", "patientInfoSheet": null, "recruitmentStart": "2006-03-01T00:00:00.000Z", "recruitmentEnd": "2008-04-01T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "HIV associated anaemia", "diseaseClass1": "Haematological Disorders", "diseaseClass2": "Other anaemias"}}, "interventions": {"intervention": {"description": "Each participant will be randomised to one of the following four groups: \n1. Intervention group 1: Haematinics (one capsule orally once daily) and erythropoietin (Wepox) 2000 IU three times per week subcutaneously for 4 weeks\n2. Intervention group 2: Haematinics (one capsule orally once daily) and erythropoietin (Wepox) 4000 IU once a week subcutaneously for 4 weeks\n3. Intervention group 3: Haematinics (one capsule orally once daily) and erythropoietin (Wepox) 2000 IU once a week subcutaneously for 4 weeks\n4. Control group: Haematinics (one capsule orally once daily) for 4 weeks\n\nThe haematinic capsule contains 305 mg ferrous fumarate equivalent to 100 mg elemental iron, 0.75 mg folic acid, 5 micrograms cyanocobalamin, 75 mg ascorbic acid and 5.0 mg zinc sulphate. \n\nInterim analysis of this study will be carried out in July 2007.  Final evaluation of the study will be carried out on completion of the study enrolment and follow-up, but the latter may be influenced by the results of the interim analysis.", "interventionType": "Other", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": null}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": null, "publicationStage": null, "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": null, "parties": {"funderId": "Funder16633-0", "contactId": "Contact54591_16633", "sponsorId": "Sponsor53146"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact54591_16633", "title": "Dr", "forename": "Francis", "surname": "Ssali", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Plot 893 Ring Road\nButikiro House - Mengo", "city": "Kampala", "country": "Uganda", "zip": "P.O. Box 10005", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+256 41 270283/270622"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "ssalifran@yahoo.co.uk"}}, "privacy": "Public"}, "sponsor": {"@id": "Sponsor53146", "organisation": "Star Pharmaceuticals Ltd (Uganda)", "website": "http://www.staruganda.com", "sponsorType": "Industry", "contactDetails": {"address": "Plot 20/3\nJinja Road\nOpposite Spear House", "city": "Kampala", "country": "Uganda", "zip": "PO Box 4391", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+256 41 232863"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "starpharm@infocom.co.ug"}}, "privacy": "Public"}, "funder": {"@id": "Funder16633-0", "name": "Star Pharmaceuticals Uganda Ltd (Uganda) - local representative for Wockhardt", "fundRef": null}}, {"trial": {"@lastUpdated": "2008-08-15T00:00:00.000Z", "@version": "21", "isrctn": {"@dateAssigned": "2007-07-19T00:00:00.000Z", "#text": "62713985"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "A double-blind, placebo-controlled, parallel-arms dose response study of two doses of HRM4396 versus placebo for anaemia in subjects treated with chemotherapy", "scientificTitle": null, "acronym": null, "studyHypothesis": "Advanced cancer is frequently associated with significant anaemia. The causes of this anaemia are multi-factorial and may include the cytotoxic effects of chemotherapeutic agents on bone marrow. \n\nPrimary objective was to determine in anaemic cancer subjects treated with chemotherapy, the efficacy of 150 and 300 U/kg of subcutaneously injected HMR4396 compared to placebo based on haemoglobin and the percent of these subjects requiring red blood cell transfusions.", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "The co-primary efficacy endpoints in this study were the determination of each subject\u0092s change in haemoglobin from baseline to week 12 and the occurrence of red blood cell transfusions during week 5 to 12 (yes/no). The primary analysis was based on the Intent-To Treat (ITT) population.", "secondaryOutcome": "Secondary efficacy endpoints were:\n1. Change in FACT-An fatigue subscale from baseline to week 12\n2. Number of RBC transfusions received during weeks 5 - 12 (expressed as a rate per 28 days)\n3. Number of RBC units transfused during weeks 5 - 12 (expressed as a rate per 28 days)\n4. Change in Haematocrit (Hct) at week 12 when compared to baseline\n5. Average Hgb during weeks 5 - 12\n6. Rate of change of Hgb from baseline to first treatment interruption or to when a blood transfusion (red cell or whole blood) was first received\n7. Average Hct during weeks 5 - 12\n8. Rate of change of Hct from baseline to first treatment interruption or to when a blood transfusion (red cell or whole blood) was first received\n9. Change in the total FACT-An score from baseline to week 12\n10. Change in each non-fatigue subscale from baseline to week 12", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "This was a multi-national, multi-centre trial with 49 centres in the United States. The independent ethics committee from each of the sites approved the study before subjects were enrolled."}, "externalRefs": {"doi": "10.1186/ISRCTN62713985", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "HMR4396B/3001"}, "trialDesign": {"studyDesign": "Phase III, randomised, multinational, double-blind, placebo-controlled, parallel arm study", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Not specified"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2000-05-18T00:00:00.000Z", "overallEndDate": "2002-06-20T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": ["England", "United Kingdom", "United States of America"]}, "trialCentres": {"trialCentre": {"@id": "812ec72b-d684-425e-a9c5-d59990d7f7e8", "name": "Shire contact for trial - no PI was identified", "address": null, "city": "Basingstoke", "state": null, "country": "United Kingdom", "zip": "RG24 8EP"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. Men or women, 18 years of age or older, with cancer except for acute leukaemias, malignancies of the myeloid cell line and myelodysplasia\n2. Receiving cancer chemotherapy with at least two cycles remaining when randomised to study medication\n3. Eastern Cooperative Oncology Group (ECOG) performance score of zero, one or two \n4. Life expectancy of three months or greater\n5. Haemoglobin (Hgb) less than or equal to 10.5 g/dL\n6. Women were to be surgically sterile, post-menopausal (greater than one year) or using an effective method of birth control and were to have had a negative serum pregnancy test (quantitative human chorionic gonadotropin radioimmunoassay test) prior to study medication\n7. Men had to agree to an effective method of contraception\n8. Laboratory values within the following parameters:\n8.1. Neutrophils greater than 500 cells/mm^3 (absolute value = 0.5 x 1000/mm^3 [as per Amendment 1])\n8.2. Platelets greater than 75,000 cells/mm^3\n8.3. Creatinine less than 2.0 mg/dL\n8.4. Serum calcium less than 12 mg/dL\n9. Serum ferritin at least 12 mg/mL and transferrin saturation at least 15% as determined by the prestudy evaluation\n10. Stool occult blood (negative)\n11. A desire and competence to self-administer the study drug or willing to come to the clinic three days each week for the duration of the study to receive study medication\n12. Informed consent was obtained for subjects before enrolment in the study", "ageRange": "Adult", "lowerAgeLimit": {"@unit": "Years", "@value": "18.0"}, "gender": "Both", "targetEnrolment": "313", "totalFinalEnrolment": null, "totalTarget": "575 subjects were screened of which 313 were randomised", "exclusion": "Subjects meeting any of the following criteria were not to be included in the study:\n1. History of any primary non-malignant heamatologic disease\n2. Clinically significant disease/dysfunction of the pulmonary, cardiovascular, endocrine, neurological, gastrointestinal, or genitourinary systems not attributable to underlying malignancy and making implementation of the protocol or interpretation of the study results difficult\n3. Uncontrolled hypertension (i.e. diastolic Blood Pressure [BP] greater than 100 mmHg) at the prestudy evaluation\n4. Evidence of folate or B12 deficiency defined as below the lower standard value for the central laboratory\n5. Androgen therapy within two months of randomisation to study medication\n6. Known hypersensitivity to erythropoietin\n7. Known hypersensitivity to products derived from mammalian cell-culture systems\n8. Experimental drug administered or experimental device used within 30 days prior to randomisation to study medication\n9. Radiation therapy completed within four weeks before randomisation to study medication or extensive radiation therapy defined as more than 40% of marrow exposed in the radiation field completed within six weeks before randomisation to study medication\n10. A malignancy requiring bone marrow transplant or stem cell transplant in the forthcoming 24 weeks (six months)\n11. Bone marrow transplant or stem cell transplant recipients\n12. Loss of blood requiring Red Blood Cell (RBC) transfusion within the last 30 days\n13. Subjects known to be Human Immunodeficiency Virus (HIV) positive\n14. Blood (500 ml) or equivalent serum donation during the last three months (as per Amendment 1)\n15. Pregnant\n16. Breast feeding\n17. Treatment with other erythropoietins within the last 12 weeks before randomisation to study medication\n18. Likelihood of requiring treatment during the study period with drugs not permitted by the study protocol\n19. Clinically relevant cardiovascular disease requiring treatment, including but not limited to: \n19.1. Myocardial infarction in the preceding six months\n19.2. Cardiac arrhythmia\n19.3. Unstable angina\n20. Current drug abuse\n21. Impaired hepatic function, defined as prestudy value for Aspartate Transaminase (AST [SGOT]) or Alanine Transaminase (ALT [SGPT]) exceeding twice the upper limit of normal of the central laboratory values\n22. A mental condition rendering the subject unable to understand the nature, scope and possible consequences of the study\n23. Subjects unlikely to comply with protocol, e.g. uncooperative attitude, inability to return for follow-up visits, and unlikely to complete the study", "patientInfoSheet": null, "recruitmentStart": "2000-05-18T00:00:00.000Z", "recruitmentEnd": "2002-06-20T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Anaemia", "diseaseClass1": "Haematological Disorders", "diseaseClass2": "Anaemia in chronic diseases classified elsewhere"}}, "interventions": {"intervention": {"description": "The intervention was administration of HMR4396 at a dose of 150 U/kg or 300 U/kg compared to placebo. All study treatments were given three times weekly subcutaneously for 12 weeks.\n\nQuality of life was evaluated using the Functional Assessment of Cancer Therapy - Anaemia (FACT-An) questionnaire.", "interventionType": "Drug", "pharmaceuticalStudyTypes": null, "phase": "Phase III", "drugNames": "HMR4396"}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": null, "publicationStage": null, "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": null, "parties": {"funderId": "Funder16616-0", "contactId": "Contact54574_16616", "sponsorId": "Sponsor53129"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact54574_16616", "title": "Dr", "forename": "Chris", "surname": "Freitag", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Shire contact for trial - no PI was identified\nHampshire International Business Park \nLime Tree Way", "city": "Basingstoke", "country": "United Kingdom", "zip": "RG24 8EP", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected"}, "sponsor": {"@id": "Sponsor53129", "organisation": "Hoechst Marion Roussel (Shire Pharmaceuticals) (France)", "website": "http://www.shire.com/shire/", "sponsorType": "Industry", "contactDetails": {"address": "102 Route de Noisy", "city": "Romainville, Cedex", "country": "France", "zip": "93235", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected", "gridId": "grid.417924.d", "rorId": "https://ror.org/02n6c9837"}, "funder": {"@id": "Funder16616-0", "name": "Hoechst Marion Roussel (Shire Pharmaceuticals) (France)", "fundRef": null}}, {"trial": {"@lastUpdated": "2008-08-15T00:00:00.000Z", "@version": "20", "isrctn": {"@dateAssigned": "2007-07-19T00:00:00.000Z", "#text": "41606826"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "An open-label extension study following the HRM4396B/3001 study (a double-blind, placebo-controlled, parallel arms, dose response study of two doses of HMR4396 versus placebo for anaemia in subjects treated with chemotherapy)", "scientificTitle": null, "acronym": null, "studyHypothesis": "Advanced cancer is frequently associated with significant anaemia. The causes of this anaemia are multi-factorial and may include the cytotoxic effects of chemotherapeutic agents on bone marrow. \n\nPrimary objective was to offer a 12-week open-label extension of treatment to subjects having completed the HMR4396B/3001 study in order to collect longer term safety and efficacy data in this population.", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "The primary efficacy endpoints in this study were: \n1. Change in haemoglobin from baseline, and\n2. The percentage of subjects receiving red blood cell transfusions during the study", "secondaryOutcome": "The secondary efficacy endpoints were:\n1. Number of red blood cell transfusions received during weeks 1 - 12\n2. Number of units transfused during weeks 1 - 12\n3. Change from baseline in haematocrit", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "This was a multi-national, multi-centre trial with 39 centres in the United States. The independent ethics committee from each of the sites approved the study before the first subject was enrolled."}, "externalRefs": {"doi": "10.1186/ISRCTN41606826", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "HMR4396B/3002"}, "trialDesign": {"studyDesign": "Phase III, open-label extension study following the HMR4396B/3001 study", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Non randomised controlled trial", "trialSettings": {"trialSetting": "Not specified"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2000-08-03T00:00:00.000Z", "overallEndDate": "2002-09-16T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": ["England", "United Kingdom", "United States of America"]}, "trialCentres": {"trialCentre": {"@id": "99fd2b7f-050b-49fc-a9ea-f3203db24de5", "name": "Shire contact for trial - no PI identified", "address": null, "city": "Basingstoke", "state": null, "country": "United Kingdom", "zip": "RG24 8EP"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. Completion of the HMR4396B/3001 study\n2. Informed consent was obtained from all subjects before enrolment into the study", "ageRange": "Adult", "gender": "Both", "targetEnrolment": "149", "totalFinalEnrolment": null, "totalTarget": "149 subjects enrolled into the study, of which 100 completed treatment with HMR4396. Nine subjects were enrolled but not treated with study medication, and 49 were withdrawn prior to study completion.", "exclusion": "Subjects meeting any of the following criteria were not to be included in the study:\n1. Pregnant\n2. Breast feeding\n3. Likelihood of requiring treatment during the study period with drugs not permitted by the study protocol\n4. Current drug abuse\n5. Mental condition rendering the subject unable to understand the nature, scope and possible consequences of the study", "patientInfoSheet": null, "recruitmentStart": "2000-08-03T00:00:00.000Z", "recruitmentEnd": "2002-09-16T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Anaemia", "diseaseClass1": "Haematological Disorders", "diseaseClass2": "Anaemia in chronic diseases classified elsewhere"}}, "interventions": {"intervention": {"description": "The intervention was administration of HMR4396 at a starting dose of 150 U/kg three times weekly for 12 weeks. The dose could be increased to 300 U/kg after four weeks if the subjects haemoglobin was less than or equal to 12 g/dL.\n\nQuality of life was evaluated using the Functional Assessment of Cancer Therapy - Anaemia (FACT-An) questionnaire.", "interventionType": "Drug", "pharmaceuticalStudyTypes": null, "phase": "Phase III", "drugNames": "HMR4396"}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": null, "publicationStage": null, "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": null, "parties": {"funderId": "Funder16617-0", "contactId": "Contact54575_16617", "sponsorId": "Sponsor53130"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact54575_16617", "title": "Dr", "forename": "Chris", "surname": "Freitag", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Shire contact for trial - no PI identified\nHampshire International Business Park \nLime Tree Way", "city": "Basingstoke", "country": "United Kingdom", "zip": "RG24 8EP", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected"}, "sponsor": {"@id": "Sponsor53130", "organisation": "Hoechst Marion Roussel (Shire Pharmaceuticals) (France)", "website": "http://www.shire.com/shire/", "sponsorType": "Industry", "contactDetails": {"address": "102 Route de Noisy", "city": "Romainville, Cedex", "country": "France", "zip": "93235", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected", "gridId": "grid.417924.d", "rorId": "https://ror.org/02n6c9837"}, "funder": {"@id": "Funder16617-0", "name": "Hoechst Marion Roussel (Shire Pharmaceuticals) (France)", "fundRef": null}}, {"trial": {"@lastUpdated": "2008-09-02T00:00:00.000Z", "@version": "20", "isrctn": {"@dateAssigned": "2007-03-28T00:00:00.000Z", "#text": "16781831"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "Randomised controlled trial of total immunosuppression withdrawal in liver transplant recipients: role of ursodeoxycholic acid", "scientificTitle": null, "acronym": null, "studyHypothesis": "In this study we investigate whether oral administration of ursodeoxycholic acid reduces the risk of rejection and recurrence of underlying disease in liver transplant recipients undergoing total immunosuppression withdrawal (TIW).", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "1. Biochemical and histological evidence of rejection\n2. Graft dysfunction without rejection\n3. Recurrence of pre-transplant disease\n4. Six months without immunosuppression and no rejection or dysfunction on repeat liver biopsy", "secondaryOutcome": "1. Development of renal failure\n2. Hypertension\n3. Extent of liver enzymes abnormalities\n4. Safety and compliance", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Ethics approval received from the University of Western Ontario, London, Ontario, Canada on 01/01/1995. Patients were informed about possible consequences of immunosuppression withdrawal (rejection, recurrence of disease, renal function)."}, "externalRefs": {"doi": "10.1186/ISRCTN16781831", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "N/A"}, "trialDesign": {"studyDesign": "Randomised, placebo-controlled trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Hospital"}, "trialTypes": {"trialType": "Prevention"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "1995-01-01T00:00:00.000Z", "overallEndDate": "1996-12-01T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": "Canada"}, "trialCentres": {"trialCentre": {"@id": "f9bea215-5bbd-4566-9031-77278f427b8e", "name": "Section of  hepatology", "address": null, "city": "Ontario", "state": null, "country": "Canada", "zip": "N6A 5A5"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "Recipients of liver transplantation at the University of Western Ontario, Canada who had stable graft function (no clinical or biochemical evidence of liver disease) for a minimum of two years were offered TIW if they met the following criteria: \n1. No documented rejection episodes for at least 24 months prior to the study\n2. A minimum post-transplant follow up period of at least 2 years\n3. A history of compliance with medications, blood testing for laboratory analyses and in the case of patients transplanted for alcohol-induced liver disease, abstinence from all alcohol beverages during the study period", "ageRange": "Not Specified", "gender": "Both", "targetEnrolment": "46", "totalFinalEnrolment": null, "totalTarget": "46", "exclusion": "1. Patients requiring triple anti-rejection therapy for frequent or severe episodes of rejection in the past\n2. More than one liver transplant\n3. Requiring anti rejection therapy for non-liver disorders (psoriasis, rheumatoid arthritis [RA] etc)", "patientInfoSheet": null, "recruitmentStart": "1995-01-01T00:00:00.000Z", "recruitmentEnd": "1996-12-01T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Liver transplantation, rejection, withdrawal of immunosuppressions", "diseaseClass1": "Injury, Occupational Diseases, Poisoning", "diseaseClass2": "Failure and rejection of transplanted organs and tissues"}}, "interventions": {"intervention": {"description": "26 liver recipients who had been free of rejection while on immunosuppressive agents for a minimum of two years will be randomised to receive either 15 mg/kg of ursodeoxycholic acid (UDCA) (N = 14) or identical placebo (N = 12) followed by sequential withdrawal of their immunosuppressive regimen over several months. \n\nPrior to TIW a baseline liver biopsy was obtained and reviewed with a pathologist to exclude sub-clinical rejection and co-existent disease in the graft. Within one week of initiating TIW, patients underwent the following evaluations: \n1. Alanine aminotransferase (ALT)\n2. Aspartate aminotransferase (AST)\n3. Alkaline phosphatase\n4. Total bilirubin\n5. Creatinine\n6. Complete blood count (CBC) \n7. Cyclosporin (CyA) levels by means of monoclonal antibody radioimmunoassay on whole blood (Cyclotrac, INCSTAR)\n\nThese same parameters were repeated every two weeks for the initial six months post-TIW and then monthly for a year thereafter. Liver biopsies were repeated in those who developed elevated liver enzymes (greater than 2 x normal) and in those who had completed six months of follow up with no immunosuppression other than the study medication. Secondary aims or endpoints such as development of renal failure, hypertension, extent of liver enzymes abnormalities as well as safety and compliance were assessed accordingly.", "interventionType": "Other", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": null}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": null, "publicationStage": null, "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": null, "parties": {"funderId": "Funder16307-0", "contactId": "Contact54264_16307", "sponsorId": "Sponsor52816"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact54264_16307", "title": "Dr", "forename": "Ghent", "surname": "Cam", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Section of  hepatology\nDepartment of Medicine, London Health Sciences Centre\n339 Windermere Road, London", "city": "Ontario", "country": "Canada", "zip": "N6A 5A5", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "cam.ghent@lhsc.on.ca"}}, "privacy": "Public"}, "sponsor": {"@id": "Sponsor52816", "organisation": "University of Western Ontario (Canada)", "website": null, "sponsorType": "University/education", "contactDetails": {"address": "c/o Dr Ghent Cam\nSection of hepatology \nDepartment of Medicine, London Health Sciences Centre\n339 Windermere Road, London", "city": "Ontario", "country": "Canada", "zip": "N6A 5A5", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "cam.ghent@lhsc.on.ca"}}, "privacy": "Public", "gridId": "grid.39381.30", "rorId": "https://ror.org/02grkyz14"}, "funder": {"@id": "Funder16307-0", "name": "University of Western Ontario (Canada) - the Liver Unit", "fundRef": null}}, {"trial": {"@lastUpdated": "2008-09-02T00:00:00.000Z", "@version": "21", "isrctn": {"@dateAssigned": "2007-03-07T00:00:00.000Z", "#text": "35472475"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "Markers of endothelial activation and damage in haematological patients in relation to efficacy of transfusion support: a pilot study", "scientificTitle": null, "acronym": "The marker study", "studyHypothesis": "Efficacy of transfusion support depends on disease and treatment related patient factors. Markers of endothelial damage have been identified, but until today not in relation to the efficacy of transfusions.", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "Efficacy of platelet transfusion or red blood cell exchange transfusion in haemato-oncological patients and sickle cell patients, respectively, in relation to several endothelial activation markers.", "secondaryOutcome": "No secondary outcome measures", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Not provided at time of registration"}, "externalRefs": {"doi": "10.1186/ISRCTN35472475", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "NTR909"}, "trialDesign": {"studyDesign": "Non-randomised, parallel group clinical trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Single-centre", "trialSettings": {"trialSetting": "Hospital"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2007-04-01T00:00:00.000Z", "overallEndDate": "2008-04-01T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": "Netherlands"}, "trialCentres": {"trialCentre": {"@id": "ea610f1b-2308-47d6-a81a-45b824024487", "name": "Haga Hospital", "address": null, "city": "Den Haag", "state": null, "country": "Netherlands", "zip": "2545 CH"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. Age greater than 18 years\n2. Haemato-oncological disease\n3. Sickle cell disease\n4. Informed consent", "ageRange": "Adult", "lowerAgeLimit": {"@unit": "Years", "@value": "18.0"}, "gender": "Not Specified", "targetEnrolment": "40", "totalFinalEnrolment": null, "totalTarget": "40", "exclusion": "1. Active cardiovascular disease\n2. Recent thrombo-embolism", "patientInfoSheet": null, "recruitmentStart": "2007-04-01T00:00:00.000Z", "recruitmentEnd": "2008-04-01T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Sickle cell disease", "diseaseClass1": "Haematological Disorders", "diseaseClass2": "Sickle-cell disorders"}}, "interventions": {"intervention": {"description": "Patients with a haemato-oncological diagnosis will receive platelet transfusion and patients with sickle cell disease will receive red blood cell exchange. Two blood samples will be drawn, before and after this intervention, and these samples will be used to test several known markers of endothelial cell activation/damage.", "interventionType": "Other", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": null}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": null, "publicationStage": null, "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": null, "parties": {"funderId": "Funder16284-0", "contactId": "Contact54241_16284", "sponsorId": "Sponsor52793"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact54241_16284", "title": "Dr", "forename": "J L H", "surname": "Kerkhoffs", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Haga Hospital\nLeyweg 275", "city": "Den Haag", "country": "Netherlands", "zip": "2545 CH", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+31 (0)70 359 2004"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "J.Kerkhoffs@hagaziekenhuis.nl"}}, "privacy": "Public"}, "sponsor": {"@id": "Sponsor52793", "organisation": "Sanquin Blood Bank South West Region (The Netherlands)", "website": null, "sponsorType": "Hospital/treatment centre", "contactDetails": {"address": "Wytemaweg 10", "city": "Rotterdam", "country": "Netherlands", "zip": "3015 CN", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected", "gridId": "grid.417732.4", "rorId": "https://ror.org/01fm2fv39"}, "funder": {"@id": "Funder16284-0", "name": "Sanquin Blood Bank South West Region (The Netherlands)", "fundRef": null}}, {"trial": {"@lastUpdated": "2008-09-02T00:00:00.000Z", "@version": "21", "isrctn": {"@dateAssigned": "2007-02-08T00:00:00.000Z", "#text": "88278819"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "Clinical effectiveness and safety of pooled, random donor platelet concentrates, leukoreduced and stored up to seven days either in additive solution with and without pathogen reduction or plasma in haemato-oncological patients", "scientificTitle": null, "acronym": "HOVON 82", "studyHypothesis": "Platelet additive solution platelet concentrates (PAS III-PC) and pathogen reduced (PR)-PAS III-PC are non-inferior compared to plasma platelet concentrates (Plasma-PC) in terms of recovery, estimated by the one-hour corrected count increments (CCI) post-transfusion.\n\nSecondary objectives:\n1. To assess the effectiveness in relation to storage time of the used platelet product\n2. To evaluate whether clinical factors interact with the different study products leading to a difference in platelet refractoriness\n3. To assess the 24-hour CCI \n4. To assess the safety (bleeding complications and adverse transfusion reactions) \n5. To assess transfusion requirement (red cells and platelets)\n6. To assess the transfusion interval", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "One-hour CCI.", "secondaryOutcome": "1. 24 hour CCI\n2. Bleeding grade minimal two (Common Terminology Criteria for Adverse Events version three [CTCAE v 3.0])\n3. Transfusion requirement, red cells and platelets\n4. Platelet transfusion interval\n5. Adverse transfusion reactions", "trialWebsite": "http://www.hovon.nl", "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Approval received from the local ethics committee (METC Zuidwest Holland) on the 22nd January 2007 (ref: METC protocol-nr 06-094) (ref. of approval letter: 2007-054)."}, "externalRefs": {"doi": "10.1186/ISRCTN88278819", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "HO82; NTR861"}, "trialDesign": {"studyDesign": "Randomised, active-controlled, parallel group multicentre trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Hospital"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2007-02-01T00:00:00.000Z", "overallEndDate": "2008-02-01T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": "Netherlands"}, "trialCentres": {"trialCentre": {"@id": "d3333789-9039-4dc2-9d95-06586be2cecd", "name": "HagaHospital", "address": null, "city": "Den Haag", "state": null, "country": "Netherlands", "zip": "2545 CH"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. Age minimal 18 years\n2. Expected minimal two platelet transfusion requirements\n3. Written informed consent\n4. Having a haemato-oncological disease", "ageRange": "Adult", "lowerAgeLimit": {"@unit": "Years", "@value": "18.0"}, "gender": "Not Specified", "targetEnrolment": "300", "totalFinalEnrolment": null, "totalTarget": "300", "exclusion": "1. Known immunological refractoriness to platelet transfusions, i.e. human leukocyte antigen (HLA)- and/or human platelet antigen (HPA)-alloimmunisation and/or clinical relevant auto-antibodies\n2. Pregnancy (or lactating)\n3. Previous inclusion in this study", "patientInfoSheet": null, "recruitmentStart": "2007-02-01T00:00:00.000Z", "recruitmentEnd": "2008-02-01T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Thrombocytopenia", "diseaseClass1": "Haematological Disorders", "diseaseClass2": "Purpura and other haemorrhagic conditions"}}, "interventions": {"intervention": {"description": "All patients will be randomised to receive one of three platelet products during one transfusion period:\nArm A: plasma stored platelet concentrates (Plasma-PC)\nArm B: PAS III stored platelet concentrates (PAS III-PC)\nArm C: pathogen reduced PAS III stored platelet concentrates (PR-PAS III-PC)\n\nDuration of study will be one transfusion period, which is defined as a period of six weeks or a maximum of five transfusions.", "interventionType": "Other", "pharmaceuticalStudyTypes": null, "phase": "Phase III", "drugNames": null}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": null, "publicationStage": null, "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": null, "parties": {"funderId": ["Funder16137-0", "Funder16137-1"], "contactId": "Contact54083_16137", "sponsorId": "Sponsor52638"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact54083_16137", "title": "Dr", "forename": "J L H", "surname": "Kerkhoffs", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "HagaHospital\nLeyweg 275", "city": "Den Haag", "country": "Netherlands", "zip": "2545 CH", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+31 (0)70 359 2004"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "J.Kerkhoffs@hagaziekenhuis.nl"}}, "privacy": "Public"}, "sponsor": {"@id": "Sponsor52638", "organisation": "Dutch Haemato-Oncology Association (Stichting Hemato-Oncologie Volwassenen Nederland) (HOVON) (The Netherlands)", "website": "http://www.hovon.nl/", "sponsorType": "Research organisation", "contactDetails": {"address": "HOVON Data Center\nErasmus Medical Centre\nDaniel den Hoed Clinic\nP.O. Box 5201", "city": "Rotterdam", "country": "Netherlands", "zip": "3008 AE", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+31 (0)10 439 1568"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "hdc@erasmusmc.nl"}}, "privacy": "Public", "gridId": "grid.476265.4", "rorId": "https://ror.org/056kpdx27"}, "funder": [{"@id": "Funder16137-0", "name": "Dutch Haemato-Oncology Association (Stichting Hemato-Oncologie Volwassenen Nederland) (HOVON) (The Netherlands)", "fundRef": null}, {"@id": "Funder16137-1", "name": "The Sanquin Blood Supply Foundation (Stichting Sanquin Bloedvoorziening) (The Netherlands)", "fundRef": null}]}, {"trial": {"@lastUpdated": "2008-09-05T00:00:00.000Z", "@version": "23", "isrctn": {"@dateAssigned": "2007-01-19T00:00:00.000Z", "#text": "52269003"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "The effect of case conferences between general practitioners and palliative care specialist teams on the quality of life of dying people", "scientificTitle": null, "acronym": null, "studyHypothesis": "For patients with life limiting disease, formal case conferences held between patients\u0092 General Practitioners (GPs) and their palliative care team will improve Quality of Life (QoL) for patients and their carers.", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "Global quality of life measures at three weeks post intervention", "secondaryOutcome": "1. Subscale measures of quality of life scales\n2. Process evaluation of GP-specialist case conferences\n\nnote: Two a priori analyses planned.  The first is using the intervention as a fixed time point, evaluating the effect from the time of the intervention. The second is using date of death as fixed time point, and evaluating intervention from time of death, independent of the time of the intervention", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "1. University of Queensland Human Research Ethics Committee (approval number B/311/Soc & PrevMed/00/PhD)\n2. Mater Adult  Hospital Research Ethics Committee (ref no: 369A)\n3. Townsville Health service District Institutional Ethics Committee\n4. Princess Alexandra Research Ethics Committee (ref: 179/01)"}, "externalRefs": {"doi": "10.1186/ISRCTN52269003", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "N/A"}, "trialDesign": {"studyDesign": "Mulit-site single blind randomised controlled trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "GP practice"}, "trialTypes": {"trialType": "Quality of life"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2001-07-01T00:00:00.000Z", "overallEndDate": "2003-05-31T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": "Australia"}, "trialCentres": {"trialCentre": {"@id": "c3a27e69-48d6-4594-a468-a5965f0f1e69", "name": "Edith Cavell Building", "address": null, "city": "Herston", "state": null, "country": "Australia", "zip": "4006"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. Adult Patients requiring palliaitve care, and their carergivers who are referred to a participating specialist palliative care service\n2. Aged over 18\n3. Life expectancy of at least one month\n4. Not confused or too unwell to be approached\n5. Could read and speak English\n6. Had a current GP", "ageRange": "Adult", "lowerAgeLimit": {"@unit": "Years", "@value": "18.0"}, "gender": "Not Specified", "targetEnrolment": "220", "totalFinalEnrolment": null, "totalTarget": "220", "exclusion": "1. Life expectancy less than one month\n2. Confused\n3. Too unwell to be approached\n4. Could not read or speak English\n5. Did not have a current GP", "patientInfoSheet": null, "recruitmentStart": "2001-07-01T00:00:00.000Z", "recruitmentEnd": "2003-05-31T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Palliative care", "diseaseClass1": "Signs and Symptoms", "diseaseClass2": "Palliative care"}}, "interventions": {"intervention": {"description": "Case conference held betwen the patient's GP and the specialist palliative care team, held by tele-conference, within three weeks of referral.\n\nThe control group receives usual care- ie communication between GPs and the specialist team was by normal means.", "interventionType": "Other", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": null}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": "2002 Results article in http://www.ncbi.nlm.nih.gov/pubmed/12098350 Participation and effectiveness results:\n2004 Thesis results in https://search.library.uq.edu.au/primo-explore/fulldisplay?vid=61UQ&docid=61UQ_ALMA2184158830003131&lang=en_US&context=L\n2005 Abstract results in http://www.ncbi.nlm.nih.gov/pubmed/15887946 Lessons from  case conferences:\n2005 Other publications in http://www.ncbi.nlm.nih.gov/pubmed/16351536 Methodology comparison:\n2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18772208 Quality of life results:", "publicationStage": "Results", "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": {"output": [{"@id": "4f604300-cdc8-4762-937b-fa3d8e9fec00", "@outputType": "resultsarticle", "@artefactType": "ExternalLink", "@dateCreated": "2002-07-15T00:00:00.000Z", "@dateUploaded": "", "@peerReviewed": "true", "@patientFacing": "false", "@createdBy": "Data migration", "externalLink": {"@url": "http://www.ncbi.nlm.nih.gov/pubmed/12098350"}, "description": "Participation and effectiveness results:", "productionNotes": null}, {"@id": "7a2e5ae0-b481-4e62-962c-8f7afe1b33f0", "@outputType": "thesis", "@artefactType": "ExternalLink", "@dateCreated": "2004-06-01T00:00:00.000Z", "@dateUploaded": "", "@peerReviewed": "false", "@patientFacing": "false", "@createdBy": "Data migration", "externalLink": {"@url": "https://search.library.uq.edu.au/primo-explore/fulldisplay?vid=61UQ&docid=61UQ_ALMA2184158830003131&lang=en_US&context=L"}, "description": null, "productionNotes": null}, {"@id": "38dc2784-cdd1-4461-8da3-4a0553dadc3f", "@outputType": "abstract", "@artefactType": "ExternalLink", "@dateCreated": "2005-05-01T00:00:00.000Z", "@dateUploaded": "", "@peerReviewed": "false", "@patientFacing": "false", "@createdBy": "Data migration", "externalLink": {"@url": "http://www.ncbi.nlm.nih.gov/pubmed/15887946"}, "description": "Lessons from  case conferences:", "productionNotes": null}, {"@id": "d46f7e22-00de-4019-8856-2ba21dd2d889", "@outputType": "otherpublications", "@artefactType": "ExternalLink", "@dateCreated": "2005-12-01T00:00:00.000Z", "@dateUploaded": "", "@peerReviewed": "true", "@patientFacing": "false", "@createdBy": "Data migration", "externalLink": {"@url": "http://www.ncbi.nlm.nih.gov/pubmed/16351536"}, "description": "Methodology comparison:", "productionNotes": null}, {"@id": "4c6c76f7-b669-4375-8308-f1a16e8bfea0", "@outputType": "resultsarticle", "@artefactType": "ExternalLink", "@dateCreated": "2008-12-01T00:00:00.000Z", "@dateUploaded": "", "@peerReviewed": "true", "@patientFacing": "false", "@createdBy": "Data migration", "externalLink": {"@url": "http://www.ncbi.nlm.nih.gov/pubmed/18772208"}, "description": "Quality of life results:", "productionNotes": null}]}, "parties": {"funderId": "Funder15919-0", "contactId": "Contact53863_15919", "sponsorId": "Sponsor52414"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact53863_15919", "title": "Dr", "forename": "Geoffrey", "surname": "Mitchell", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Edith Cavell Building\nUniverissty of Queensland Medical School\nHerston Road", "city": "Herston", "country": "Australia", "zip": "4006", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+61 (0)7 3365 5504"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "g.mitchell@uq.edu.au"}}, "privacy": "Public"}, "sponsor": {"@id": "Sponsor52414", "organisation": "University of Queensland Medical School (Australia)", "website": "http://www.som.uq.edu.au/research/person.asp?pid=20148", "sponsorType": "University/education", "contactDetails": {"address": "c/o A/Prof Geoffrey Mitchell\nEdith Cavell Building\nHerston Road", "city": "Herston", "country": "Australia", "zip": "4006", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+61 (0)7 3365 5504"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "g.mitchell@uq.edu.au"}}, "privacy": "Public", "gridId": "grid.1003.2", "rorId": "https://ror.org/00rqy9422"}, "funder": {"@id": "Funder15919-0", "name": "Australian Government  Department of Health and Ageing, National Health Development Fund (Australia)", "fundRef": null}}, {"trial": {"@lastUpdated": "2008-09-02T00:00:00.000Z", "@version": "21", "isrctn": {"@dateAssigned": "2006-11-22T00:00:00.000Z", "#text": "33216118"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "Thrombin generation after abrupt cessation versus weaning over eight hours of continuous infusion of unfractionated heparin in intensive care unit patients after discontinuation of continuous venovenous haemofiltration", "scientificTitle": null, "acronym": "Heparin Rebound", "studyHypothesis": "Our hypothesis is that rebound thrombin generation occurs in intensive care unit (ICU)-patients after abrupt cessation of heparin treatment in terms of elevation of coagulation-markers and reduction fibrinolysis-markers; intravenous (IV)-weaning of heparin reduces this rebound thrombin generation.", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "Thrombin-antithrombin complexes (TATc)", "secondaryOutcome": "1. Activated partial thromboplastin time (aPTT)\n2. Anti-factor Xa (anti-Xa)\n3. Factor VII/VIIa\n4. Tissue factor (TF)\n5. Tissue factor pathway inhibitor (TFPI)-antigen\n6. TFPI activity\n7. Protein C/activated protein C (aPC)\n8. Activated protein C sensitivity ratio (aPC-sr)\n9. Prothrombin fragment 1.2, ETP (endogenous thrombin potential)\n10. Fibrin monomers\n11. Soluble thrombomodulin\n12. Plasmin-a2-anti-plasmin complexes (PAPc)\n13. Plasminogen-activator inhibitor (PAI)", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Ethics approval received from the local medical ethics committee"}, "externalRefs": {"doi": "10.1186/ISRCTN33216118", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "0001; NTR742"}, "trialDesign": {"studyDesign": "Randomised controlled trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Not specified"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2006-09-01T00:00:00.000Z", "overallEndDate": "2007-09-01T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": "Netherlands"}, "trialCentres": {"trialCentre": {"@id": "8490a132-5676-45fe-80f6-86f771a70eb0", "name": "Academic Medical Centre", "address": null, "city": "Amsterdam", "state": null, "country": "Netherlands", "zip": "1105 AZ"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. Patients scheduled to stop treatment with continuous venovenous haemofiltration (CVVH) because they no longer require it (physicians discretion/local protocol)\n2. Age more than 18 years\n3. At least 48 hours of CVVH treatment with concomitant continuous infusion of unfractionated heparin (UFH)\n4. At least 36 hours of continuous UFH infusion in the last 48 hours prior to inclusion", "ageRange": "Adult", "lowerAgeLimit": {"@unit": "Years", "@value": "18.0"}, "gender": "Not Specified", "targetEnrolment": "20", "totalFinalEnrolment": null, "totalTarget": "20", "exclusion": "1. Patients with known coagulation disorders\n2. Patients receiving any anti-coagulant treatment for reasons other than CVVH", "patientInfoSheet": null, "recruitmentStart": "2006-09-01T00:00:00.000Z", "recruitmentEnd": "2007-09-01T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Venovenous haemofiltration", "diseaseClass1": "Haematological Disorders", "diseaseClass2": "Haematological procedures"}}, "interventions": {"intervention": {"description": "Therapeutic protocol:\nProphylactic low molecular weight heparin (LMWH) will not be given within 24 hours of discontinuation of CVVH. Patients are treated with help of standard guidelines effective in our units. The full medical treatment will be under the discretion of the supervising staff-intensivists who are not directly involved in the study.\n\nStudy protocol:\nRandomisation will take place using sealed envelopes:\n1. In ten patients UFH infusion will be stopped simultaneous to stopping of CVVH\n2. In ten patients UFH infusion will be reduced to 50% from the previous infusion rate. After four hours the infusion rate will be reduced again by 50% (25% of original infusion rate) and discontinued four hours later. \n\nBlood samples will be taken at specific intervals to evaluate thrombin generation.", "interventionType": "Drug", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": "Low molecular weight heparin (LMWH)"}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": null, "publicationStage": null, "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": null, "parties": {"funderId": "Funder15851-0", "contactId": "Contact53791_15851", "sponsorId": "Sponsor52344"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact53791_15851", "title": "Dr", "forename": "J J H", "surname": "Hofstra", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Academic Medical Centre\nIntensive Care Unit\nP.O. Box 22660", "city": "Amsterdam", "country": "Netherlands", "zip": "1105 AZ", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+31 (0)20 5668224"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "J.J.H.Hofstra@amc.uva.nl"}}, "privacy": "Public"}, "sponsor": {"@id": "Sponsor52344", "organisation": "Academic Medical Centre (AMC) (The Netherlands)", "website": "http://www.amc.uva.nl", "sponsorType": "Hospital/treatment centre", "contactDetails": {"address": "Department of Intensive Care\nP.O. Box 22660", "city": "Amsterdam", "country": "Netherlands", "zip": "1100 DD", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected", "gridId": "grid.5650.6", "rorId": "https://ror.org/03t4gr691"}, "funder": {"@id": "Funder15851-0", "name": "Academic Medical Centre (AMC) (The Netherlands)", "fundRef": null}}, {"trial": {"@lastUpdated": "2008-09-01T00:00:00.000Z", "@version": "25", "isrctn": {"@dateAssigned": "2006-07-14T00:00:00.000Z", "#text": "56520131"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "A multi-centre study to evaluate community hospital care for older people", "scientificTitle": null, "acronym": "The 'PATCH' study", "studyHypothesis": "1. Do older people transferred to a community hospital obtain and maintain a greater degree of functional independence?\n2. Is carer burden and strain reduced?\n3. Is the patient and carer experience more favourable?\n4. Are the \"whole system\" costs (Health and Social Services combined) comparable or less with the community hospital model of care?", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "1. Patient: Nottingham Extended Activities of Daily Living Scale\n2. Carer: General Health Questionnaire 28", "secondaryOutcome": "1. Patient:\na. Barthel Index\nb. Nottingham Health Profile\nc. Hospital Anxiety and Depression Scale\nd. Euroqol (EQ5D)scale\ne. service satisfaction\nf. mortality\ng. discharge destination\nh. resource use\n2. Carer: Carer Strain Index", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Medical Research Ethics Committee (MREC) approval gained on 1/3/35. \n\nApproval also gained from the following boards: \n1. East Cumbria LREC (no reference number). \n2. South Birmingham LREC (reference number: 5787M). \n3. Northallerton LREC (no reference number). \n4. York LREC (reference number: 01/08/012)."}, "externalRefs": {"doi": "10.1186/ISRCTN56520131", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "121/7509"}, "trialDesign": {"studyDesign": "A mixed methods design incorporating a single 'blind', randomised, prospective multi-centre trial implemented in five study locations", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Hospital"}, "trialTypes": {"trialType": "Quality of life"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2000-03-01T00:00:00.000Z", "overallEndDate": "2003-03-01T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": ["England", "United Kingdom"]}, "trialCentres": {"trialCentre": {"@id": "226aa0ab-25fa-493e-bc5a-43c400f58a92", "name": "Academic Unit of Elderly Care and Rehabilitation", "address": null, "city": "Bradford", "state": null, "country": "United Kingdom", "zip": "BD5 0NA"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "All patients (casualty and direct from general practitioner) admitted to the participating departments of elderly care with a postcode address corresponding to the locality served by the seven Community Hospitals will be eligible for inclusion to the trial.\n\nThe patient must be sufficiently medically stable for the non-district general hospital care to be clinically appropriate.", "ageRange": "Senior", "gender": "Both", "targetEnrolment": "500", "totalFinalEnrolment": null, "totalTarget": "500", "exclusion": "Acutely ill or medically unstable patients will be exluded.", "patientInfoSheet": null, "recruitmentStart": "2000-03-01T00:00:00.000Z", "recruitmentEnd": "2003-03-01T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "All older patients admitted to the department of elderly care.", "diseaseClass1": "Other", "diseaseClass2": "All older patients admitted to the department of elderly care."}}, "interventions": {"intervention": {"description": "Intervention group: post-acute care in a community hospital providing a multi-disciplinary rehabilitation approach\nControl group: extended general hospital stay with multi-disciplinary care", "interventionType": "Other", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": null}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": "2007 Results article in https://pubmed.ncbi.nlm.nih.gov/17979957/\n2008 Other publications in http://www.ncbi.nlm.nih.gov/pubmed/18515290", "publicationStage": "Results", "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": {"output": [{"@id": "09169e1b-b3e0-464b-8614-466f08596848", "@outputType": "resultsarticle", "@artefactType": "ExternalLink", "@dateCreated": "2007-12-01T00:00:00.000Z", "@dateUploaded": "", "@peerReviewed": "true", "@patientFacing": "false", "@createdBy": "Data migration", "externalLink": {"@url": "https://pubmed.ncbi.nlm.nih.gov/17979957/"}, "description": null, "productionNotes": null}, {"@id": "c0305e1a-c9b6-4651-9ae9-6075f1ae5503", "@outputType": "otherpublications", "@artefactType": "ExternalLink", "@dateCreated": "2008-09-01T00:00:00.000Z", "@dateUploaded": "", "@peerReviewed": "true", "@patientFacing": "false", "@createdBy": "Data migration", "externalLink": {"@url": "http://www.ncbi.nlm.nih.gov/pubmed/18515290"}, "description": null, "productionNotes": null}]}, "parties": {"funderId": "Funder15203-0", "contactId": "Contact53091_15203", "sponsorId": "Sponsor51640"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact53091_15203", "title": "Prof", "forename": "John", "surname": "Young", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Academic Unit of Elderly Care and Rehabilitation\nUniversity of Leeds\nSt Luke's Hospital\nLittle Horton Lane", "city": "Bradford", "country": "United Kingdom", "zip": "BD5 0NA", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+44 (0) 127 436 5311"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "john.young@bradfordhospitals.nhs.uk"}}, "privacy": "Public"}, "sponsor": {"@id": "Sponsor51640", "organisation": "National Institute for Health Research Central Commissioning Facility (NIHR-CCF) (UK)", "website": "http://www.nihr-ccf.org.uk/site/default.cfm", "sponsorType": "Government", "contactDetails": {"address": "PO Box 407", "city": "Teddington", "country": "United Kingdom", "zip": "TW11 0XX", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected", "gridId": "grid.473755.7", "rorId": "https://ror.org/03c1etk80"}, "funder": {"@id": "Funder15203-0", "name": "Department of Health/Medical Research Council (reference number: 1217509) under the umbrella of the National Intermediate Care Evaluation Programme - part of the department's policy research programme to support the national service framework for older people: the Older People and Unscheduled care Services group (OPUS) programme.", "fundRef": null}}, {"trial": {"@lastUpdated": "2008-08-15T00:00:00.000Z", "@version": "23", "isrctn": {"@dateAssigned": "2006-06-09T00:00:00.000Z", "#text": "25172408"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "Efficacy of a school-based psychosocial intervention to deal with the psychosocial impact of armed conflict on school-aged children in Indonesia", "scientificTitle": null, "acronym": null, "studyHypothesis": "A psychosocial school-based program is capable of reducing conflict-related psychosocial symptoms, and increasing children's strength to deal with armed-conflict related psychosocial difficulties", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "Post-traumatic stress disorder (PTSD) and depressive symptoms", "secondaryOutcome": "1. Anxiety\n2. Aggression\n3. Daily functioning\n4. Social support\n5. Sociometric measurements (sociogram)\n6. Coping\n7. Family functioning\n8. Hope\n9. School functioning (grades, absenteeism)", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Ongoing at ethical review board of Vrije Universiteit Amsterdam as of 09/06/06"}, "externalRefs": {"doi": "10.1186/ISRCTN25172408", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "N/A"}, "trialDesign": {"studyDesign": "Cluster randomisation of schools to intervention (structured school-based psychosocial program) or waitlist condition (receiving treatment after the research)", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Not specified"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2006-03-15T00:00:00.000Z", "overallEndDate": "2007-05-31T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": ["Indonesia", "Netherlands"]}, "trialCentres": {"trialCentre": {"@id": "7b74397d-cc86-4f92-a219-150a909b8f85", "name": "c/o HealthNet TPO", "address": null, "city": "Amsterdam", "state": null, "country": "Netherlands", "zip": "1074 VJ"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "Children screened for exposure to traumatic events, post-traumatic stress symptoms or depressive anxiety symptoms, with the use of symptom checklists", "ageRange": "Child", "gender": "Both", "targetEnrolment": "240", "totalFinalEnrolment": null, "totalTarget": "110 per treatment arm (10 selected groups); total 240 children", "exclusion": "Serious psychopathology and psychiatric disorders (mutism, retardation, psychotic symptoms) or incapability to function in a group (conduct disorders, harming others), as judged by local psychosocial counsellors", "patientInfoSheet": null, "recruitmentStart": "2006-03-15T00:00:00.000Z", "recruitmentEnd": "2007-05-31T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Multiple impact of armed conflict on psychosocial wellbeing (post-traumatic stress disorder)", "diseaseClass1": "Mental and Behavioural Disorders", "diseaseClass2": "Post-traumatic stress disorder"}}, "interventions": {"intervention": {"description": "Classroom-based structured, manualized psychosocial intervention, called the class-room based intervention (CBI), as designed by the Center for Trauma Psychology (Boston, Massachusetts) versus the waitlist condition.\nThe CBI entails a 15-session program that encompasses working with the trauma narrative, creative techniques (drama, music), and specifically designed games. The waitlist condition simply entails the provision of treatment after the research is finished.", "interventionType": "Other", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": null}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": "2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18698064 Results", "publicationStage": "Results", "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": {"output": {"@id": "c54a4c0a-ec94-43a8-a228-78a093148490", "@outputType": "resultsarticle", "@artefactType": "ExternalLink", "@dateCreated": "2008-08-13T00:00:00.000Z", "@dateUploaded": "", "@peerReviewed": "true", "@patientFacing": "false", "@createdBy": "Data migration", "externalLink": {"@url": "http://www.ncbi.nlm.nih.gov/pubmed/18698064"}, "description": "Results", "productionNotes": null}}, "parties": {"funderId": "Funder14752-0", "contactId": "Contact52520_14752", "sponsorId": "Sponsor51040"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact52520_14752", "title": "Prof", "forename": "Joop", "surname": "de Jong", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "c/o HealthNet TPO\nTolstraat 127\n1074 VJ", "city": "Amsterdam", "country": "Netherlands", "zip": "1074 VJ", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+31 (0)20 6200005"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "jdejong@healthnettpo.org"}}, "privacy": "Public"}, "sponsor": {"@id": "Sponsor51040", "organisation": "HealthNet TPO (The Netherlands)", "website": "http://www.healthnettpo.org", "sponsorType": "Charity", "contactDetails": {"address": "Tolstraat 127\n1074 VJ", "city": "Amsterdam", "country": "Netherlands", "zip": "1074 VJ", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+31 (0)20 6200005"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "jdejong@healthnettpo.org"}}, "privacy": "Public", "gridId": "grid.429145.f", "rorId": "https://ror.org/0088fqs38"}, "funder": {"@id": "Funder14752-0", "name": "Plan International (UK)", "fundRef": null}}, {"trial": {"@lastUpdated": "2008-09-02T00:00:00.000Z", "@version": "20", "isrctn": {"@dateAssigned": "2006-04-28T00:00:00.000Z", "#text": "88941850"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "Prenatal and neonatal screening of haemoglobinopathies: a prospective study", "scientificTitle": null, "acronym": null, "studyHypothesis": "The carrier frequence of haemoglobinopathies is greater than 0.05 and screening for primary prevention is cost-effective.", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "Carrier frequence of haemoglobinopathies.", "secondaryOutcome": "1. Serum ferritin\n2. Compliance to prenatal testing\n3. Cost-effectiveness", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Ethics approval received from the local medical ethics committee"}, "externalRefs": {"doi": "10.1186/ISRCTN88941850", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "METC-nr 05-83; NTR622"}, "trialDesign": {"studyDesign": "Cross sectional study", "primaryStudyDesign": "Observational", "secondaryStudyDesign": "Cross-section survey", "trialSettings": {"trialSetting": "Not specified"}, "trialTypes": {"trialType": "Screening"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2006-03-01T00:00:00.000Z", "overallEndDate": "2007-02-28T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": "Netherlands"}, "trialCentres": {"trialCentre": {"@id": "e3648174-9c21-497e-a66d-3d01136123e9", "name": "HagaHospital", "address": null, "city": "The Hague", "state": null, "country": "Netherlands", "zip": "2545 CH"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. Pregnant females before the 16th week of pregnancy and newborns\n2. Informed consent", "ageRange": "Adult", "gender": "Female", "targetEnrolment": "2000", "totalFinalEnrolment": null, "totalTarget": "2000", "exclusion": "Known haemoglobinopathy", "patientInfoSheet": null, "recruitmentStart": "2006-03-01T00:00:00.000Z", "recruitmentEnd": "2007-02-28T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Haemoglobinopathies", "diseaseClass1": "Haematological Disorders", "diseaseClass2": "Other hereditary haemolytic anaemias"}}, "interventions": {"intervention": {"description": "Unselected group of pregnant females (n = 1000) and a group of newborns (n = 1000) will be screened for haemoglobinopathies.", "interventionType": "Other", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": null}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": null, "publicationStage": null, "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": null, "parties": {"funderId": "Funder15021-0", "contactId": "Contact52841_15021", "sponsorId": "Sponsor51390"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact52841_15021", "title": "Dr", "forename": "J.L.H.", "surname": "Kerkhoffs", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "HagaHospital\nLeyweg 275", "city": "The Hague", "country": "Netherlands", "zip": "2545 CH", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+31 (0)70 3592004"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "J.Kerkhoffs@hagaziekenhuis.nl"}}, "privacy": "Public"}, "sponsor": {"@id": "Sponsor51390", "organisation": "HagaZiekenhuis (The Netherlands)", "website": null, "sponsorType": "Hospital/treatment centre", "contactDetails": {"address": "Leyweg 275", "city": "The Hague", "country": "Netherlands", "zip": "2545 CH", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected", "gridId": "grid.413591.b", "rorId": "https://ror.org/03q4p1y48"}, "funder": {"@id": "Funder15021-0", "name": "The Netherlands Organisation for Health Research and Development (ZonMw) (The Netherlands)", "fundRef": null}}, {"trial": {"@lastUpdated": "2008-08-15T00:00:00.000Z", "@version": "23", "isrctn": {"@dateAssigned": "2006-02-21T00:00:00.000Z", "#text": "03001669"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "European Community SYStemic VASculitis TRIALs group", "scientificTitle": null, "acronym": "ECSYSVASTRIAL", "studyHypothesis": "Plasma exchange is superior to high dose intravenous methylprednisolone in the treatment of severe renal vasculitis.", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "Renal recovery at three months", "secondaryOutcome": "End stage renal disease at one year, severe adverse events", "trialWebsite": "http://www.vasculitis.org", "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Received from the Cambridge Local Research Ethics Committee in March 1995."}, "externalRefs": {"doi": "10.1186/ISRCTN03001669", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "N/A"}, "trialDesign": {"studyDesign": "Interventional, randomised, controlled trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Not specified"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "1995-03-01T00:00:00.000Z", "overallEndDate": "2001-01-31T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": ["England", "United Kingdom"]}, "trialCentres": {"trialCentre": {"@id": "f7174f0d-d2bc-41de-b9dd-75388a952c4c", "name": "Box 118", "address": null, "city": "Cambridge", "state": null, "country": "United Kingdom", "zip": "CB2 2QQ"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. New diagnosis of Wegener granulomatosis (WG), micropolyarteritis (MP) or its renal-limited variant, in accordance with the Chapel Hill Consensus criteria, with active vasculitis, as indicated by the presence of active necrotising glomerulonephritis on renal biopsy\n2. Anti-neutrophilic cytoplasmic antibodies (ANCA) positivity: either a typical cytoplasmic-ANCA pattern by immunofluorescence test (IIF), and/or positivity in the proteinase-3 enzyme-linked immunosorbent assay (Pr3 ELISA), or positivity in the myeloperoxidase (MPO) ELISA, with or without perinuclear-ANCA (ANCA result will be confirmed by a nominated reference laboratory)\n3. Biopsy-proven necrotising and/or crescentic glomerulonephritis, in the absence of another defined glomerulopathy, with severe renal impairment as defined by either:\n3.1. Oliguria (less than 400 ml/24 hr) or\n3.2. Intention to commence dialysis within 48 hours of admission", "ageRange": "Adult", "gender": "Both", "targetEnrolment": "150", "totalFinalEnrolment": null, "totalTarget": "150", "exclusion": "1. Aged less than 18 or over 80\n2. Inadequate contraception in women of child-bearing age\n3. Pregnancy\n4. Usually exclude patients with previous malignancy (unless agreed with trial coordinators)\n5. Hepatitis B antigenaemia or detectable anti-hepatitis C virus antibody\n6. Known anti-human immunodeficiency virus (anti-HIV) (HIV testing is not a requirement for this trial)\n7. Diagnosis of Churg-Strauss syndrome, Henoch-Schonlein purpura, rheumatoid vasculitis, mixed essential cryoglobulinaemia, systemic lupus erythematosus, or the presence of circulating anti-glomerular basement membrane (anti-GBM) antibodies and linear gamma G immunoglobulin (IgG) staining of the GBM on renal biopsy, with intent to treat as anti-GBM mediated nephritis\n8. Life-threatening non-renal manifestations of vasculitis, including alveolar haemorrhage requiring mechanical ventilation within 24 hours of admission\n9. On dialysis for more than two weeks prior to referral\n10. Significant baseline renal impairment: creatinine greater than 200 mmol/l one year or more before presentation\n11. A second clearly defined cause of renal failure (e.g. urinary tract obstruction; not acute tubular necrosis [ATN])\n12. Previous episode of biopsy-proven necrotising and/or crescentic glomerulonephritis\n13. Intravenous methylprednisolone (IVMeP), plasma exchange (PE) or pulsed intravenous cyclophosphamide within the preceding year\n14. More than two weeks treatment with oral cyclophosphamide (Cyc) or azathioprine (Aza)\n15. More than three months treatment with oral corticosteroids (OCS)\n16. Allergy to study medications (excluding prophylactic agents)\n17. Previous IVMeP therapy, which exceeds a single dose of 500 mg prior to referral to the participating centre", "patientInfoSheet": null, "recruitmentStart": "1995-03-01T00:00:00.000Z", "recruitmentEnd": "2001-01-31T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "ANCA associated vasculitis", "diseaseClass1": "Circulatory System", "diseaseClass2": "Other disorders of arteries and arterioles"}}, "interventions": {"intervention": {"description": "Plasma exchange versus high dose intravenous methyl prednisolone", "interventionType": "Drug", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": "Methyl prednisolone"}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": "2007 Results article in http://www.ncbi.nlm.nih.gov/pubmed/17582159 Results", "publicationStage": "Results", "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": {"output": {"@id": "58774377-383e-4b72-aa94-39ed16c584e7", "@outputType": "resultsarticle", "@artefactType": "ExternalLink", "@dateCreated": "2007-07-01T00:00:00.000Z", "@dateUploaded": "", "@peerReviewed": "true", "@patientFacing": "false", "@createdBy": "Data migration", "externalLink": {"@url": "http://www.ncbi.nlm.nih.gov/pubmed/17582159"}, "description": "Results", "productionNotes": null}}, "parties": {"funderId": "Funder14721-0", "contactId": "Contact52483_14721", "sponsorId": "Sponsor50998"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact52483_14721", "title": "Dr", "forename": "David", "surname": "Jayne", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Box 118\nRenal Unit\nAddenbrookes Hospital", "city": "Cambridge", "country": "United Kingdom", "zip": "CB2 2QQ", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+44 (0)1223 217259"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "dj106@cam.ac.uk"}}, "privacy": "Public"}, "sponsor": {"@id": "Sponsor50998", "organisation": "Addenbrookes Hospital NHS Trust (UK)", "website": null, "sponsorType": "Hospital/treatment centre", "contactDetails": {"address": "Addenbrookes Hospital\nHills road", "city": "Cambridge", "state": "England", "country": "United Kingdom", "zip": "CB2 2QQ", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected", "gridId": "grid.120073.7", "rorId": "https://ror.org/055vbxf86"}, "funder": {"@id": "Funder14721-0", "name": "European Union (Belgium) - Biomedical and Health Research Programme (BIOMED) (contract number BMH4-CT97-2328)", "fundRef": null}}, {"trial": {"@lastUpdated": "2008-08-15T00:00:00.000Z", "@version": "20", "isrctn": {"@dateAssigned": "2005-12-20T00:00:00.000Z", "#text": "14473912"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "Low dose vitamin K to improve therapeutic quality control of oral anticoagulant treatment: a randomised double-blind placebo controlled trial", "scientificTitle": null, "acronym": null, "studyHypothesis": "1. Oral anticoagulant control is less stable at a low average intake of vitamin K\n2. As a consequence, a low dose vitamin K supplement results in a more stable anticoagulant effect in patients using vitamin K antagonists (VKA)\n3. Dietary intake of vitamin K is associated with sensitivity to VKA and stability of anticoagulant treatment\n4. Polymorphisms of the VKORC1 gene are associated with sensitivity to VKA and stability of anticoagulant treatment", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "1. Quality of anticoagulant treatment\n2. Expressed as time in therapeutic range", "secondaryOutcome": "1. Number of international normalised ratios (INRs) in therapeutic range\n2. Bleeding and thromboembolic complications", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Ethics approval received from the local medical ethics committee"}, "externalRefs": {"doi": "10.1186/ISRCTN14473912", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "Project 2005.2; NTR314"}, "trialDesign": {"studyDesign": "Randomised, double-blinded, placebo controlled parallel group trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Hospital"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2004-11-16T00:00:00.000Z", "overallEndDate": "2006-06-01T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": "Netherlands"}, "trialCentres": {"trialCentre": {"@id": "d3eb02d1-c2c7-49d9-a628-fabe09b10a8b", "name": "Leiden University Medical Center", "address": null, "city": "Leiden", "state": null, "country": "Netherlands", "zip": "2300 RC"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. Patients treated at the Leiden anticoagulation clinic with an indication for long-term oral anticoagulant therapy using the vitamin K antagonist phenprocoumon\n2. Age between 18 and 80 years\n3. Informed consent", "ageRange": "Adult", "lowerAgeLimit": {"@unit": "Years", "@value": "18.0"}, "upperAgeLimit": {"@unit": "Years", "@value": "80.0"}, "gender": "Both", "targetEnrolment": "200", "totalFinalEnrolment": null, "totalTarget": "200", "exclusion": "1. Treatment by a medical specialist for liver failure\n2. Haemo or peritoneal dialysis\n3. Pregnancy or a planned pregnancy, puerperium\n4. Any chronic condition with an expected median survival of less than 6 months\nan expected interruption of oral anticoagulant treatment of more than 1 week\n5. Self-management of oral anticoagulant therapy\n6. Other drugs affecting haemostasis (aspirin, heparin, clopidogrel)", "patientInfoSheet": null, "recruitmentStart": "2004-11-16T00:00:00.000Z", "recruitmentEnd": "2006-06-01T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Thrombosis, emboly, anticoagulant treatment", "diseaseClass1": "Haematological Disorders", "diseaseClass2": "Anticoagulant treatment"}}, "interventions": {"intervention": {"description": "1. Treatment group: 100 microgram vitamin K for 24 weeks\n2. Placebo group: placebo for 24 weeks", "interventionType": "Supplement", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": "Vitamin K"}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": null, "publicationStage": null, "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": null, "parties": {"funderId": "Funder14514-0", "contactId": "Contact52123_14514", "sponsorId": "Sponsor50726"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact52123_14514", "title": "Dr", "forename": "F.J.M.", "surname": "van der Meer", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Leiden University Medical Center\nDepartment of Hematology\nP.O. Box 9600", "city": "Leiden", "country": "Netherlands", "zip": "2300 RC", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+31 (0)71 5263901"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "f.j.m.van_der_meer@lumc.nl"}}, "privacy": "Public"}, "sponsor": {"@id": "Sponsor50726", "organisation": "Leiden University Medical Center (LUMC) (The Netherlands)", "website": "http://www.lumc.nl/english/start_english.html", "sponsorType": "Charity", "contactDetails": {"address": "Department of Hematology \nP.O. Box 9600", "city": "Leiden", "country": "Netherlands", "zip": "2300 RC", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected", "gridId": "grid.10419.3d", "rorId": "https://ror.org/05xvt9f17"}, "funder": {"@id": "Funder14514-0", "name": "Dutch Thrombosis Foundation (Trombosestichting Nederland) (The Netherlands)", "fundRef": null}}, {"trial": {"@lastUpdated": "2008-09-02T00:00:00.000Z", "@version": "22", "isrctn": {"@dateAssigned": "2005-12-20T00:00:00.000Z", "#text": "60446748"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "Comparative study of the stability of oral anticoagulant therapy using phenprocoumon or warfarin.", "scientificTitle": null, "acronym": null, "studyHypothesis": "Long acting coumarin derivatives can reach a more stable anticoagulant effect. Short acting coumarins are more easy to adjust. The half-life of warfarin lies between the half-life of acenocoumarol and phenprocoumon and can thereby possibly have the advantage of long acting coumarins as well as the advantage of short acting coumarins.", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "Time spent within therapeutic range, time to the first international normalised ratio (INR) in range, percentage of INRs above range after initiation scheme, reaction of INR to interruption of coumarin or vitamin K administration.", "secondaryOutcome": "1. Bleeding complications\n2. Thrombotic complications", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Ethics approval received from the local medical ethics committee"}, "externalRefs": {"doi": "10.1186/ISRCTN60446748", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "P99-134; NTR319"}, "trialDesign": {"studyDesign": "Randomised, active controlled, parallel group trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Not specified"}, "trialTypes": {"trialType": "Not Specified"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2004-03-01T00:00:00.000Z", "overallEndDate": "2006-12-31T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": "Netherlands"}, "trialCentres": {"trialCentre": {"@id": "68d69474-5669-4c7b-bf22-fe30d6c0e2d1", "name": "Leiden University Medical Centre (LUMC)", "address": null, "city": "Leiden", "state": null, "country": "Netherlands", "zip": "2300 RC"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. No current use of anticoagulants\n2. Aged 18 to 85 years\n3. Indication for the use of oral anticoagulants\n4. Living in the working area of the Leiden Anticoagulation Clinic\n5. Adequate intelligence, informed consent", "ageRange": "Adult", "lowerAgeLimit": {"@unit": "Years", "@value": "18.0"}, "upperAgeLimit": {"@unit": "Years", "@value": "85.0"}, "gender": "Both", "targetEnrolment": "500", "totalFinalEnrolment": null, "totalTarget": "500", "exclusion": "1. Pregnancy\n2. Chemotherapy\n3. Haemo- or peritoneal dialysis\n4. Plasmapheresis\n5. Contra-indication for the use of oral anticoagulants", "patientInfoSheet": null, "recruitmentStart": "2004-03-01T00:00:00.000Z", "recruitmentEnd": "2006-12-31T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Anticoagulant treatment", "diseaseClass1": "Haematological Disorders", "diseaseClass2": "Other coagulation defects"}}, "interventions": {"intervention": {"description": "1. Treatment group: oral anticoagulant treatment with warfarin\n2. Control group:  oral anticoagulant treatment with phenprocoumon", "interventionType": "Drug", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": "Phenprocoumon, warfarin"}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": null, "publicationStage": null, "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": null, "parties": {"funderId": "Funder14518-0", "contactId": "Contact52238_14518", "sponsorId": "Sponsor50754"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact52238_14518", "title": "Prof", "forename": "F.R.", "surname": "Rosendaal", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Leiden University Medical Centre (LUMC)\nDepartment of Clinical Epidemiology\nP.O. Box 9600", "city": "Leiden", "country": "Netherlands", "zip": "2300 RC", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+31 (0)71 5264037"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "f.r.rosendaal@lumc.nl"}}, "privacy": "Public"}, "sponsor": {"@id": "Sponsor50754", "organisation": "Leiden University Medical Centre (LUMC) (Netherlands)", "website": "http://www.lumc.nl/", "sponsorType": "University/education", "contactDetails": {"address": "Albinusdreef 2\nP.O. Box 9600", "city": "Leiden", "state": null, "country": "Netherlands", "zip": "2300 RC", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected", "gridId": "grid.5132.5", "rorId": "https://ror.org/027bh9e22"}, "funder": {"@id": "Funder14518-0", "name": "Leiden University Medical Centre (LUMC) (The Netherlands)", "fundRef": null}}, {"trial": {"@lastUpdated": "2008-08-15T00:00:00.000Z", "@version": "20", "isrctn": {"@dateAssigned": "2005-12-20T00:00:00.000Z", "#text": "61345286"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "Randomised study on haemoglobin response in iron-deficient anaemic patients with solid malignancies receiving epoetin alfa (rHuEPO) in combination with either oral or parental iron supplementation during treatment with non-platinum containing chemotherapy", "scientificTitle": null, "acronym": null, "studyHypothesis": "To determine optimal route of iron supplementation during treatment with non-platinum containing chemotherapy for solid tumours.", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "Increase in Hb", "secondaryOutcome": "1. Number of required blood transfusions\n2. Total dose of administered recombinant human erythropoietin alpha (rHuEPO)", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Ethics approval received from the local medical ethics committee"}, "externalRefs": {"doi": "10.1186/ISRCTN61345286", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "NTR250"}, "trialDesign": {"studyDesign": "Multicentre, randomised, active controlled, parallel group trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Hospital"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2001-02-01T00:00:00.000Z", "overallEndDate": "2003-07-30T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": "Netherlands"}, "trialCentres": {"trialCentre": {"@id": "fb35c403-93ac-4004-8994-c9941448f809", "name": "VU Medical Centre", "address": null, "city": "Amsterdam", "state": null, "country": "Netherlands", "zip": "1007 MB"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. Confirmed diagnosis of a solid malignancy and planned to receive further non-platinum containing chemotherapy for at least 12 weeks\n2. Haemoglobin (Hb) less than or equal to 7.5 mmol/L at any time during chemotherapy\n3. Transferrin saturation (TSAT) less than 20% and/or serum ferritin less than 100 ng/ml\n4. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2\n5. Life expectancy at least 3 months\n6. Aged between 18 - 75 years\n7. Sex: male or female. Female subjects must be either postmenopausal (for at least for 1 year), sterilised or, if of childbearing potential, be practising an acceptable method of birth control.\n8. Subjects must have read and signed the informed consent form", "ageRange": "Adult", "lowerAgeLimit": {"@unit": "Years", "@value": "18.0"}, "gender": "Both", "targetEnrolment": "34", "totalFinalEnrolment": null, "totalTarget": "34", "exclusion": "1. Mean corpuscular volume (MCV) less than 80 fL and mean corpuscular haemoglobin count (MCHC) less than 195 mmol/L\n2. MCV greater than 100 fL\n3. Clinically significant chronic blood loss\n4. Clinically significant disease/dysfunction of the pulmonary, cardiovascular, endocrine, neurological, gastrointestinal, or genitourinary systems not attributable to underlying malignancy or chemotherapy. This dysfunction is only an exclusion criteria if it causes an expected early withdrawal from the study.\n5. Uncontrolled hypertension, defined as a diastolic blood pressure greater than 100 mmHg, despite antihypertensive medication\n6. History of seizures\n7. Known hypersensitivity to Epoetin alfa or one of its components\n8. Administration of intravenous iron preparations within 3 months before study entry\n9. Participation in any other clinical trial involving unlicensed medication or procedures\n10. Androgen therapy within two months of study entry", "patientInfoSheet": null, "recruitmentStart": "2001-02-01T00:00:00.000Z", "recruitmentEnd": "2003-07-30T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Anaemia", "diseaseClass1": "Haematological Disorders", "diseaseClass2": "Anaemia in chronic diseases classified elsewhere"}}, "interventions": {"intervention": {"description": "Epoetin alfa, iron (III)-hydroxyde-sucrose, ferrofumarate.", "interventionType": "Supplement", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": "Iron supplementation, Epoetine alfa, iron (III)-hydroxyde-sucrose, ferrofumarate"}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": null, "publicationStage": null, "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": null, "parties": {"funderId": "Funder14458-0", "contactId": "Contact52258_14458", "sponsorId": "Sponsor50855"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact52258_14458", "title": "Prof", "forename": "Giuseppe", "surname": "Giaccone", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "VU Medical Centre\nPrincipal Investigator Medical Oncology\n6 Z 170\nP.O. Box 7057", "city": "Amsterdam", "country": "Netherlands", "zip": "1007 MB", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+31 (0)20 4444321"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "g.giaccone@vumc.nl"}}, "privacy": "Public"}, "sponsor": {"@id": "Sponsor50855", "organisation": "Vrije University Medical Centre (VUMC) (The Netherlands)", "website": "http://www.vumc.nl", "sponsorType": "University/education", "contactDetails": {"address": "Van der Boechorststraat 7", "city": "Amsterdam", "country": "Netherlands", "zip": "1081 BT", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected", "gridId": "grid.16872.3a", "rorId": "https://ror.org/00q6h8f30"}, "funder": {"@id": "Funder14458-0", "name": "Vrije University Medical Centre (VUMC) (The Netherlands)", "fundRef": null}}, {"trial": {"@lastUpdated": "2008-09-02T00:00:00.000Z", "@version": "20", "isrctn": {"@dateAssigned": "2005-12-20T00:00:00.000Z", "#text": "10353850"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "Use of preoperative desmopressin in preventing bleeding in patients treated with selective serotonin reuptake inhibitors (SSRIs)", "scientificTitle": null, "acronym": null, "studyHypothesis": "Not provided at time of registration", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "Pre- and post-operative blood loss.", "secondaryOutcome": "1. Peri- and post-operative haemoglobin\n2. Number of peri-operative blood transfusion\n3. Peri-operative fluid infusion\n4. Post-operative drainage", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Not provided at time of registration"}, "externalRefs": {"doi": "10.1186/ISRCTN10353850", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "UMCU 04-298; NTR175"}, "trialDesign": {"studyDesign": "Randomised, double-blinded, placebo controlled, parallel group trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Not specified"}, "trialTypes": {"trialType": "Not Specified"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2005-01-01T00:00:00.000Z", "overallEndDate": "2007-06-01T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": "Netherlands"}, "trialCentres": {"trialCentre": {"@id": "19167d67-b11b-436f-959f-04b1e039e226", "name": "Willy Brandtlaan 10", "address": null, "city": "Ede", "state": null, "country": "Netherlands", "zip": "6716 RP"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. Patients aged over 18 who receive a serotonergic antidepressant (fluvoxamine, fluoxetine, paroxetine, sertraline, venlafaxine, clomipramine, citalopram) at least started two weeks before the surgery\n2. Surgery: orthopedic, abdominal, breast", "ageRange": "Adult", "lowerAgeLimit": {"@unit": "Years", "@value": "18.0"}, "gender": "Not Specified", "targetEnrolment": "300", "totalFinalEnrolment": null, "totalTarget": "300. Patients have been recruited since 07/04/05.", "exclusion": "1. No informed consent\n2. Disorder in primary haemostasis \n3. Hyponatraemia (sodium [serum] less than 130 mmol/l)\n4. Laparoscopic surgery\n5. Use of vitamin K antagonists, aspirin, iron supplements, methotrexate, heparin\n6. Acute coronary syndrome (unstable angina and myocardial infarction)\n7. Spinal anaesthesia during surgery", "patientInfoSheet": null, "recruitmentStart": "2005-01-01T00:00:00.000Z", "recruitmentEnd": "2007-06-01T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Primary haemostasis disorder", "diseaseClass1": "Surgery", "diseaseClass2": "Procedural bleeding"}}, "interventions": {"intervention": {"description": "Pre-operative infusion placebo/desmopressin:\n1. Less than 50 kg: 15 \u00b5g\n2. 50 - 100 kg: 30 \u00b5g\n3. Greater than 100 kg: 45 \u00b5g", "interventionType": "Drug", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": "Desmopressin"}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": null, "publicationStage": null, "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": null, "parties": {"funderId": "Funder14396-0", "contactId": "Contact52231_14396", "sponsorId": "Sponsor50608"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact52231_14396", "title": "Dr", "forename": "S.C.", "surname": "Marczinski", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Willy Brandtlaan 10", "city": "Ede", "country": "Netherlands", "zip": "6716 RP", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+31 (0)318 435546"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "Marczinskis@zgv.nl"}}, "privacy": "Public"}, "sponsor": {"@id": "Sponsor50608", "organisation": "Hospital Gelderse Vallei (The Netherlands)", "website": null, "sponsorType": "Hospital/treatment centre", "contactDetails": {"address": "P.O. Box 9025", "city": "Ede", "country": "Netherlands", "zip": "6710 HN", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected", "gridId": "grid.415351.7", "rorId": "https://ror.org/03862t386"}, "funder": {"@id": "Funder14396-0", "name": "Hospital Gelderse Vallei (The Netherlands)", "fundRef": null}}, {"trial": {"@lastUpdated": "2008-08-21T00:00:00.000Z", "@version": "21", "isrctn": {"@dateAssigned": "2005-09-30T00:00:00.000Z", "#text": "95861257"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "The effect of pumicing prior to the use of a self-etching primer bonding system", "scientificTitle": null, "acronym": null, "studyHypothesis": "Is it necessary to polish the teeth prior to the use of a self etching primer?", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "The outcome measures were bracket ie bond failures during treatment and Adhesive Remnant Scores ie how much adhesive was left on the teeth. However, \nthe bond failure rate was so high we discontinued the trial at 14 patients.", "secondaryOutcome": "Not provided at time of registration", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Not provided at time of registration"}, "externalRefs": {"doi": "10.1186/ISRCTN95861257", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "N0212123054"}, "trialDesign": {"studyDesign": "Randomised controlled trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Not specified"}, "trialTypes": {"trialType": "Not Specified"}, "overallStatusOverride": "Stopped", "reasonAbandoned": "The bond failure rate was so high we discontinued the trial at 14 patients.", "overallStartDate": "2003-04-01T00:00:00.000Z", "overallEndDate": "2005-03-01T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": ["England", "United Kingdom"]}, "trialCentres": {"trialCentre": {"@id": "c6d3b969-c250-49d8-a7a5-f9aefdfb13a8", "name": "Orthodontics", "address": null, "city": "Bath", "state": null, "country": "United Kingdom", "zip": "BA1 3NG"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "Patients attending for the provision of full and lower fixed appliances", "ageRange": "Not Specified", "gender": "Not Specified", "targetEnrolment": "14", "totalFinalEnrolment": null, "totalTarget": "Initially 30 patients but discontinued at 14 patients", "exclusion": "Patients without heavily restored teeth", "patientInfoSheet": null, "recruitmentStart": "2003-04-01T00:00:00.000Z", "recruitmentEnd": "2005-03-01T00:00:00.000Z", "recruitmentStatusOverride": "Stopped"}, "conditions": {"condition": {"description": "Oral Health", "diseaseClass1": "Oral Health", "diseaseClass2": null}}, "interventions": {"intervention": {"description": "Randomised controlled trial", "interventionType": "Other", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": null}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": "2006 Results article in http://www.ncbi.nlm.nih.gov/pubmed/16448279 results", "publicationStage": "Results", "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": {"output": {"@id": "b92f77db-1b75-401d-8d25-dfe39cc07494", "@outputType": "resultsarticle", "@artefactType": "ExternalLink", "@dateCreated": "2006-01-01T00:00:00.000Z", "@dateUploaded": "", "@peerReviewed": "true", "@patientFacing": "false", "@createdBy": "Data migration", "externalLink": {"@url": "http://www.ncbi.nlm.nih.gov/pubmed/16448279"}, "description": "results", "productionNotes": null}}, "parties": {"funderId": "Funder13994-0", "contactId": "Contact51666_13994", "sponsorId": "Sponsor50215"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact51666_13994", "title": "Mr", "forename": "Anthony", "surname": "Ireland", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Orthodontics\nRoyal United Hospital", "city": "Bath", "country": "United Kingdom", "zip": "BA1 3NG", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+44 (0)1225 824269"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "Tony.Ireland@ruh-bath.swest.nhs.uk"}}, "privacy": "Public"}, "sponsor": {"@id": "Sponsor50215", "organisation": "Department of Health", "website": "http://www.dh.gov.uk/Home/fs/en", "sponsorType": "Government", "contactDetails": {"address": "Richmond House\n79 Whitehall", "city": "London", "country": "United Kingdom", "zip": "SW1A 2NL", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+44 (0)20 7307 2622"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "dhmail@doh.gsi.org.uk"}}, "privacy": "Public"}, "funder": {"@id": "Funder13994-0", "name": "Royal United Hospital Bath NHS Trust (UK)", "fundRef": null}}, {"trial": {"@lastUpdated": "2008-08-27T00:00:00.000Z", "@version": "22", "isrctn": {"@dateAssigned": "2005-09-30T00:00:00.000Z", "#text": "15806146"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "The effect of modulating gut microflora on clinical outcome in elective surgical patients.", "scientificTitle": null, "acronym": null, "studyHypothesis": "The aim of this study is to investigate whether or not modulation of gastrointestinal microflora might impact upon septic morbidity in surgical patients?", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "Gut microflora:\n1. Nasogastric aspirate\n2. Fecal samples.\n\nGut barrier function: \n1. Bacterial Translocation\n2. Intestinal Permeability.\n\nInflammatory response:\n1. C reactive protein (CRP)\n2. Interleukin-6 (IL-6)\n3. AntiEndotoxin core antibody (IgM Endo CAB).\n\nSeptic morbidity:\n1. Wound infection\n2. Intra-abdominal abscess\n3. Chest Infection\n4. UTI.", "secondaryOutcome": "Not provided at time of registration", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Not provided at time of registration"}, "externalRefs": {"doi": "10.1186/ISRCTN15806146", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "N0285150582"}, "trialDesign": {"studyDesign": "Randomised controlled trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Not specified"}, "trialTypes": {"trialType": "Not Specified"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2004-07-19T00:00:00.000Z", "overallEndDate": "2005-10-01T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": ["England", "United Kingdom"]}, "trialCentres": {"trialCentre": {"@id": "8fb7eb30-4956-4419-ac99-14c3cb372fb0", "name": "Dept of General Surgery", "address": null, "city": "Scarborough", "state": null, "country": "United Kingdom", "zip": "YO12 6QL"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "Using bacterial translocation as the primary end point for sample size calculation, if the sample size in each of the 4 groups is 20, alpha=0.05 (2-tailed) a chi-square test will have 80% power to detect a difference in proportions.", "ageRange": "Not Specified", "gender": "Not Specified", "targetEnrolment": "80", "totalFinalEnrolment": null, "totalTarget": "80", "exclusion": "Failure to obtain informed consent, patients with co-existing infections, patients on antibiotics in the previous 2 weeks before recruitment and patients with severe hepatic or renal failure.", "patientInfoSheet": null, "recruitmentStart": "2004-07-19T00:00:00.000Z", "recruitmentEnd": "2005-10-01T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Signs and Symptoms: Sepsis", "diseaseClass1": "Signs and Symptoms", "diseaseClass2": "Sepsis"}}, "interventions": {"intervention": {"description": "Patients will be recruited from the elective colorectal admissions at Scarborough Hospital and will be randomised by a series of sealed envelopes into one of the four groups when they are seen in the pre-assessment clinic.\n\nGroup 1 - Control group. \nGroup 2 - Will receive Neomycin prior to surgery plus bowel preparation. \nGroup 3 - Neomycin, bowel prep, plus synbiotics. Group 4 -  Neomycin, symbiotics but no bowel preparation.", "interventionType": "Other", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": null}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": "2007 Results article in http://www.ncbi.nlm.nih.gov/pubmed/17443852 results", "publicationStage": "Results", "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": {"output": {"@id": "134329f9-695e-4033-87a7-8ce33472eb48", "@outputType": "resultsarticle", "@artefactType": "ExternalLink", "@dateCreated": "2007-05-01T00:00:00.000Z", "@dateUploaded": "", "@peerReviewed": "true", "@patientFacing": "false", "@createdBy": "Data migration", "externalLink": {"@url": "http://www.ncbi.nlm.nih.gov/pubmed/17443852"}, "description": "results", "productionNotes": null}}, "parties": {"funderId": ["Funder14063-0", "Funder14063-1"], "contactId": "Contact51670_14063", "sponsorId": "Sponsor50215"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact51670_14063", "title": "Mr", "forename": "Bala S", "surname": "Reddy", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Dept of General Surgery\nScarborough General Hospital\nWoodlands Drive", "city": "Scarborough", "country": "United Kingdom", "zip": "YO12 6QL", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+44 (0)1723 368111"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "drbalasreddy@yahoo.co.uk"}}, "privacy": "Public"}, "sponsor": {"@id": "Sponsor50215", "organisation": "Department of Health", "website": "http://www.dh.gov.uk/Home/fs/en", "sponsorType": "Government", "contactDetails": {"address": "Richmond House\n79 Whitehall", "city": "London", "country": "United Kingdom", "zip": "SW1A 2NL", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+44 (0)20 7307 2622"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "dhmail@doh.gsi.org.uk"}}, "privacy": "Public"}, "funder": [{"@id": "Funder14063-0", "name": "North Yorkshire Alliance R&D Unit (UK)", "fundRef": null}, {"@id": "Funder14063-1", "name": "Scarborough & NE Yorkshire Healthcare NHS Trust (UK)", "fundRef": null}]}, {"trial": {"@lastUpdated": "2008-08-27T00:00:00.000Z", "@version": "21", "isrctn": {"@dateAssigned": "2005-09-30T00:00:00.000Z", "#text": "36070540"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "A comparison between the Insulin Tolerance Test (ITT) and the combined growth Hormone Releasing Hormone and Arginine test to determine Growth Hormone (GH) status in cranially irradiated patients.", "scientificTitle": null, "acronym": null, "studyHypothesis": "We aim to study the pattern of growth hormone response to a combination of GHRH (growth hormone releasing hormone) plus Arginine in adults with radiation induced growth hormone deficiency, to find out whether this stimulation test can successfully replace the Insulin Tolerance Test (ITT) for the diagnosis of radiation-induced growth hormone.", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "Primary end point: growth hormone response to different provocative tests.", "secondaryOutcome": "Not provided at time of registration", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Not provided at time of registration"}, "externalRefs": {"doi": "10.1186/ISRCTN36070540", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "N0063072321"}, "trialDesign": {"studyDesign": "Randomised controlled trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Hospital"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2000-05-26T00:00:00.000Z", "overallEndDate": "2008-12-31T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": ["England", "United Kingdom"]}, "trialCentres": {"trialCentre": {"@id": "47d399fc-d8fa-45ad-bb1d-0aac5b2b8bb0", "name": "Endocrinology", "address": null, "city": "Manchester", "state": null, "country": "United Kingdom", "zip": "M20 4BX"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "Not provided at time of registration", "ageRange": "Adult", "gender": "Not Specified", "targetEnrolment": "40", "totalFinalEnrolment": null, "totalTarget": "30-40 patients from the Trust will be entered to this study.", "exclusion": "1. Patients with pituitary tumours or previous surgery in the hypothalamic-pituitary field (non radiation-induced damage)\n2. Patients with active or uncured malignancy\n3. Patients who are suffering from any condition or disease or taking any medication that might affect the function of the hypothalamic-pituitary axis or interfere with the interpretation of the tests\n4. Failure to sign an informed consent", "patientInfoSheet": null, "recruitmentStart": "2000-05-26T00:00:00.000Z", "recruitmentEnd": "2008-12-31T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Nutritional, Metabolic, Endocrine: Growth hormone deficiency", "diseaseClass1": "Nutritional, Metabolic, Endocrine", "diseaseClass2": "Growth hormone deficiency"}}, "interventions": {"intervention": {"description": "Patients will be reviewed in Endocrine Clinic.  Those who fulfil the inclusion criteria will be invited to participate.  An information sheet will provide full details of the study and what is involved.  It is established practice that patients sign an informed consent before undergoing GH tests.  Patients will undergo the ITT and GHRH+ARG. Stimulation tests in random order, at least three days apart.  After overnight fasting, the patient will be admitted to the endocrine unit at 08:30h. A cannula will be inserted into a forearm vein and kept patent by normal saline.  For the ITT, a bolus of 0.1u/kgregular insulin (actrapid) will be given intravenously and the blood glucose level measured (by glucometer) every 15 min.  The patient will not be left unattended until the test is finished and the blood glucose level has returned to normal.\nFor the GHRH+Arginine test, a bolus of 1ug/kg GHRH24 will be infused over 30 min, from 0 to 30 min.  Blood samples will be taken every 15 min from -15 to 120 min.  They will be assayed for GH, IGF-I, IGFBP3 and Acid Labile sub-unit (ALS).", "interventionType": "Drug", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": "combination of GHRH (growth hormone releasing hormone) plus Arginine"}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": "2003 Results article in http://www.ncbi.nlm.nih.gov/pubmed/12519836 results", "publicationStage": "Results", "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": {"output": {"@id": "3e4fda80-0cf5-4a19-969e-7be4fc26a240", "@outputType": "resultsarticle", "@artefactType": "ExternalLink", "@dateCreated": "2003-01-01T00:00:00.000Z", "@dateUploaded": "", "@peerReviewed": "true", "@patientFacing": "false", "@createdBy": "Data migration", "externalLink": {"@url": "http://www.ncbi.nlm.nih.gov/pubmed/12519836"}, "description": "results", "productionNotes": null}}, "parties": {"funderId": "Funder13905-0", "contactId": "Contact51787_13905", "sponsorId": "Sponsor50215"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact51787_13905", "title": "Prof", "forename": "S M", "surname": "Shalet", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Endocrinology\nChristie Hospital NHS Trust\nWilmslow Road\nWithington", "city": "Manchester", "country": "United Kingdom", "zip": "M20 4BX", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+44 (0)161 446 3667"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "stephen.m.shalet@manchester.ac.uk"}}, "privacy": "Public"}, "sponsor": {"@id": "Sponsor50215", "organisation": "Department of Health", "website": "http://www.dh.gov.uk/Home/fs/en", "sponsorType": "Government", "contactDetails": {"address": "Richmond House\n79 Whitehall", "city": "London", "country": "United Kingdom", "zip": "SW1A 2NL", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+44 (0)20 7307 2622"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "dhmail@doh.gsi.org.uk"}}, "privacy": "Public"}, "funder": {"@id": "Funder13905-0", "name": "Christie Hospital NHS Trust, Christie Endocrinology Department Research Fund (UK), NHS R&D Support Funding", "fundRef": null}}, {"trial": {"@lastUpdated": "2008-08-20T00:00:00.000Z", "@version": "18", "isrctn": {"@dateAssigned": "2005-09-16T00:00:00.000Z", "#text": "94256573"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "First International Randomised trial in Locally Advanced and Metastatic Adrenocortical Cancer Treatment  -  Etoposide, Doxorubicin, Cisplatin and Mitotane versus Streptozotocin and Mitotane", "scientificTitle": null, "acronym": "FIRM-ACT", "studyHypothesis": "Primary objective of this trial is to investigate whether Etoposide, Doxorubicin, Cisplatin plus Mitotane (EDP-M) as first line treatment will prolong survival as compared to Streptozotocin plus Mitotane (Sz-M) as first line treatment for advanced Adrenocortical Carcinoma (ACC).", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "Overall survival", "secondaryOutcome": "1. Quality of life as measured by EORTC QLQ-C30\n2. Time to progression\n3. Best overall response rate and duration of response\n4. Number of disease-free patients\n5. Impact of reaching mitotane blood levels between 14-20 mg/l in both arms on survival and best overall response rate\n6. Best overall response rate of both regimens as second line treatment in case of failure of the initial other regime", "trialWebsite": "http://www.firm-act.org", "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Not provided at time of registration"}, "externalRefs": {"doi": "10.1186/ISRCTN94256573", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "CO-ACT-001"}, "trialDesign": {"studyDesign": "Randomised controlled trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Not specified"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2004-07-01T00:00:00.000Z", "overallEndDate": "2011-12-31T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": ["Australia", "France", "Germany", "Italy", "Netherlands", "Sweden", "United States of America"]}, "trialCentres": {"trialCentre": {"@id": "9cf910a4-c6ee-4443-a756-83cbd30300ee", "name": "University Hospital Uppsala", "address": null, "city": "Uppsala", "state": null, "country": "Sweden", "zip": "75185"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. Histologically confirmed diagnosis of adrenocortical carcinoma\n2. Locally advanced or metastatic disease not amenable to radical surgical resection (Stage III-IV)\n3. Radiologically monitorable disease\n4. Eastern Cooperative Oncology Group (ECOG) performance status zero to two\n5. Life expectancy more than three months\n6. Age above 18 years\n7. Adequate bone marrow reserve (neutrophils more than or equal to 1500/mm^3 and platelets more than or equal to 100,000/mm^3)\n8. Effective contraception in pre-menopausal female and male patients\n9. Patient\u0092s written informed consent\n10. Ability to comply with the protocol procedures (including availability for follow-up visits)\n11. Previous palliative surgery, radiotherapy or radiofrequency ablation is acceptable as long as radiologically monitorable disease is verifiable afterwards.", "ageRange": "Adult", "lowerAgeLimit": {"@unit": "Years", "@value": "18.0"}, "gender": "Both", "targetEnrolment": "300", "totalFinalEnrolment": null, "totalTarget": "300", "exclusion": "1. History of prior malignancy, except for cured non-melanoma skin cancer, cured in situ cervical carcinoma, or other cancers treated with no evidence of disease for at least five years\n2. Previous cytotoxic chemotherapy (prior therapy with mitotane is allowed) for adrenocortical carcinoma\n3. Renal insufficiency (serum creatinine more than or equal to 2 mg/dl or creatinine clearance less than or equal to 50 ml/min)\n4. Hepatic insufficiency (serum bilirubin more than or equal to two times the institutional upper limit of normal range and/or serum transaminases more than or equal to three times the institutional upper limit of normal range; exception: in patients on mitotane transaminase levels up to five times the institutional upper limit of normal range are acceptable)\n5. Pregnancy or breast feeding\n6. Known hypersensitivity to any drug included in the treatment protocol\n7. Presence of active infection\n8. Any other severe clinical condition that in the judgment of the local investigator would place the patient at undue risk or interfere with the study completion\n9. Decompensated heart failure (ejection fraction less than 50%), myocardial infarction or revascularization procedure during the last six months, unstable angina pectoris, and uncontrolled cardiac arrhythmia\n10. Current treatment with other experimental drugs and/or previous participation in clinical trials with other experimental agents for adrenocortical carcinoma \n11. Prisoners", "patientInfoSheet": null, "recruitmentStart": "2004-07-01T00:00:00.000Z", "recruitmentEnd": "2011-12-31T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Adrenocortical Carcinoma", "diseaseClass1": "Cancer", "diseaseClass2": "Adrenocortical carcinoma"}}, "interventions": {"intervention": {"description": "Etoposide, Doxorubicin, Cisplatin plus Mitotane (EDP/M) or Streptozotocin plus Mitotane (Sz/M) as first line treatment.\n\nThe syudy protocol is available on http://www.firm-act.org/documents/FIRM_ACT_Synopsis.pdf and http://www.firm-act.org/documents/FIRM_ACT_protocol_final.pdf", "interventionType": "Drug", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": "Etoposide, Doxorubicin, Cisplatin and Mitotane versus Streptozotocin and Mitotane"}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": null, "publicationStage": null, "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": null, "parties": {"funderId": "Funder13398-0", "contactId": "Contact51031_13398", "sponsorId": "Sponsor49424"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact51031_13398", "title": "Prof", "forename": "Britt", "surname": "Skogseid", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "University Hospital Uppsala\nEntrance 40, 5th floor", "city": "Uppsala", "country": "Sweden", "zip": "75185", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+46 186113768"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "britt.skogseid@medsci.uu.se"}}, "privacy": "Public"}, "sponsor": {"@id": "Sponsor49424", "organisation": "Collaborative group for Adrenocortical Carcinoma Therapy (CO-ACT) (Germany)", "website": "http://www.firm-act.org", "sponsorType": "Research organisation", "contactDetails": {"address": "c/o University Hospital Uppsala (Sweden) and University Hospital Wuerzburg (Germany)\nJosef-Schneider-Str. 2", "city": "Wuerzburg", "country": "Germany", "zip": "97080", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+49 (0) 931 201 36507"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "Fassnacht_m@medizin.uni-wuerzburg.de"}}, "privacy": "Public"}, "funder": {"@id": "Funder13398-0", "name": "Investigator funded trial (CO-ACT)", "fundRef": null}}, {"trial": {"@lastUpdated": "2008-08-19T00:00:00.000Z", "@version": "19", "isrctn": {"@dateAssigned": "2005-08-02T00:00:00.000Z", "#text": "85659215"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "Evaluation of Acetyl-L-Carnitine (ST 200) to reduce intensity of taxanes- or platinum-induced sensory neuropathy", "scientificTitle": null, "acronym": null, "studyHypothesis": "The clinical hypothesis to be verified is 20% response rate in the placebo group versus 40% response rate in the Acetyl-L-Carnitine group where a responder is defined as a patient having obtained a decrease of at least one grade in the NCI-CTC sensory score at treatment end as compared to baseline.\n\nPlease note that this record was updated on 05/11/2007. Changes were made to the countries of recruitment, the inclusion criteria, and the anticipated end date. The previous end date for this trial was 31/12/2006.", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "The sensory item of NCI-CTC version 3.0 dated December 12th 2003 will be the primary endpoint. In accordance with the primary objective of the study, the proportion of responder patients measured at treatment end (i.e. visit 2) will be the primary endpoint.", "secondaryOutcome": "1. Motor item of NCI-CTC version 3.0\n2. Ulnar, sural and common peroneal nerve conduction velocity (NCV)\n3. Symptoms/signs of peripheral damage\n4. Vibration perception threshold\n5. Total neuropathy score (TNS)\n6. Plasma NGF level\nAll the variables will be descriptively analysed by treatment and visit (mean, median, standard deviation, minimum and maximum for continuous variables, frequency distribution for categorical variables). Efficacy analysis will be applied in all populations. Results from the ITT population will be considered the primary ones.", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Ethics approval received from the following ethics committees:\n1. Universit\u00e0 degli Studi G. d'Annunzio on the 21st July 2005\n2. Direzione Sanitaria del P.O.S. Gerardo on the 16th September 2005\n3. Presidio Arcispedale Santa Maria Nuova on the 9th September 2005\n4. dell'A.U.S.L. Roma H on the 19th September 2005\n5. Servizio di Farmacia on the 26th September 2005\n6. Segreteria del Comitato Etico on the 15th September 2005\n7. Comitato Etico per la Sperimentazione clinica dei medicinalion the 6th February 2006\n8. Commessione Etico-Scientifica - ASL Rimini on the 12th October 2005\n9. Istituto Nazionale per lo Studio e la Cura dei Tumori on the 20th February 2006"}, "externalRefs": {"doi": "10.1186/ISRCTN85659215", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "ST200-DM-04-005"}, "trialDesign": {"studyDesign": "Randomised controlled trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Not specified"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2005-07-01T00:00:00.000Z", "overallEndDate": "2009-06-01T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": ["Belgium", "France", "Italy"]}, "trialCentres": {"trialCentre": {"@id": "8628d104-8b6e-417e-a8b6-9fa99b5af2cd", "name": "Via Pontina km 30,400", "address": null, "city": "Pomezia (Rome)", "state": null, "country": "Italy", "zip": "00040"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "Current inclusion criteria as of 05/11/2007:\nPatients (male and female aged 18 or more years and Karnofsky greater than 60) previously treated with taxanes- or platinum-based chemotherapy and presenting sensory neuropathy, will be randomised to receive placebo or Acetyl-L-Carnitine. \n\nPrevious inclusion criteria:\nPatients (male and female age between 18 and 70 years and Karnofsky >60) previously treated with taxanes- or platinum-based chemotherapy and presenting sensory neuropathy, will be randomised to receive placebo or Acetyl-L-Carnitine.", "ageRange": "Adult", "lowerAgeLimit": {"@unit": "Years", "@value": "18.0"}, "gender": "Both", "targetEnrolment": "172", "totalFinalEnrolment": null, "totalTarget": "172", "exclusion": "1. Pre-existing neuropathies of different origin than those considered in this trial\n2. Diabetes mellitus, insulin-dependent\n3. Symptomatic brain metastases\n4. Leptomeningeal involvement\n5. Significant infective ilness or active inflamed focus\n6. Concomitant therapy with other neuroprotective agents\n7. Any previous use of neuro-protectant drugs if performed from the last chemoteraphy administration, onwards\n8. Any neurotoxic chemotherapy since one month prior to baseline\n9. Predictable lack of patient's co-operation\n10. Pregnancy, nursing, or women of childbearing potential not using an effective method of birth control\n11. Previous treatment with platinum for those patients who enter the study due to taxanes-induced sensory neuropathy\n12. Previous treatment with taxanes for those patients who enter the study due to platinum-induced sensory neuropathy", "patientInfoSheet": null, "recruitmentStart": "2005-07-01T00:00:00.000Z", "recruitmentEnd": "2009-06-01T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Taxanes- or platinum-induced neuropathy", "diseaseClass1": "Nervous System Diseases", "diseaseClass2": "Taxanes- or platinum-induced neuropathy"}}, "interventions": {"intervention": {"description": "Placebo versus Acetyl-L-Carnitine. \n\nEfficacy:\nNeuropathy will be assessed by a neurologist at each study visit  using: sensory and motor items of National Cancer Institute - Common Toxicity Criteria (NCI-CTC) version 3.0; vibration examination; total neuropathy score (TNS); clinical neurological evaluation; electroneurography (ENG).\n\nSafety:\nPhysical examinations, electrocardiograms (ECGs), vital signs, laboratory tests, adverse events and concomitant medications will be considered for the safety and tolerability evaluation.", "interventionType": "Drug", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": "Acetyl-L-Carnitine  (ST 200)"}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": null, "publicationStage": null, "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": null, "parties": {"funderId": "Funder13110-0", "contactId": "Contact50649_13110", "sponsorId": "Sponsor49033"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact50649_13110", "title": "Mr", "forename": "Massimo", "surname": "Ildebrando", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Via Pontina km 30,400", "city": "Pomezia (Rome)", "country": "Italy", "zip": "00040", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected"}, "sponsor": {"@id": "Sponsor49033", "organisation": "Sigma-Tau (Italy)", "website": null, "sponsorType": "Industry", "contactDetails": {"address": "Industrie Farmaceutiche Riunite, SpA\nVia Pontina km 30,400", "city": "Rome", "country": "Italy", "zip": "00040", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected", "gridId": "grid.452807.c", "rorId": "https://ror.org/03bxtpd68"}, "funder": {"@id": "Funder13110-0", "name": "Sigma-Tau i.f.r. S.p.A. (Italy) (Protocol ref: ST200-DM-04-005)", "fundRef": null}}, {"trial": {"@lastUpdated": "2008-08-15T00:00:00.000Z", "@version": "21", "isrctn": {"@dateAssigned": "2005-06-07T00:00:00.000Z", "#text": "78768405"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "Efficacy and safety of rectal artesunate in paediatric patients - a randomised controlled study (Ghana and Tanzania)", "scientificTitle": null, "acronym": null, "studyHypothesis": "Hypothesis that clinical response rates in children aged 3 to 24 months with non per os malaria treated with rectal artesunate will not be inferior to those who receive standard treatment of parenteral Quinine. \n\nPlease note that as of 15/08/2008, this record was updated to include Tanzania in the countries of recruitment list. This country started recruitment on 08/05/2008 and was added in order to add to the patient numbers. Ethics approval for this site has also been added to this record, and the anticipated end date has also been updated. The previous anticipated end date for this trial was 30/09/2007.", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "28-day disease-free survival, defined as patients who survived the 28-day period of follow-up with the peripheral blood free of the original genotype of malaria parasites.", "secondaryOutcome": "The parasitological outcomes and tolerability of a single dose of the rectal artesunate in children aged 3 to 24 months with non per os falciparum malaria.", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Approved by:\n1. The Committee on Human Research Publication and Ethics (CHRPE) of the School of Medical Sciences, Kwame Nkrumah University of Science and Technology, Kumasi on 20th January 2003\n2. World Health Organization (WHO) Ethics Committee on 30th June 2003 and continuing review 15th November 2005 and 13 November 2007\n3. The National Institute of Medical Research, Tanzania on 28th August 2007"}, "externalRefs": {"doi": "10.1186/ISRCTN78768405", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "A20210 and A70334"}, "trialDesign": {"studyDesign": "Randomised controlled trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Not specified"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2003-06-30T00:00:00.000Z", "overallEndDate": "2010-06-30T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": ["Ghana", "Switzerland", "Tanzania"]}, "trialCentres": {"trialCentre": {"@id": "1da265f0-a8ba-4145-b0ba-abed3dc15530", "name": "World Health Organization", "address": null, "city": "Geneva-27", "state": null, "country": "Switzerland", "zip": "CH 1211"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. Aged 3 to 24 months\n2. Suspected malaria with no other obvious cause of illness\n3. P. falciparum asexual parasitaemia greater than ++ (5 - 10 parasites/High Power Field [HPF])\n4. Unable to eat, suck or drink, or repeatedly vomiting (more than three episodes over past 24 hours); or prostrate (unable to sit or stand if previously able to do so)\n5. History of convulsions over the preceding 24 hours or impaired consciousness (Blantyre Coma Score less than five)\n6. Parent/guardian informed consent", "ageRange": "Child", "lowerAgeLimit": {"@unit": "Months", "@value": "3.0"}, "upperAgeLimit": {"@unit": "Months", "@value": "24.0"}, "gender": "Both", "targetEnrolment": "246", "totalFinalEnrolment": null, "totalTarget": "246", "exclusion": "1. Ability to tolerate oral intake\n2. Acute diarrhoea defined as the presence of more than three episodes of watery stools in the preceding 24 hours\n3. History of allergy to artemisinin compounds and/or quinine", "patientInfoSheet": null, "recruitmentStart": "2003-06-30T00:00:00.000Z", "recruitmentEnd": "2010-06-30T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Malaria", "diseaseClass1": "Infections and Infestations", "diseaseClass2": "Malaria"}}, "interventions": {"intervention": {"description": "Group A: Artesunate 10 mg/kg, rectal\nGroup B: Quinine 20 mg dihydrochloride salt/kg, intra-muscular injection (followed by 10 mg/kg at 12 and 24 hours)", "interventionType": "Drug", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": "Artesunate, quinine"}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": null, "publicationStage": null, "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": null, "parties": {"funderId": "Funder12978-0", "contactId": "Contact50501_12978", "sponsorId": "Sponsor48879"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact50501_12978", "title": "Dr", "forename": "Melba", "surname": "Gomes", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "World Health Organization\n20 Avenue Appia", "city": "Geneva-27", "country": "Switzerland", "zip": "CH 1211", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+41 (0)22 791 3813"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "gomesm@who.int"}}, "privacy": "Public"}, "sponsor": {"@id": "Sponsor48879", "organisation": "UNICEF/UNDP/World Bank/WHO - Special Programme for Research and Training in Tropical Diseases (TDR)", "website": "http:///www.who.int", "sponsorType": "Research organisation", "contactDetails": {"address": "World Health Organization \n20 Avenue Appia", "city": "Geneva-27", "country": "Switzerland", "zip": "CH-1211", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected", "gridId": "grid.3575.4", "rorId": "https://ror.org/01f80g185"}, "funder": {"@id": "Funder12978-0", "name": "United Nations Children's Fund (UNICEF)/United Nations Development Programme (UNDP)/World Bank/World Health Organization (WHO) - Special Programme for Research and Training in Tropical Diseases (TDR)", "fundRef": null}}, {"trial": {"@lastUpdated": "2008-08-20T00:00:00.000Z", "@version": "23", "isrctn": {"@dateAssigned": "2004-04-01T00:00:00.000Z", "#text": "31330564"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "Testosterone undecanoate combined with depomedroxyprogesterone acetate in two month intervals in Asian men", "scientificTitle": null, "acronym": null, "studyHypothesis": "To assess the efficacy of 500 mg Testosterone Undecanoate (TU) in combination with either 150 or 250 mg Depomedroxyprogesterone Acetate (DMPA) in suppression of sperm production, while maintaining adequate testosterone levels in fertile Asian men.\n\nDue to funding limitations and focus on an alternative intervention, the study was never initiated and has been withdrawn from the World Health Organization (WHO) directory.", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "1. Changes in sperm concentrations to azoospermia or severe oligozoospermia at 24 weeks\n2. Time to suppress spermatogenesis at 24 weeks", "secondaryOutcome": "Suppression of gonadotropins and maintenance of normal blood testosterone levels at 24 weeks.", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Not provided at time of registration"}, "externalRefs": {"doi": "10.1186/ISRCTN31330564", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "WHO/HRP ID A15242"}, "trialDesign": {"studyDesign": "Randomised controlled trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Not specified"}, "trialTypes": {"trialType": "Not Specified"}, "overallStatusOverride": "Stopped", "reasonAbandoned": "Due to funding limitations and focus on an alternative intervention, the study was never initiated and has been withdrawn from the World Health Organization (WHO) directory.", "overallStartDate": "2003-06-01T00:00:00.000Z", "overallEndDate": "2004-06-01T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": ["China", "India", "Indonesia", "Switzerland"]}, "trialCentres": {"trialCentre": {"@id": "41e71367-1787-4b4b-be72-850bae1a72d6", "name": "World Health Organization", "address": null, "city": "Geneva", "state": null, "country": "Switzerland", "zip": "CH-1211"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. Men in good health, aged 20 to 45\n2. No desire for children for next 15 months\n3. Normal reproductive state:\na. sperm concentrations greater than or equal to 20 million/ml\nb. sperm motility greater than 50% (rapid and slow progressive) or grade a greater than 15%\nc. morphology greater than 15% normal forms using the World Health Organisation (WHO) strict criteria, or \nd. within the normal range for the centre\n4. Body mass index between 20 and 29 kg/m^2", "ageRange": "Adult", "gender": "Male", "targetEnrolment": "64", "totalFinalEnrolment": null, "totalTarget": "64", "exclusion": "No exclusion criteria", "patientInfoSheet": null, "recruitmentStart": "2003-06-01T00:00:00.000Z", "recruitmentEnd": "2004-06-01T00:00:00.000Z", "recruitmentStatusOverride": "Stopped"}, "conditions": {"condition": {"description": "Male contraception", "diseaseClass1": "Pregnancy and Childbirth", "diseaseClass2": "Male contraception"}}, "interventions": {"intervention": {"description": "1. 500 mg TU and 150 mg DMPA injected at eight week intervals (n = up to 32)\n2. 500 mg TU and 250 mg DMPA injected at eight week intervals (n = up to 32)", "interventionType": "Drug", "pharmaceuticalStudyTypes": null, "phase": "Phase II", "drugNames": "Testosterone undecanoate (TU),  depomedroxyprogesterone acetate (DMPA)"}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": null, "publicationStage": null, "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": null, "parties": {"funderId": "Funder8223-0", "contactId": "Contact30642_8223", "sponsorId": "Sponsor26388"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact30642_8223", "title": "Dr", "forename": "Kirsten", "surname": "Vogelsong", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "World Health Organization\n20 Avenue Appia", "city": "Geneva", "country": "Switzerland", "zip": "CH-1211", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "vogelsongk@who.int"}}, "privacy": "Public"}, "sponsor": {"@id": "Sponsor26388", "organisation": "UNDP/UNFPA/WHO/World Bank - Special Programme of Research, Development and Research Training in Human Reproduction", "website": "http://www.who.int/reproductive-health/hrp/", "sponsorType": "Research organisation", "contactDetails": {"address": "World Health Organization\n20 Avenue Appia", "city": "Geneva", "country": "Switzerland", "zip": "CH-1211", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected", "gridId": "grid.3575.4", "rorId": "https://ror.org/01f80g185"}, "funder": {"@id": "Funder8223-0", "name": "United Nations Development Programme (UNDP)/United Nations Population Fund (UNFPA)/World Health Organization (WHO)/World Bank - Special Programme of Research, Development and Research Training in Human Reproduction (HRP)", "fundRef": null}}, {"trial": {"@lastUpdated": "2008-08-26T00:00:00.000Z", "@version": "22", "isrctn": {"@dateAssigned": "2003-09-12T00:00:00.000Z", "#text": "12878702"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "Randomised single blind patient controlled trial of VNUS closure compared with groin dissection and long saphenous vein (LSV) stripping for recurrent varicose veins", "scientificTitle": null, "acronym": null, "studyHypothesis": "To determine whether VNUS is as effective as groin re-exploration for recurrent varicose veins in association with a recurrently incompetent long saphenous vein (LSV). Assessment will be by Duplex scan at 6 weeks, 1 year and 5 years.", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "Operative time, visual analogue scales for pain and bruising, costs of procedure, recurrence rates.", "secondaryOutcome": "Not provided at time of registration", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Not provided at time of registration"}, "externalRefs": {"doi": "10.1186/ISRCTN12878702", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "N0192119061"}, "trialDesign": {"studyDesign": "Randomised controlled trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Not specified"}, "trialTypes": {"trialType": "Not Specified"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2002-07-31T00:00:00.000Z", "overallEndDate": "2004-12-12T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": ["England", "United Kingdom"]}, "trialCentres": {"trialCentre": {"@id": "551045af-695b-4fab-a810-b14b6ba6994d", "name": "Department of Vascular Surgery", "address": null, "city": "Nottingham", "state": null, "country": "United Kingdom", "zip": "NG7 2UH"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "Age 18-80", "ageRange": "Adult", "lowerAgeLimit": {"@unit": "Years", "@value": "18.0"}, "upperAgeLimit": {"@unit": "Years", "@value": "80.0"}, "gender": "Not Specified", "targetEnrolment": "60", "totalFinalEnrolment": null, "totalTarget": "60", "exclusion": "Not provided at time of registration", "patientInfoSheet": null, "recruitmentStart": "2002-07-31T00:00:00.000Z", "recruitmentEnd": "2004-12-12T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Cardiovascular: Recurrent varicose veins", "diseaseClass1": "Circulatory System", "diseaseClass2": "Recurrent varicose veins"}}, "interventions": {"intervention": {"description": "VNUS closure compared with groin dissection and long saphenous vein (LSV) stripping for recurrent varicose veins", "interventionType": "Other", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": null}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": "2006 Results article in http://www.ncbi.nlm.nih.gov/pubmed/16137898 results", "publicationStage": "Results", "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": {"output": {"@id": "8142e302-0592-48e5-932d-03407f1b49e2", "@outputType": "resultsarticle", "@artefactType": "ExternalLink", "@dateCreated": "2006-02-01T00:00:00.000Z", "@dateUploaded": "", "@peerReviewed": "true", "@patientFacing": "false", "@createdBy": "Data migration", "externalLink": {"@url": "http://www.ncbi.nlm.nih.gov/pubmed/16137898"}, "description": "results", "productionNotes": null}}, "parties": {"funderId": "Funder5461-0", "contactId": "Contact6944_5461", "sponsorId": "Sponsor5287"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact6944_5461", "title": "Mr", "forename": "BD", "surname": "Braithwaite", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Department of Vascular Surgery\nC Floor West Block\nUniversity Hospital", "city": "Nottingham", "country": "United Kingdom", "zip": "NG7 2UH", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+44 (0)115 924 9924"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "BRUCE.BRAITHWAITE@QMC.NHS.UK"}}, "privacy": "Public"}, "sponsor": {"@id": "Sponsor5287", "organisation": "Department of Health (UK)", "website": "http://www.doh.gov.uk", "sponsorType": "Government", "contactDetails": {"address": "Richmond House\n79 Whitehall", "city": "London", "state": null, "country": "United Kingdom", "zip": "SW1A 2NL", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected"}, "funder": {"@id": "Funder5461-0", "name": "Queen's Medical Centre University Hospital NHS Trust (UK)", "fundRef": null}}, {"trial": {"@lastUpdated": "2008-08-15T00:00:00.000Z", "@version": "21", "isrctn": {"@dateAssigned": "2003-02-11T00:00:00.000Z", "#text": "35571063"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "QAASM: an evaluation of three methods of external quality assurance for patient self-management of oral anticoagulation", "scientificTitle": null, "acronym": "QAASM", "studyHypothesis": "Aim: \nTo evaluate three different methods of external quality assurance (EQA) for home management. \n\nPrimary objective: \nTo compare patients' treatment related quality of life in relation to external quality assurance for home anticoagulation management, with or without supervision. \n\nSecondary objective: \nTo compare three different methods of EQA, one unsupervised and two supervised in terms of: \n1. Reliability of EQA results\n2. Impact on international normalised ratio (INR) control  \n3. Costs associated with each method of EQA", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "Difference in treatment related quality of life scores between non supervised and supervised EQA models", "secondaryOutcome": "1. Comparison of EQA results between three models of EQA\n2. Comparison of therapeutic INR control in terms of the percentage of time spent within therapeutic range\n3. Cost comparison of EQA models", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Not provided at time of registration"}, "externalRefs": {"doi": "10.1186/ISRCTN35571063", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "G106/970"}, "trialDesign": {"studyDesign": "Randomised controlled trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Not specified"}, "trialTypes": {"trialType": "Not Specified"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2000-08-01T00:00:00.000Z", "overallEndDate": "2004-07-31T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": ["England", "United Kingdom"]}, "trialCentres": {"trialCentre": {"@id": "d684b18d-1330-4a5f-a4b5-319d5aad5603", "name": "Department of Primary Care and General Practice", "address": null, "city": "Edgbaston", "state": null, "country": "United Kingdom", "zip": "B15 2TT"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. Patients aged 18 or over\n2. A long term (greater than 12 months) indication for oral anticoagulation\n3. Have taken warfarin for at least six months\n4. Are willing (or in the case of dependent patients both they and their carer are willing) to participate in the study", "ageRange": "Adult", "lowerAgeLimit": {"@unit": "Years", "@value": "18.0"}, "gender": "Both", "targetEnrolment": "260", "totalFinalEnrolment": null, "totalTarget": "260", "exclusion": "1. Patients with a short-term indication (less than 12 months) for warfarin therapy\n2. Aged under 18 years\n3. Housebound patients \n4. Patients confined to a nursing home", "patientInfoSheet": null, "recruitmentStart": "2000-08-01T00:00:00.000Z", "recruitmentEnd": "2004-07-31T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Anticoagulant therapy", "diseaseClass1": "Haematological Disorders", "diseaseClass2": "Anticoagulant therapy"}}, "interventions": {"intervention": {"description": "Patients from the SMART trial (Self-management of warfarin: a randomised trial) will be randomly allocated to two main groups at practice level for supervised or non-supervised External Quality Control (EQA). Twenty-four practices into groups 1 and 2. \n\nThe practices randomised to supervised EQA will then be further randomly allocated to different methods of supervised EQA, Groups 2A and 2B.\n\nUnsupervised group: formal EQA scheme (National Quality Assessment Scheme NEQAS).\n\nSupervised groups: International normalised ratio (INR) results from venous samples sent to the local laboratory will be compared with contemporaneous near patient testing (NPT) capillary samples at the practice using the patient's NPT system, or INR results from patient NPT system capillary sample tests will be compared to results from an NPT system weekly quality control tested using samples from NEQAS at the practice, NPT to NPT.", "interventionType": "Other", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": null}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": "2002 Results article in http://www.ncbi.nlm.nih.gov/pubmed/12401823 Results", "publicationStage": "Results", "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": {"output": {"@id": "0241372a-6a53-451d-b79a-ce948546af83", "@outputType": "resultsarticle", "@artefactType": "ExternalLink", "@dateCreated": "2002-11-01T00:00:00.000Z", "@dateUploaded": "", "@peerReviewed": "true", "@patientFacing": "false", "@createdBy": "Data migration", "externalLink": {"@url": "http://www.ncbi.nlm.nih.gov/pubmed/12401823"}, "description": "Results", "productionNotes": null}}, "parties": {"funderId": "Funder1672-0", "contactId": "Contact5270_1672", "sponsorId": "Sponsor5055"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact5270_1672", "title": "Ms", "forename": "Ellen", "surname": "Murray", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Department of Primary Care and General Practice\nUniversity of Birmingham", "city": "Edgbaston", "country": "United Kingdom", "zip": "B15 2TT", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+44 (0)121 414 3761"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "e.t.murray@bham.ac.uk"}}, "privacy": "Public"}, "sponsor": {"@id": "Sponsor5055", "organisation": "Medical Research Council (MRC) (UK)", "website": "http://www.mrc.ac.uk", "sponsorType": "Research council", "contactDetails": {"address": "20 Park Crescent", "city": "London", "state": null, "country": "United Kingdom", "zip": "W1B 1AL", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+44 (0)20 7636 5422"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "clinical.trial@headoffice.mrc.ac.uk"}}, "privacy": "Public"}, "funder": {"@id": "Funder1672-0", "name": "Medical Research Council (MRC) (UK) - Special Training Fellowship in HSR", "fundRef": null}}, {"trial": {"@lastUpdated": "2008-09-02T00:00:00.000Z", "@version": "25", "isrctn": {"@dateAssigned": "2001-07-01T00:00:00.000Z", "#text": "57679341"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "LCH-II Langerhans cell histiocytosis: treatment protocol of the second international study", "scientificTitle": null, "acronym": null, "studyHypothesis": "To compare intensification of treatment with an improved outcome.", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "Not provided at time of registration", "secondaryOutcome": "Not provided at time of registration", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Not provided at time of registration"}, "externalRefs": {"doi": "10.1186/ISRCTN57679341", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "LCH 9605"}, "trialDesign": {"studyDesign": "Randomised controlled trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Hospital"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2002-01-01T00:00:00.000Z", "overallEndDate": "2007-12-31T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": ["Austria", "England", "United Kingdom"]}, "trialCentres": {"trialCentre": {"@id": "0ec655d8-fbd4-4846-9e6d-6a9db26c5bb8", "name": "UKCCCR Register Co-ordinator", "address": null, "city": "London", "state": null, "country": "United Kingdom", "zip": "NW1 2DA"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. Definitive diagnosis of Langerhans cell histiocytosis \n2. Aged under 18 years with involvement of haematopetic system, liver, lungs or spleen or aged under 2 years \n3. No prior treatment for Langerhans cell histiocytosis", "ageRange": "Child", "upperAgeLimit": {"@unit": "Years", "@value": "18.0"}, "gender": "Both", "targetEnrolment": "193", "totalFinalEnrolment": null, "totalTarget": "193", "exclusion": "Does not comply with above criteria", "patientInfoSheet": null, "recruitmentStart": "2002-01-01T00:00:00.000Z", "recruitmentEnd": "2007-12-31T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Langerhans cell histiocytosis", "diseaseClass1": "Haematological Disorders", "diseaseClass2": "Certain diseases involving lymphoreticular tissue and reticulohistiocytic system"}}, "interventions": {"intervention": {"description": "Risk group patients are randomised to either: \n1. Arm A: Initial treatment with oral prednisone and vinblastine. Continuation treatment with oral 6-mercaptopurine plus pulses of oral prednisone and vinblastine. \n2. Arm B: Initial treatment with oral prednisone and vinblastine. Continuation treatment with oral 6-mercaptopurine plus pulses of oral prednisone and vinblastine followed by etoposide.", "interventionType": "Other", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": null}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": "2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18089850 Results", "publicationStage": "Results", "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": {"output": {"@id": "d8275c63-c4f3-4898-9387-74bde24d63cd", "@outputType": "resultsarticle", "@artefactType": "ExternalLink", "@dateCreated": "2008-03-01T00:00:00.000Z", "@dateUploaded": "", "@peerReviewed": "true", "@patientFacing": "false", "@createdBy": "Data migration", "externalLink": {"@url": "http://www.ncbi.nlm.nih.gov/pubmed/18089850"}, "description": "Results", "productionNotes": null}}, "parties": {"funderId": "Funder1209-0", "contactId": "Contact5427_1209", "sponsorId": "Sponsor5086"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact5427_1209", "title": "Dr", "forename": "-", "surname": "-", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "UKCCCR Register Co-ordinator\nMRC Clinical Trials Unit\n222 Euston Road", "city": "London", "country": "United Kingdom", "zip": "NW1 2DA", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected"}, "sponsor": {"@id": "Sponsor5086", "organisation": "UK Co-ordinating Committee for Cancer Research (UKCCCR)", "website": null, "sponsorType": "Government", "contactDetails": {"address": "MRC Clinical Trials Unit\n222 Euston Road", "city": "London", "country": "United Kingdom", "zip": "NW1 2DA", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected", "gridId": "grid.11485.39", "rorId": "https://ror.org/054225q67"}, "funder": {"@id": "Funder1209-0", "name": "Children's Cancer Research Institute (Austria)", "fundRef": null}}]}}